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Abstract 
 
CYP24A1 (25-hydroxyvitamin D-24-hydroxylase) is a useful enzyme target for a range of 
medical conditions including cancer, cardiovascular and autoimmune disease, which show 
elevated CYP24A1 levels and corresponding reduction of calcitriol (the biologically active 
form of vitamin D). Calcitriol has antiproliferative and pro-differentiating properties, however 
use of calcitriol as a therapeutic drug is limited by hypercalcaemia. An alternative approach is 
the use of CYP24A1 inhibitors to prevent the metabolism of calcitriol. The aim of this research 
is to design and synthesise novel inhibitors of CYP24A1 to enhance the endogenous levels of 
circulating calcitriol. Furthermore, it is important to develop compounds that are selective for 
CYP24A1 over CYP27B1 so that the generation of calcitriol itself is not blocked. In order to 
understand the requirements of inhibitor binding to the enzyme-active site, it would be useful 
to have a 3D structure of both human CYP24A1 and CYP27B1. However, to date, no human 
crystal structures are available for either of these enzymes. Therefore, a homology model for 
CYP24A1 has been developed and published. A CYP27B1 homology model  was developed, 
using a combination of homology modelling, molecular dynamics simulations, and molecular 
docking to understand the satisfactory explanation of the binding selectivity of the CYP27B1 
model with the natural substrate and with selective inhibitor complexes. Docking results for 
CYP27B1 showed amino acids Arg107, Asn387 and Asp320 have an important role in binding 
interactions to form hydrogen bonds with inhibitors. The development of potent and selective 
inhibitors from three azole series was investigated. Development of series one using pyridine, 
imidazole and triazole as the haem binding group was synthesised successfully. The 
compounds exhibited weak potency and IC50 ranging between 10.2 to 28.4 µM against 
CYP24A1. Owing to the low CYP24A1 inhibitory activity the compounds were not evaluated 
against CYP27B1. The series two bis(3-methyl-1-phenyl-1H-pyrazol-5ol) was synthesised 
successfully. Two compounds were the moderate CYP24A1 inhibitors and so were further 
evaluated against CYP27B1. However, these compounds showed enzymatic inhibition (IC50 = 
0.57 μM and 0.41 μM) against CYP27B1, that is they were more selective for CYP27B1 
which could be rationalised from docking experiments. A series of (E)-N-(2-(1H-imidazol-1-
yl)-2-(phenylethyl)-3/4-styrylbenzamides have been synthesised using an efficient synthetic 
route and shown to be potent inhibitors of CYP24A1 (IC50 0.11 - 0.35 µM) compared with the 
standard ketoconazole. Molecular modelling using our CYP24A1 homology model showed the 
inhibitors to fill the hydrophobic binding site, forming key transition metal interaction between 
the imidazole nitrogen and the haem Fe3+ and multiple interactions with the active site amino 
acid residues. 
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1 Introduction 
 
1.1 Introductory remarks  
The sun is the primary source of energy in this biosphere, providing earth’s heat and 
light, protecting people from disease, and governing photosynthesis in the plant 
kingdom. Notably, the sun works as a cofactor to enhance the production of vitamins, 
such as vitamin D, which is synthesised from the skin by exposure to ultraviolet β 
radiation to produce vitamin D3 (cholecalciferol) through a non-enzymatic pathway1. 
Production of sufficient vitamin D from the skin depends on the strength of the 
ultraviolet β radiation, the length of time spent in the sun, the amount of pigment in 
the skin2, and the exposure of arms and legs for around 30 minutes between 10 am and 
3 pm twice a week3. Depending on the intensity of the ultraviolet β radiation from 
sunlight, which varies according to season and latitude, this can be adequate to prevent 
vitamin D deficiency4. 
 
1.2 History of Vitamin D 
McCollum3 discovered vitamin D in 1913, and termed it “D” as it was the fourth 
known vitamin3,5. Vitamins are classified into two classes depending on whether they 
attract (hydrophilic) or repel (hydrophobic) water6. The hydrophobic vitamins, 
comprising A, D, E and K, are stored mostly in adipose tissues and the liver whereas 
hydrophilic vitamins, such as C and the B complex (B1, B2, B3, B6 and B12)7, cannot be 
stored in the tissues, and therefore, humans need to obtain these vitamins from their 
diet2,8,9. Vitamin D is a lipophilic compound known as a pro-hormone, and there are 
two major physiologically active forms, namely, vitamin D2 (calciferol) and vitamin D3 
(cholecalciferol) 10. Vitamin D has no hormonal activity, and therefore, it is converted 
to biologically active 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), also known as 
calcitriol11, by two successive hydroxylations, the first in the liver and the second in the 
kidneys12,9,13. 
 
1.3 Transport of Vitamin D  
Vitamin D and its metabolites are hydrophobic in nature; therefore, their transportation 
in the circulatory system is facilitated by binding to serum proteins, such as vitamin D-
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binding protein (DBP) and albumin14,15. DBP is the primary transport protein for 
calcitriol, contributing approximately 88% of the total bound calcitriol16 ; the remainder 
is bound to albumin, leaving less than 1% of 25(OH)D3 in an unbound state17. DBP 
influences how cells can access vitamin D either by defining the amount of free vitamin 
D metabolites available for passive diffusion into the cell or by actively facilitating the 
acquisition of vitamin D metabolites18. 
 
In the glomerulus, DBP-bound 25(OH)D3 and other vitamin D metabolites are filtered 
out of the blood into the filtrate. Therefore, DBP-25(OH)D3 is reabsorbed from the 
luminal filtrate in the renal proximal tubule by binding to megalin19. In addition, cubilin 
is another membrane receptor expressed on the apical side of the proximal tubule that 
plays a role in the renal uptake of DBP-25(OH)D3 complexes20. 
 
1.4 Physiological role of vitamin D 
1.4.1 Mineral homeostasis 
Vitamin D, commonly regarded as the sunlight hormone or sunshine vitamin, plays an 
essential role in calcium and phosphorus homeostasis21. A deficiency of vitamin D 
results in osteomalacia and has been shown to affect approximately 50% of the 
population worldwide within all ethnic and age groups22. Hypovitaminosis D disease 
can be attributed mostly to reduced outdoor activities as well as air pollution factors 
that reduce exposure to sunlight, which is required for ultraviolet-𝛽-induced vitamin D 
production in the skin23. Indeed, one of the best-described functions of calcitriol is the 
control of circulating calcium levels in the body24. When extracellular calcium levels 
are low, the calcium-sensing receptor of the parathyroid gland responds by stimulating 
the synthesis and secretion of parathyroid hormone (PTH)25. Consequently, PTH 
stimulates the synthesis of calcitriol by increasing CYP27Bl26. Simultaneously, PTH 
suppresses the renal expression of CYP24A1, which results in a rise in the circulating 
levels of calcitriol20. Furthermore, calcitriol stimulates the active absorption of dietary 
calcium from the small intestine by stimulating the key proteins involved, such as 
calbindin-D9k and calcium transporter-127. In addition, calcitriol increases the 
reabsorption of calcium in the distal renal tubules by stimulating the gene 
transactivation of the receptor activator of nuclear factor KB (NF-KB)28,29. 
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Vitamin D-regulated mineralisation of the skeleton and the maintenance of calcium 
levels are accomplished by the following two mechanisms30 (Figure 1). 
1. Proteins involved in the active intestinal absorption of calcium are induced by 
stimulating the active intestinal absorption of phosphate31. 
2. Blood calcium concentrations remain in the normal range even when there is 
no calcium from the diet. Therefore, if the calcium concentration is inadequate, 
renal 1α-hydroxylase is activated, and calcitriol, the active form of vitamin 
D3, is synthesised32.  
Vitamin D-dependent rickets type I is related to defects in CYP27B133 and is quickly 
relieved by the administration of calcitriol33. Likewise, vitamin D-dependent rickets 
type II appears to result from a mutation in the vitamin D receptor gene and is also 
managed by the administration of calcitriol34. 
 
Figure 1: Effect of calcitriol on calcium 
 
1.4.2 Kidney disease 
Vitamin D is thought to play a pivotal job in several disease processes that are closely 
related to chronic kidney disease (CKD)35, for example, mineral bone disorder, 
anaemia, and inflammation. Calcitriol governs multiple signalling routes that are 
related to renal damage, and in adults with CKD, treatment with vitamin D derivatives 
is beneficial in reducing proteinuria and inflammation36. 
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Abnormalities in vitamin D metabolism have been linked to the pathogenesis of 
secondary hyperparathyroidism in CKD37. There are several mechanisms involved in 
the reduction in the levels of calcitriol that occur in kidney disease38. Therefore, a 
reduction in renal mass will limit the quantities of 1α-hydroxylase that are available 
for the production of calcitriol. A reduction in the glomerular filtration rate could limit 
the delivery of substrate to the 1α-hydroxylase, which may also limit the ability of the 
kidney to produce calcitriol. Chronic renal failure, such as that resulting from polycystic 
kidney disease or diabetic nephropathy, is related to severe metabolic bone disease39,40. 
Several studies have reported that treatment with vitamin D analogues, such as 
calcitriol, alfacalcidol, and paricalcitol, results in an increase in the life expectancy of 
patients with renal failure41. 
Recent observations have demonstrated that kidney disease seems to be associated with 
a high incidence of vitamin D deficiency38. Fortunately, vitamin D receptors are present 
in the parathyroid gland, and a major function of vitamin D is to suppress parathyroid 
cell proliferation. Several vitamin D analogues have been developed to treat the 
secondary hyperparathyroidism linked with chronic renal failure (Figure 2), such as 19-
nor-1α,25-dihydroxyvitamin D2 and 1α-hydroxyvitamin D2 and 22-oxa-1α,25-
dihydroxyvitamin D3. 
 
Figure 2: Effect of chronic kidney disease (CKD) on vitamin D, glomerular filtration rate (GFR), 
fibroblast growth factor-23 (FGF-23) and Pi phosphate (inorganic). 
 
1.4.3 Cardiovascular system complications 
Heart disease is currently considered as one of the leading causes of illness and death 
in the world. Vitamin D insufficiency has been distinguished as a possible risk factor 
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for numerous illnesses not traditionally associated with vitamin D42, for example, 
tumour and cardiovascular disease, and there is evidence to confirm the relation 
between low 25-hydroxyvitamin D levels and cardiovascular disease31. In particular, 
vitamin D deficiency is reported to be linked to risk factors of heart disease, such as 
hypertension and diabetes mellitus; atherosclerosis events, for example, myocardial 
infarction and stroke; as well as congestive heart failure43. Vitamin D receptors are 
expressed in a variety of tissues, including cardiomyocytes, vascular smooth muscle 
cells, and endothelial cells, and vitamin D deficiency has been shown to affect 
inflammation, and cell proliferation and differentiation44. Furthermore, recent studies 
have disclosed a relationship between blood levels of calcitriol and the incidence of 
stroke45. Moreover, the association between vitamin D deficiency and hypertension, 
metabolic syndrome, and diabetes mellitus has also been studied46,47 (Figure 3). 
 
Figure 3: Relationship between vitamin D and cardiovascular risk 
 
1.4.4 Skin complication 
Vitamin D imparts therapeutic benefits to acne, which has traditionally been treated by 
retinoic acid48. The skin is a target of vitamin D action, and numerous literature reports 
have clearly established the presence of the vitamin D receptor in keratinocytes, 
sebocytes, and dermal papilla cells by the treatment of acne and psoriasis using 
calcitriol, calcipotriol and 22-oxa-1,25-(OH)2D340. 
Recently, it has been shown that analogues of the vitamin D hormone can be useful in 
the Rhino mouse model of acne49, indicating the potential use of such compounds for 
the treatment of this disorder49.  
Antihypertensive  effect
of vitamin D
Renin angiotensin aldosterone
PTH
Antiatherosclerotic Anti-inflammatoryeffect
Beneficial effect
on cardiovascular
risk
(plaques)
Chapter one                                                                                                Introduction 	
	
6 
	
Furthermore, several studies have shown vitamin D analogues to be efficient treatment 
options for psoriasis50. Vitamin D3 analogues are also used in combination with 
phototherapy to manage psoriasis through their immunomodulatory properties by 
suppressing T-cell proliferation51. In addition, vitamin D analogues influence the 
regulation of antimicrobial peptides, cathelicidin, and human β-defensin 2, which are 
involved in the pathogenesis of psoriasis52.  
1.4.5 Psoriasis 
Psoriasis is a chronic inflammatory skin disease affecting approximately 5 % of the 
global population48; it is characterised by the hyperproliferation of keratinocytes 
leading to the redness, thickening, and scaling of the epidermis followed by itching and 
the appearance of lesions (Figure 4)49. Although, the pathogenesis of psoriasis is not 
entirely clear, there is evidence of dysregulation of the immune cells in the skin, acutely 
T cells, which play a critical function in psoriasis expansion53. Mostafa et al.54 reviewed 
the possible role of vitamin D deficiency in psoriasis. However, calcitriol is known to 
suppress the T helper1 cell and T helper17 cell proliferation55. Likewise, topical 
treatment with calcipotriol has been revealed to pointedly decrease cutaneous levels of 
human 𝛽 defensins 2, human 𝛽 defensins 356, IL-17A, IL-17F, and IL-8, which play 
critical roles in psoriasis56.  
 
Figure 4: Clinical symptom of psoriasis57 
 
1.4.6 Autoimmune diseases 
The role of vitamin D cannot be ruled out in several autoimmune diseases58, including 
inflammatory bowel disease, autoimmune thyroiditis, rheumatoid arthritis, diabetes 
mellitus type 1, mixed connective tissue disease, scleroderma, systemic lupus 
erythematosus, and allergic encephalomyelitis59. A few studies have suggested that the 
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risk of rheumatoid arthritis and type I diabetes mellitus is reduced in humans with a 
high vitamin D intake60. In addition, it influences a broad range of immune cells, such 
as T lymphocytes, B lymphocytes, and dendritic cells61. Furthermore, it has been 
observed that vitamin D receptors are located in immune cells, including antigen-
presenting cells, macrophages, and activated T cells, which could be inhibited notably 
by calcitriol62,63. In line with this, an inverse relationship between exposure to 
ultraviolet light and the incidence of multiple sclerosis has been noted64. The impact of 
multiple sclerosis cases was observed to be low in countries near the equator whereas 
it increases progressively in countries closer to the poles65. 
 
1.4.7 Type 1 diabetes (T1D) 
Type 1 diabetes (T1D) is an autoimmune disease in which β cells are destroyed and 
vitamin D elicits its preventive function. Treatment with calcitriol alleviates the 
symptoms of type I diabetes66. Moreover, recent studies have established a relationship 
between sunlight exposure and the incidence of type I diabetes67 where calcitriol 
prevents the disease in animal models by modifying the T-cell differentiation, the 
modulation of dendritic cell action, the induction of cytokine secretion and the shifting 
of the balance to regulatory T cells68.  
In general, T1D is a consequence of the T-cell mediated destruction of insulin-
producing pancreatic β-cells with a distinctive inception in childhood or 
adolescence68. Therefore, vitamin D administration during the juvenile period is 
considered a protective measure against the development of T1D69. Similarly, a 33% 
reduced risk of developing T1D was noted among children who received vitamin D 
supplementation during their infantile stage70. Additionally, in non-obese diabetic 
mice, the supplementation of calcitriol or vitamin D analogues prevented or at least 
postponed the onset of diabetes71.  
Moreover, vitamin D receptor (VDR) polymorphism is associated with type I diabetes 
mellitus72. Several studies have reported associations of T1D with polymorphisms in 
the CYP27B1 gene and have provided evidence of their association with T1D73. 
Therefore, VDR can be regarded as a master regulator of transcription, which is present 
in pancreatic β-cells, and vitamin D is essential for normal insulin secretion71,74. 
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1.4.8 Type 2 diabetes (T2D) 
Type 2 diabetes (T2D) is a disease that threatens the health and life quality of citizens. 
Presently, 285 million people worldwide are suffering from this disease75, and this 
number is projected to reach 439 million after 202575. Type 2 diabetes mellitus is a 
multifactorial disease characterised by chronic hyperglycaemia, based on two factors: 
altered insulin secretion and insulin resistance. In addition, it can also be expressed by 
diminished glucose tolerance, which results from islet β cell dysfunction, followed by 
insulin deficiency in skeletal muscle, liver, and adipose tissues76. The role of vitamin 
D in insulin secretion is justified by the presence of vitamin D receptors in β-cells and 
vitamin D-dependent calcium binding proteins in pancreatic tissue77. Similarly, vitamin 
D deficiency has been proven to alter insulin synthesis and secretion in humans78. 
Vitamin D deficiency may also affect glucose intolerance, altered insulin secretion, and 
type II diabetes mellitus79. Moreover, vitamin D deficiency results in decreased 
pancreatic insulin secretion, without altering glucagon secretion80.  
 
1.4.9 Cancer 
Vitamin D deficiency leads to cancer. Genes coding the metabolic enzymes, CYP24A1 
and CYP27B1, are discovered to remain down-regulated among numerous tumours, for 
example, breast and prostate tumours81.  
The antitumour mechanism of calcitriol is the promotion of cell apoptosis. Key 
mediators of apoptosis, such as the anti-apoptotic, pro-survival proteins Bcl-2 and Bcl-
XL, are repressed through calcitriol, although it induces the expression of pro-apoptotic 
proteins, for example, BAX, BAK, and BAD82. Huang and Bao83 reported that calcitriol 
also has a role in angiogenesis inhibition by inhibiting vascular endothelial growth 
factor and enhancing the potent anti-angiogenic factor thrombospondin 183. 
E-cadherin, a transmembrane linker of the intercellular junctions, is a membrane 
protein that is categorised as a cancer suppressor gene84. E-cadherin binds to β-catenin, 
preventing its nuclear translocation. In the nucleus, β-catenin binds to T-cell 
transcription factor/lymphoid enhancer-binding factor 1 (TCF/LEF1), a transcription 
factor involved in cell proliferation control. Calcitriol treatment increases the level of 
E-cadherin, resulting in the sequestration of β-catenin in the cytoplasm and obstructing 
the TCF/LEF1 gene regulation85. Moreover, Chakraborti86 has demonstrated that 
calcitriol displays antiproliferative and differentiation properties towards many cell 
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types by controlling many of the genes involved in proliferation, differentiation, 
apoptosis, and angiogenesis86. Colston et al.87 reported that many malignant cell types 
have been shown to respond by intake of calcitriol, as they possess VDR.  Calcitriol-
mediated action on tumour cells revealed that the incubation of malignant melanoma in 
the presence of calcitriol-inhibited cell proliferation showed a noticeable increase in 
cell doubling time87. Several reports have documented the cancer activity of calcitriol 
in a varied range of normal and tumour cells. However, clinical trials of calcitriol for 
the treatment of prostate cancer and leukaemia have been unsuccessful due to its toxic 
hypercalcaemic side effect. The risk of toxicity can be thwarted by reducing the 
dosage88. Brawer89 reported a randomised phase II clinical study for the treatment of 
prostate cancer, which demostrated that using a weekly treatment regimen consisting 
of high dose (45μg) calcitriol and docetaxel was associated with improved survival 
compared with placebo and docetaxel89 alone. Therefore, it can be concluded that 
calcitriol has antiproliferative, anti-inflammatory, and immunomodulatory activities. 
Calcitriol suppresses the growth of numerous malignant cells by arresting cell cycle 
and motivating apoptosis90. So, calcitriol inhibits cell proliferation by  
1.  Expression and significant down-regulation cyclins and the cyclin-dependent 
kinase after calcitriol treatment were showed in pancreatic cancer88,91 
2. inducing apoptosis through mitochondrial disruption and activating the intrinsic 
pathway 92 
3. thwarting cancer angiogenesis, stimulating healthy cells and promoting the 
inhibition of proliferation. Angiogenesis, the process of the formation of new 
blood vessels from the existing vasculature, is a crucial step in the continued 
growth, progression, and metastasis of tumours. Moreover, COX-2 promotes 
tumour development by stimulating angiogenesis. COX-2 inhibitors have been 
used to block angiogenesis and tumour proliferation. The pro-angiogenin effect 
of COX-2-produces PGE2, which might increase HIF-1α protein synthesis in 
cancer cells.  
Thus, calcitriol plays a vital role in the development of specific types of cancers, such 
as oesophageal, stomach, colon, rectal, gall bladder, pancreatic, lung, breast, uterus, 
ovary, prostate, urinary bladder, kidney, skin, thyroid, and hematopoietic system (e.g., 
Hodgkin's lymphoma, non-Hodgkin’s lymphoma, multiple myeloma)93.   
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1.4.9.1 Breast cancer 
There is a reverse relation between the intake of calcitriol and the risk of breast cancer. 
An improvement has been observed with patients given a high dosage of vitamin D 94. 
Indeed, vitamin D insufficiency has been found in a majority of women suffering from 
breast cancer95. In addition, growth inhibition has been found in patients using a 
combination of vitamin D3 and tamoxifen
96. Calcitriol inhibits action by preventing the 
synthesis and blocking the biological action of oestrogens and reducing the gene coding 
aromatase97. Furthermore, calcitriol helps to regulate the oestrogen receptor and is 
effective against both oestrogen receptor positive and negative breast cancers. 
Moreover, Masuda and Jones have also reviewed that some vitamin D analogues inhibit 
angiogenesis and decrease metastatic potential98. 
 
1.4.9.2 Prostate cancer  
Benign prostate hyperplasia (BPH) is the most prevalent prostate medical condition in 
the elderly and one of the most frequent chronic conditions in the male population, with 
a histological prevalence of 50% in men aged 50 to 60 years and 90% in men aged over 
80 years99. Furthermore, prostate cancer is the most frequently diagnosed and the 
second leading cause of cancer mortality in males in the United States100. Clinical 
indication of BPH associated with benign prostatic enlargement leads to blockage of 
the urethra. BPH101 is caused by complex cellular alterations including changes in 
proliferation, differentiation, apoptosis, and senescence101. Prostate cancer occurrence 
and mortality rates are found more in patients with vitamin D insufficiency102. The 
prostate is recognized as an extra renal site of vitamin D synthesis and action through 
the expression of CYP27B1 and the vitamin D receptor103. Maj et al.104 have shown in 
their data reports that calcitriol has a significant anticancer effect and might increase 
the efficacy of chemotherapy104. Krishnan et al.105 showed the antiproliferative effect 
of calcitriol in prostate cancer cells, including the promotion of cell cycle arrest, the 
induction of apoptosis, and the modulation of kinase pathways105,106. Calcitriol is used 
in the treatment of many diseases106, for example, psoriasis, cardiovascular system 
complications and cancers. Nonetheless, there is a limitation in the broader clinical use 
of calcitriol as a single anticancer agent due to its toxicity at higher doses 
(hypercalcemia). In addition, calcitriol has limited bioavailability at the tumour site. 
Calcitriol anticancer activity is mainly dependent on its dose, and its serum 
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concentration ranges escalate from 0.5 to 41 ng/ml, resulting in significant changes107. 
Furthermore, Kaeding el al.108 showed the efficiency of calcitriol to inhibit the 
proliferation of both prostate cancer types (androgen dependent and androgen 
independent)108. It also induces apoptosis and inhibits the cell growth in androgen-
sensitive and androgen-independent prostate cancer cells102. 
1.4.9.3 Colorectal cancer 
Colorectal cancer is a malignant tumour, which is caused by a group of tumorous cells 
developing in either the colon or the rectum. A colon tumour starts in the cells of the 
colon, while colorectal cancer starts in either the colon or the rectum109. Ma et al.110 
found a relation between low levels of calcitriol and colorectal tumours110. Individuals 
who have high levels of calcitriol in their human body are less likely to progress to 
colorectal cancer, and patients with higher calcitriol levels who previously have had 
colorectal cancer are more likely to have better outcomes. The mortality rates from 
colorectal cancer are higher in the northern and north eastern United States, compared 
with the Southwest, Hawaii and Florida and this correlate directly with an individual's 
vitamin D status111. Calcitriol helps to maintain a standard calcium gradient in the 
various colon epithelial cells112. With elevated levels of blood serum calcitriol 
associated with a noticeable decrease in proliferation of non-cancerous cells111, 
calcitriol significantly increases the expression and activity of alkaline phosphatase and 
induces colonic differentiation inhibition of proliferation113. Endogenous synthesis of 
calcitriol from 25-hydroxyvitamin D3 in gut mucosa plays a significant role in the 
control of cellular growth and differentiation in the colorectal mucosa114.  
Lin et al.115 established that there is an inverse correlation between the serum levels of 
vitamin D and the incidence of polyps and adenomas with the inverse relationship 
between dietary vitamin D3 intake or sunlight exposure and human colorectal 
cancer115,116.  
 
1.4.9.4 Blood cancer 
Calcitriol in human myeloid leukaemic cells inhibits proliferation and enhances the 
differentiation of monocytes and macrophages117. Intake of calcitriol in acute myleloid 
leukaemia leads to growth inhibition, the stimulation of monocyte differentiation, and 
apoptosis118. Recent gene expression profiling experiments of lymphocytic leukaemia 
have recognised that the vitamin D receptors were prominent compared with normal B 
Chapter one                                                                                                Introduction 	
	
12 
	
and T lymphocytes. The growth of a malignant tumour is delayed by intake of calcitriol 
in patients suffering from blood cancer119. 
 
1.4.9.5 Skin cancer 
Calcitriol has a critical function in the prevention of the induction and development of 
severe skin tumours, as it is involved in the regulation of several signalling pathways 
that have implications in carcinogenesis119, including the inhibition of the hedgehog 
signalling pathway, the pathway underlying the development of basal cell carcinomas, 
and the upregulation of nucleotide excision repair enzymes120. Furthermore, skin cancer 
metastasis depends on the tumour microenvironment, where calcitriol plays a 
significant role in the inhibition of certain molecular events involved in cancer 
development120. Calcitriol regulates cellular growth and apoptosis in human 
keratinocytes, plays an antioxidative, cytoprotective and immunomodulatory role in the 
skin, and protects human keratinocytes. Calcitriol works to decrease the number of 
cyclobutane pyrimidine dimers, which are the more common DNA photoproducts 
caused by insufficient DNA repair after UV radiation121,122. Melanoma cells express the 
vitamin D receptor and can convert the 25(OH)D3 into calcitriol. Calcitriol slows down 
the proliferation of these cells, promotes apoptosis, and inhibits the proliferation of 
human melanoma cells in vitro123. 
 
1.5 Metabolism pathway of vitamin D 
Vitamin D consists of 3 rings with 27 carbons. There are two forms of vitamin D: 
vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). Vitamin D3 is produced 
by the conversion of 7-dehydrocholesterol (7-DHC) in the epidermis and dermis of 
humans, and ergocalciferol is formed in mushrooms and yeast and is synthesised by the 
ultraviolet β irradiation of ergosterol. The chemical difference between cholecalciferol 
and ergocalciferol is in the side chain (ergocalciferol has a double bond between C22 
and C23 and a methyl group on C24)7 (Figure 5). 
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Figure 5: Chemical structure of cholecalciferol and ergocalciferol 
 
Vitamin D is part of an endocrinal system, which  plays a major role in the maintenance 
of calcium and phosphate homeostasis and is essential for the maintenance of a healthy 
skeleton124. Vitamin D is synthesised in the skin by the reaction of 7-dehydrocholestrol, 
which is found in the epidermal layers, with ultraviolet β radiation (when skin is 
exposed to the sun), or it is obtained from the diet. Provitamin D3 is produced by 
opening of the steroid nucleus (B ring broken by UV light with spectrum 280 - 320 
ultraviolet β radiation 125). Provitamin D3 is an unstable compound and isomerises into 
vitamin D3126. 
The three most important steps in vitamin D metabolism, 25-hydroxylation, 1𝛼-
hydroxylation, and 24-hydroxylation, are all performed by cytochrome P450 enzymes4. 
The initial step of vitamin D metabolism is the hydroxylation of vitamin D3 at position 
C25 of vitamin D3 by CYP27A1 (endoplasmic reticulum) and CYP2R (mitochondrial) 
(25-droxylase), found in the liver to produce 25(OH)D3 (an inactive form of vitamin 
D)125 (Scheme 1). Calcitriol, an active form of vitamin D, is produced by a second 
hydroxylation in the renal distal convoluted tubule at position 1α by CYP27B1, a 
cytochrome P450 monooxygenase, which helps in many of the reactions involved in 
drug metabolism and the synthesis of cholesterol, steroids, and other lipids127.  
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Scheme 1: Vitamin D metabolic pathway 
CYP27B1 contains 508 amino acids and was classified as a class I cytochrome located 
in the mitochondria and is stimulated by PTH, hypophosphatemia, and hypocalcaemia 
and leads to the direct stimulation of the absorption of calcium in the duodenal intestine. 
However, the regulation of CYP27B1 in other tissues is independent of PTH, which 
does not induce the expression of CYP27B1 despite its strong stimulation of CYP27B1 
gene expression in the kidney128, and it is indirectly deactivated by fibroblast growth 
factor (23 FGF-23). Calcitriol deficiency in humans produces defects in bone formation 
and mineralisation, for example, rickets in children and osteomalacia in adults129. 
Recently, a CYP27B1 gene expression has been reported in non-renal tissues and is 
expressed widely in the human body, such as in keratinocytes, lungs, liver, placenta, 
thymus, stomach, brain, lung cancer, breast and skin in normal and cancer tissues,130 
cultured bone cells, macrophages 131, prostate cells, colon and islet cells of the pancreas. 
The function of CYP27B1 in renal and non-renal tissues is to produce calcitriol132 
(Scheme 2).  Subsequently, the VDR binds with calcitriol to enhance the production of 
target genes133. Calcitriol was positively regulated with CYP27B1, and there is negative 
feedback regarding hydroxylation at position C24 of 25(OH)D3 due to the effect of 
CYP24A1 producing polar inactive compounds that are readily excreted from the body 
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(e.g. calcitroic acid)134. Also, 20,23-dihydroxyvitamin D3 [20, 23(OH)2D3] is a 
biologically active metabolite produced by the action of CYP11A1 on calcitriol134. 
Several reports have  illustrated the effect of P450 families on calcitriol to produce 20-
hydroxyvitamin D3 [20(OH)D3], 20,23-dihydroxyvitamin D3, and 17,20,23-
trihydroxyvitamin D3135. 20(OH)D3 and 20,23(OH)2D3, possess many of the properties 
of calcitriol, such as the inhibition of proliferation, the promotion of differentiation, and 
the suppression of inflammation136. 
 
Scheme 2: Metabolic pathway for vitamin D with negative feedback loop 
 
Importantly, defects in vitamin D metabolism include vitamin D deficiency, resistance, 
and vitamin D biosynthesis, which include mutations in CYP27B1 and CYP2R1136 
(Scheme 2). These disorders lead to rickets. There are two forms of vitamin D-
dependent rickets, namely, type 1, also called pseudo-vitamin D deficiency rickets, and 
type 2 rickets, which is due to inactivating mutations in the vitamin D receptor. Failure 
in the positive and adverse regulation between CYP27B1 and CYP24A1 can result in 
tumours, and there are pathologic diseases, where CYP27B1 is elevated, such as in 
basal cell carcinoma or the decreased action of CYP27B1 on active metabolites 
resulting in colon tumour137.  
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1.6 Vitamin D analogues 
The active vitamin D metabolite, calcitriol, has shown cancer activities in vitro and in 
vivo in several cancer types. Hypercalcemia may be the dose-limiting factor for the 
application of calcitriol in the hospital; therefore, efforts have been made to develop 
analogues of calcitriol with antiproliferative and low calcaemic effects. Vitamin D 
analogues are chemically classified as secosteroids, which are steroids with one broken 
bond. In addition, both the synthetic analogues and the natural analogues of vitamin D 
are called vitamers:  
1. Vitamin D1 is a molecular complex of ergocalciferol (D2) and lumisterol in a 
1:1 ratio. 
2. Ergocalciferol is a secosteroid and is the least expensive among the vitamin D 
analogues. As indicated in its name, 9,10 is the seco portion whereas ergosta 
shows the presence of 28 atoms in the carbon skeleton. The half-life is 19 hours, 
and the duration of action is up to 24 weeks138.  
3. Vitamin D4 is an analogue known as 22-dihydroergocalciferol or 9,10-ergosta-
5,7,22-trien-3-ol. 
The primary role of calcitriol is to balance serum calcium and phosphorus 
concentrations. Therefore, designing calcitriol analogues with selective actions against 
certain diseases is a great challenge because newly designed compounds should be 
devoid of plasma calcium-increasing activity139. DeLuca28 reported that C2 analogous 
of vitamin D produced a much more stable transcription complex compared with 
vitamin D analogues without C2 modifications28. In addition, analogues can be 
designed, for example, 2-methylene-19-nor-20S-1𝛼,25-dihydroxyvitamin D3 (2MD), 
which are very selective for their action on bone, with 2MD approximately 90 times 
more active than calcitriol in effecting bone calcium mobilisation140. Moreover, the 
main side effect when treating human osteoblasts with 2MD is the formation of bone 
nodules within two weeks141, 142 (Figure 6). However, incubation of the same cells with 
high concentrations of calcitriol produced slight bone nodules or no change28,143,144.  
Chapter one                                                                                                Introduction 	
	
17 
	
 
Figure 6: Bone nodules caused by 2MD145  
 
Two other analogues modified at C2 (2MP and 2MbisP)146 (Figure 7)) bind well to the 
VDR and are active in transcription, but, even when given orally to animals at high 
doses, are unable to increase serum calcium28. 
  
Figure 7 :Vitamin D analogues modified at C2  
 
1.6.1 19-nor-1α,25(OH)2D2 (19-norD2) (paricalcitol)  
 
Figure 8: Chemical structure of paricalcitol  
OH
OH
HO
12
OHHO
12
2MP
OHHO
  2MbisP
12
HO OH
OH
Paricalcitol
Chapter one                                                                                                Introduction 	
	
18 
	
Paricalcitol differs from calcitriol in that it lacks the exocyclic carbon 19 and has a 
vitamin D2 side chain instead of a vitamin D3 side chain147 (Figure 8). In normal and 
uremic rats, paricalcitol was approximately ten times less calcaemic and phosphatemic, 
but only three times less active in suppressing PTH.  Intravenous paricalcitol was for 
use in dialysis patients in 1998 and for oral use in 2005 and is marketed by Abbott 
Laboratories under the brand name Zemplar®. Hyperparathyroidism is a very common 
complication of chronic renal failure148. For patients on haemodialysis intravenous 
calcitriol achieves active the suppression of elevated PTH levels149. Nevertheless, 
hypercalcaemia is a frequent complication that limits the calcitriol therapy. The newly 
approved synthetic vitamin D analogue paricalcitol appears to represent an efficient 
agent to control the secondary hyperparathyroidism associated with end-stage renal 
disease150. Calcitriol and paricalcitol have the same vitamin D binding protein affinity 
and circulating half-life. Also, paricalcitol is capable of reducing parathyroid gland 
weight while calcitriol is not able to reduce the parathyroid gland151.  
 
1.6.2 1α(OH)D2 (doxercalciferol) 
Doxercalciferol is a prodrug and, like vitamin D3, it must be activated in vivo. 1α
(OH)D2 is reported to be less toxic than calcitriol13. Doxercalciferol has been tested 
directly in patients on dialysis; studies in experimental animal models of renal failure 
have been reported only recently152; oral doxercalciferol was approved for use in 
patients in the US in 1999 under the brand name Hectorol®. 
 
1.6.3 Calcipotriol 
Calcipotriol has been recognised as a successful treatment strategy for psoriasis in 
numerous countries because it can be applied topically to the skin where it undergoes 
biotransformation, thus avoiding systemic circulation153. 
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Figure 9: Chemical structure of calcipotriol  
 
Calcipotriol is composed of a C22-C23 double bond, a C24 hydroxyl group (Figure 9), 
and a cyclopropane ring and has been employed in tumour trials126. This compound has 
been reported to have anti-proliferative and pro-differentiative properties towards 
human keratinocytes and prostate cancer cells154.  
 
1.6.4 OCT (maxacalcitol) 155 
OCT has an oxygen atom instead of carbon at the 22 position126 (Figure 10); it is 
approved for the treatment of psoriasis and secondary hyperparathyroidism in Japan156 
and is now available in Japan under the brand name Ox
 
(Chugai Pharmaceuticals) for 
patients who have CKD with secondary hyperparathyroidism (HPT)157. OCT was found 
to be substantially less hypercalcaemic than calcitriol158,154.  
  
 
Figure 10: Chemical structure of OCT  
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1.6.5 ED-71 (eldecalcitol) 
Eldecalcitol has been found to restore bone mass with minimal effect on serum calcium 
levels126 (Figure 11). ED-71 has a higher affinity for vitamin D binding protein with a 
longer half-life in blood, which may contribute to its particular effect on bone159,160.  
 
Figure 11: Chemical structure of eldecalcitol 
 
1.6.6 Inecalcitol 
Since calcitriol causes hypercalcaemia, the dose that can be given to patients is less 
than the amount ideally required for antitumour activity. Therefore, new analogues of 
vitamin D3 that are potent but less calcaemic have been synthesised and tested. 19-nor-
14-epi-23-yne-1α,25(OH)2D3 (inecalcitol) is a synthetic analogue of vitamin D3 that 
has a 14-epi modification107 (Figure 12).  
 
Figure 12: Chemical structure of inecalcitol  
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This reduction of hypercalcaemic effects might be due to the proprietary chemical 
structure of inecalcitol, a unique conformation of the carbon atom in position 14. 
Consequently, inecalcitol binds to the VDR but in a different conformation than 
calcitriol.  
 
1.7 Cytochromes P450s 
The cytochrome P450 monooxygenases are catalytic enzymes, and they have been 
found in all animals, plants, and microorganisms. Around 12 different types of reaction 
are related to cytochromes. They are present either in the endoplasmic reticulum or the 
mitochondria. Most of the cytochrome P450 enzymes have unknown functions, 
especially in microorganisms. Most human cytochromes belong to the CYP1, CYP2, 
and CYP3 families, and most of them are in the endoplasmic reticulum of the liver137. 
The cytochrome P450 enzymes are proteins that contain a haem (iron-protoporphyrin 
IX) prosthetic group that is the active centre for catalysis. Furthermore, the haem also 
interacts with the thiolate of the conserved cysteine residue that functions as the fifth 
ligand. Cytochrome P450 enzymes can be divided into four classes depending on how 
the electrons from Nicotinamide adenine dinucleotide phosphate (NADPH) are 
delivered to the catalytic site. Class I proteins require both an flavin adenine 
dinucleotide (FAD)-containing reductase and an iron-sulfur redox. Class II proteins 
need only a FAD/ flavin adenine mononucleotide (FMN) containing cytochrome P450 
reductase to transfer electrons. Class III enzymes are self-sufficient and require no 
electron donor; however, cytochrome P450 enzymes from class IV receive electrons 
straight from NADPH. The structural conservation is established in the core of the 
protein around the haem and reveals a common mechanism of electron and proton 
transfer and oxygen activation. The conserved centre is formed by a four-helix (D, E, I 
and L) bundle, helices J and K, two sets of β sheets, and a coil called the ‘meande161. 
Also conserved are the haem-binding loop, containing the most specific cytochrome 
P450 consensus sequence (Phe-X-X-Gly-X-Arg-X-Cys-X-Gly), placed on the 
proximal face of the haem just before the L helix and the conserved Glu-X-X-Arg motif 
in helix K. Moreover, the proximal side of haem is needed to stabilise the core 
structure162. Furthermore, the central part of the I helix, containing another consensus 
sequence considered as a cytochrome P450 signature (Ala/Gly-Gly-X-Asp/Glu-Thr-
Thr/Ser), corresponds to the proton transfer channel on the distal side of the haem163. 
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The haem group in cytochrome P450 enzymes includes four pyrrole rings linked by 
four methyl bridges, which form a tetrapyrrole ring. Pyrrole rings that have numbers 
IV and I relate to a methyl group, and pyrrole rings II and III each contain a vinyl and 
methyl group. 
Cytochrome P450 enzymes are classified as per the rules set by a nomenclature 
committee. These rules depend on amino acid identity and phylogenetic criteria 163. The 
cytochrome P450 enzymes are divided into families; for each family, the prefix CYP is 
linked with a capital letter and a number, for example, (CYP1A1, CYP4A2, CYP7B1, 
etc.) (Table 1). 
 
Table 1: Cytochrome P450 mammalian families164  
 
1.7.1 Catalytic cycle of cytochrome P450 enzymes 
Cytochrome P450 enzymes catalyse different types of reactions, such as 
dehalogenations, oxygenations, deaminations, dealkylations, dehydrogenations and 
isomerisations, and of these, the most vital reaction is oxygenation. The cytochrome 
Family No of subfamily genes Function 
CYP1 2 3 metabolism of foreign chemicals, arachidonic acid, eicosanoids 
CYP2 13 16 metabolism of foreign chemicals, arachidonic acid, eicosanoids 
CYP3 1 4 metabolism of foreign chemicals, arachidonic acid, eicosanoids 
CYP4 5 12 metabolism of fatty acids, arachidonic acid, eicosanoids 
CYP5 1 1  metabolism of thromboxane A2 synthase 
CYP7 2 2 cholesterol, bile acid synthesis 
CYP8 2 2 prostacyclin synthase, bile-acid synthesis 
CYP11 2 3 steroidogenesis 
CYP17 1 1 steroid 17α-hydroxylase, 17/20-lyase 
CYP19 1 1 aromatase to form oestrogen 
CYP20 1 1 unknown 
CYP21 1 1 steroid 21-hydroxylase 
CYP24 1 1 vitamin D3 24-hydroxylase 
CYP26 3 3 retinoic acid hydroxylase 
CYP27 3 3 bile acid biosynthesis, vitamin D3 hydroxylations 
CYP39 1 1 24-hydroxycholesterol-7α-hydroxylase 
CYP46 1 1 cholesterol 24-hydroxylase 
CYP51 1 1 lanosterol 14α-desmethylase 
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P450 enzymes are usually named as mixed-function oxidases or monooxygenases, as 
they insert one atom of O2 into the substrate and one atom of O2 into H2O. When the 
system is uncoupled, the reducing equivalents and oxygen consumed deviate from the 
normal pathway of substrate hydroxylation, resulting in the formation of one or more 
of the side products of oxygen reduction (H2O, H2O2 and O-2)165. The H2O2 and O-2 can 
be converted into the highly toxic OH radicals in the presence of reduced transition 
metals, such as iron in cytochrome P450 enzymes165,166  
The hydroxylation of the saturated R-H bond, the epoxidation of double bonds, the 
oxidation of heteroatoms, dealkylation reactions, and the oxidations of aromatics167 
occur when O2 inserts one of its oxygen atoms into a substrate (S), and transforms the 
second oxygen atom into an H2O molecule, utilising two electrons that are provided by 
NADPH via a reductase protein168.  
 
Cytochrome P450  enzymes have been categorised according to the electron-transfer 
proteins that deliver electrons from NADH or NADPH to the oxygenase protein168; this 
is classified as  class I, which refers to mammalian mitochondrial enzymes involved in 
steroid synthesis and which transfer the electrons by Fe2S2168. 
Class II is placed in the endoplasmic reticulum of liver cells; the electrons are afforded 
by FAD and FMN, which contain reductases and which are involved in drug 
metabolism.  
Estabrook et al.169 observed a cyclic reaction for cytochrome P450 enzymes by 
oxygenation reactions. The reaction starts when the substrate binds to the active site of 
the cytochrome P450 enzyme to form a substrate ferric haem complex,170. NADPH-
cytochrome P450 reductase, which holds two flavin prosthetic groups, can receive two 
electrons from NADPH and concurrently transfer one electron each to two different 
cytochrome P450 enzymes171. The first electron works on Fe in the cytochrome P450 
enzyme, which is reduced to FeII, and O2 binds to the cytochrome P450 complex. A 
second electron is provided to the cytochrome P450 enzymes from NADPH-
cytochrome P450 reductase (the proportion of NADPH-cytochrome P450 reductase to 
cytochrome P450 enzymes in liver microsomal is around 19:1)171 and leads to the 
generation of H2O or H2O2 (Figure 13).	
S + O2 + 2e- + 2H+ Cytochrome P450 SO + H2O
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Figure 13:  Catalytic cycle of cytochrome P450 enzymes. RH is substrate, and ROH is product.  
 
 
Hrcay and O’Brien172 illustrated the reductive activity of cytochrome P450 enzymes, 
whereby the haem protein decreases and detoxifies biological peroxides such as H2O2, 
lipid hydroperoxides, steroid hydroperoxides, and organic peroxides. The cytochrome 
P450 enzymes use H2O2 and other peroxy molecules as oxygen providers to catalyse 
the oxygenation of substrates. The cycle begins with cytochrome P450 haem FeIII(A), 
R + O2 + NADPH + H+ + 2e- RO + H2O +NADP+
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and regenerates according to the following steps. In the first step, the substrate binds to 
low spin ferric cytochrome P450 enzymes and forms a high spin ferric cytochrome 
P450-substrate complex, which is reduced to FeII state (B), with the first electron 
provided by NADPH through redox protein partners. The reduction of ferric 
cytochrome P450 enzymes depends on the existence of the substrate and can be linked 
with substrate-induced changes in the spin state and the oxidation reduction potential. 
In the second step, ferrous haem iron binds O2 to generate a stable nucleophilic 
ferrisuperoxo anion complex 
 
Next, in the third step, the move of a second electron produces a super nucleophilic 
dinegatively charged ferriperoxo intermediate(D) containing one (-) on the oxygen and 
a second (-) delocalised above the whole cysteine. 
 
The above intermediate has sometimes been inaccurately described as an oxygen 
dianion complex 
 
In the fourth step, a proton is added to O2 to generate a ferrihydroperoxo intermediate 
(-Cys–FeIII–OOH) (E) holding one (-) cysteine. In the fifth step, a second distal 
protonation produces a transient iron oxo–H2O adduct (FeIII–OOH2), which directly 
dissociates by a heterolytic O–O bond and generates H2O with a 𝜋	radical FeIV oxo 
intermediate as (Por.+ FeIV=O) (F). In the sixth step, the Por+ FeIV=O oxotransfer entity 
moves O2 to the substrate, creating a product (AO) and a renewed ferric cytochrome 
P450. In the fifth step, the formal oxidation state of the cytochrome P450 iron centre 
increases from FeIII to FeV. The steps 2A and 3A are shown to be H2O2 producing 
pathways. Furthermore, ferric cytochrome P450 FeIII is able to react with oxotransfer 
(RO) and XOOH to produce the Por.+ FeIV=O (F) through the shunt pathway (step 7). 
The H2O2 produced in step 3A of the cytochrome P450 cycle can be changed to hydroxy 
with the availability of ferrous iron through the Fenton reaction (Figure 14).  
  
 
 
(FeIII O-2 )
(-Cys FeIII O-2)
(FeIII O2-2)
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Figure 14:  General cytochrome P450 catalytic cycle 
 
1.7.2  General Function of cytochrome P450 enzymes 
Cytochrome P450 enzymes help to metabolise large numbers of drugs by phase I 
metabolism, such as oxidation, reduction, hydroxylation, and demethylation, and so 
convert medicines into generally more water-soluble compounds that are easily 
eliminated. This metabolism is also called functionalisation metabolism. Cytochrome 
P450 enzymes are also responsible for thromboxane A2, cholesterol, and steroid 
synthesis. Cytochrome P450 enzymes are distinguished from other proteins, such as 
collagen, insulin, and albumin, by their capacity to catalyse naturally important 
chemical reactions173. Cytochrome P450 enzymes are most commonly found in the 
liver, kidneys, small intestine, and lungs174. Cytochrome P450 enzymes work as 
cofactors and support the hydroxylation of carbon atoms of methyl groups, methylene 
carbons, and aromatic rings to hydrophilic metabolites. The human cytochrome P450 
superfamily includes 57 genes. These genes code for enzymes that can have a function 
in the metabolism of medicines and biochemical compounds. Currently, there are more 
than 270 different cytochrome gene families, in which 18 are noted in mammals161. In 
addition, cytochrome P450 molecules have a role in antibiotic synthesis from fungi, 
that is, herbicide resistance in plants, as well as in multiple biosynthetic and metabolic 
pathways in bacterial species175. For example, the biotechnological purposes of the 
cytochrome P450 enzymes include the bioremediation of herbicide-contaminated soils, 
such as the catalysis of various chemical reactions, which are costly when achieved by 
A
FeII
BPor
.+FeIV=O
-Cys-FeIIIOOH
E
-Cys-FeIIIO2-
D
FeIIIO2-
C
FeIII
O2- H2O2		+	O2-
O2-
2H+
H2O2
2H+
e-H+
H+-H2O
-AO e-
O2-H+
Step	1
Step	2
Step	3
Step	5
RO
Step	2A
Step	3A
F
Chapter one                                                                                                Introduction 	
	
27 
	
laboratory procedures. Furthermore, the synthesis of prostaglandins and polyethylene 
can be generated only by the cytochrome P450 molecule. The cytochrome P450 
molecule also has many medical applications, such as the production of the anticancer 
drug, synthetic progesterone; hydrocortisone; vitamin D precursors; and antibiotics. In 
addition, human cytochrome P450 enzyme deficiency leads to monogenic disorders 
related to steroid hormones, cholesterol, eicosanoids, and vitamin D3. As a result, the 
main function of cytochrome P450 molecules can be summarised as follows:  
1. Detoxification - many substrates are lipid-soluble and affect the metabolism of 
foreign chemicals. 
2. Metabolism of arachidonic acid, and eicosanoids. 
3. Metabolism of fatty acids and eicosanoids, which are essential in eukaryotic 
sterol biosynthesis.   
4. Production of steroid hormones, vitamins A and vitamin D. 
 
1.7.2.1 Metabolism of foreign chemicals 
Foreign chemicals include medicines, secondary metabolites from plants or fungi 
consumed with food, and pollutants, for example, polycyclic aromatic hydrocarbons, 
arylamines, the ingredients of industrial mixtures, pesticides, and cigarettes. Human 
cytochromes like P450 enzymes, which metabolise xenobiotics, are found especially in 
CYP1, CYP2, CYP3, and CYP4 164. Class I and class II cytochrome P450 enzymes 
from all organisms contribute to the detoxification or, occasionally, the activation of 
xenobiotics. Besides, class II cytochrome P450 enzymes are the most common in 
eukaryotes. Type II cytochrome P450 enzymes from plants are involved in the 
biosynthesis or catabolism of a range of hormones176. Furthermore, cytochrome P450 
enzymes are the major site of drug metabolism, mainly hydroxylation reactions in the 
presence of particular electron transport systems and molecular oxygen177. Therefore, 
the cytochrome P450 enzymes play an important role in maintaining the therapeutic 
level of a drug in the body174. However, most side effects of medicines are related to 
the cytochrome P450 enzymes. The side effects can result in more than one effect, such 
as drug-drug interactions. Furthermore, the drug-induced toxicity can also result from 
reactive oxygen species generated during drug metabolism, due to the uncoupling of 
oxygen utilisation and drug hydroxylation, which is a problem with many drugs165.  
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1.7.2.2 Metabolism of arachidonic acid, and eicosanoids  
Cytochrome P450 enzymes undoubtedly have twin purposes; these can be seen in the 
cytochrome P450 enzymes, which metabolise arachidonic acid, which is changed into 
more than 100 eicosanoid metabolites178. The metabolism of arachidonic acid appears 
in different tissues, such as the liver, the kidneys, and the heart179. The cytochrome 
P450 enzymes work on arachidonic acid metabolism in two definite ways: first, by the 
ω-hydroxylase, and second, by epoxygenase pathways180. Prostaglandins and 
leukotrienes, which are products of arachidonic acid metabolism, are potent mediators 
of inflammation. In addition, the prostaglandins D2, F2, and E2 have several functions 
including vasoconstriction, bronchial dilation/constriction, smooth muscle contraction, 
allergic response, inhibition of platelet aggregation, and pain response. Furthermore, 
CYP5A1 (the thromboxane A2 synthase) and CYP8A1 (prostacyclin synthase) have 
opposite functions in blood clotting. Thromboxane A2, the product of the CYP5A1 
enzyme, reduces cyclic AMP levels in platelets and so stimulates their aggregation181. 
However, CYP8A1 raises intracellular cyclic AMP concentrations and inhibits platelet 
aggregation. Mutations in the CYP5A1 or CYP8A1 genes are thus predicted to lead to 
clotting and inflammatory disorders, including coronary artery disease and pulmonary 
hypertension182. 
 
1.7.2.3 Cholesterol metabolism, bile acid biosynthesis and steroid metabolism 
Cytochrome P450 enzymes have a function for changing acetate into sterols and bile 
acids181. CYP51A1 is essential for synthesising cholesterol183. In addition, the synthesis 
of bile acids from cholesterol was found in the main catabolic pathway for the clearance 
of cholesterol in mammals184. Furthermore, sexual differentiation of the genital ridge 
in early embryogenesis is mainly regulated by P450 enzymes involved in steroid 
hormone synthesis, i.e. CYP11A1, CYP11B1, and CYP11B2 182. Cortisol, testosterone, 
and oestrogen are synthesised by CYP17A1; however, CYP19A1 changes androgen 
into oestrogens. The hydroxylation of steroid precursors at C21 is an important point in 
the production of glucocorticoids and mineralocorticoids, which are catalysed by 
CYP21A2. Any mutations that occur, which interrupt 21-hydroxylation, cause more 
than 90% of congenital adrenal hyperplasia, which can be caused by mutations in 
CYP11A1, CYP11B1, CYP11B2, CYP17A1 or CYP19A1 (Figure 15). 
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Figure 15: Pathways and cytochrome P450 enzymes involved in the biosynthesis and metabolism 
of different sterols 
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1.7.2.4 Retinoic acid hydroxylation  
Retinoic acid (RA), the active form of vitamin A, is vital during vertebrate 
development; it operates through many retinoic acid receptors and retinoid X receptors 
and plays an important role in development, differentiation, and homeostasis inside the 
human body. Retnoic acid is metabolised primarily by CYP26A1, however CYP26B1 
and CYP26C1 also have roles in the metabolic pathways of all-trans-RA and 9- and 
13-cis-RA. 
1.7.2.5 Vitamin biosynthesis 
Vitamin D is previously described in detail in this Chapter.   
 
 
1.7.3 25-hydroxyvitamin D3-24-hydroxylase (CYP24A1) 
CYP24A1 was recognised as the main enzyme responsible for calcitriol catabolism;  
CYP24A1 works in balance with CYP27B1, which is responsible for changing 25-
hydroxyvitamin D3 to calcitriol in the kidney185 (Scheme 2). CYP24A1 was first 
described in the early 1970s186, and the enzyme activity is the result of a combination 
of three constituents: ferredoxin, ferredoxin reductase, and CYP24A1187. CYP24A1 
catalyses the conversion of calcitriol into 24-hydroxylated products, which are 
metabolised further to produce calcitroic acid, identified as a biliary catabolite188. Most 
species of CYP24A1 have Ala326, resulting in 24-hydroxylation to calcitroic acid 
while embryonic organisms have Gly326, resulting in mainly 23-hydroxylation to give 
a 23,26-lactone product189,190. Annalora et al.190 elucidated the crystal structure of rat 
CYP24A1, which revealed a canonical cytochrome P450 structure of helices and 𝛽-
sheets surrounding a prosthetic haem group and a substrate binding cavity (Figure 16). 
 
Figure 16: CYP24A1 model191 
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The CYP24A1 gene is found at position 13 on chromosome 20 long arms (q). The 
interaction of calcitriol with the VDR, followed by the binding of the calcitriol-VDR 
complex to retinoid-X-receptor regulates the CYP24A1 enzyme91. The selective 
inhibition of the CYP24A1 enzyme decreases the catabolism rate and prolongs the 
serum calcitriol half-life. This increases the endogenous levels of calcitriol and 
enhances the cells exposure to calcitriol. More efficacy and inhibition potency could be 
achieved with ligands designed to target the CYP24A1 binding pocket191. Thus, the 
development of CYP24A1 enzyme inhibitors based upon the calcitriol structure is a 
feasible option191.  
Calcitriol is transformed first into 1α,23S,25-(OH)3D and then into 1α,23S,25,26-
(OH)4D by successive hydroxylations at carbon 23 and carbon 26192. Then, it is 
transformed into 1,25-(OH)2D-26,23-lactol, which is subsequently metabolised to the 
final product 1𝛼,25-(OH)2D-26,23-lactone, which is then eliminated by the 
kidney193,194. The same steps apply to 25-(OH)D, which is first transformed into 23,25-
(OH)2D, then 23,25,26-(OH)3, and is then converted into 25-(OH)D-26,23-lactol and 
finally, 25-(OH)D-26,23-lactone193. The pharmacological effect of the C23- pathway 
metabolites remains slightly doubtful, but it is assumed that the lactone product could 
work as a VDR antagonist126. The second hydroxylation pathway for calcitriol by 
CYP24A1 at C24, includes five individual enzymatic steps and finally produces the 
metabolite calcitroic acid. Calcitriol is first hydroxylated at carbon 24 to produce 
1,24,25-(OH)3D; that is then converted to 24-oxo-1𝛼,25-(OH)2D. The next step is the 
hydroxylation of carbon 23 providing 24-oxo-1𝛼,23,25-(OH)3D. The oxidative 
cleavage of the bond between C23 and C24 leads to the generation of 24,25,26,27-
tetranor-1𝛼,23-(OH)2D; this is converted to calcitroic acid, which is eliminated in the 
bile126,194 (Scheme 3). 
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Scheme 3: Catabolism pathway of calcitriol 
 
1.7.4 CYP27B1 
CYP27B1 is a gene located on chromosome 12 that encodes 25-hydroxyvitamin D3 1
α-hydroxylase, a vitamin D-activating enzyme that plays an essential role in vitamin 
D metabolism in humans. CYP27B1 has 508 amino acids with a molecular mass of 
around 55 kDa195.  
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Entry of 25-(OH)D into the proximal renal tubular cells requires receptor-mediated 
uptake by a vitamin D binding protein (DBP), degradation of DBP by legumain, and 
endocytic internalisation and translocation of 25-(OH)D to mitochondria 196. Megalin, 
a member of the low density lipoprotein receptor family, is essential for the 
reabsorption of filtered DBP-bound 25 vitamin D197. Several considerations are related 
to the tight regulation of CYP27B1 enzyme expression and activity in the kidney. These 
include calcium, PTH, calcitonin, growth hormone (GH), insulin-like growth factor-1 
(IGF-I), and fibroblast198. CYP27B1 activity is regulated by PTH and calcitriol, and the 
expression of CYP27B1 mRNA is regulated by intracellular Cyclic adenosine 
monophosphate (cAMP)199. A homology model of human CYP27B1 based on the 
crystal structure of rabbit CYP2C5 as a template200 has been reported, and the sequence 
identity between CYP2C5 and CYP27B1 is 23.5 %200.   
 
1.7.5 CYP24A1 inhibitors 
Selective inhibitors of CYP24A1 might be useful to enhance the anticancer activities 
of calcitriol, and they have the potential to be used clinically for cancer treatment. In 
addition, there is also a link between increased CYP24A1 levels in diseased states such 
as cancer, which suggests that CYP24A1 may be a useful therapeutic target152. 
However, while the inactivation of CYP24A1 leads to hypercalcaemia, many cancer 
cell lines display elevated levels of CYP24A1 expression as they progress to more 
tumourigenic phenotypes, suggesting that these tumours have an increased ability to 
catabolise calcitriol. Subsequently, several CYP24A1 inhibitors have been designed for 
the treatment of diseases associated with elevated vitamin D catabolism. However, the 
challenge in the design of CYP24A1 inhibitors is designing CYP24A1 inhibitors 
selective over CYP27B1. CYP24A1 inhibitors could be classified into two main 
categories: azole and non-azole inhibitors 
 
1.7.5.1 Vitamin D derivatives as CYP24A1 inhibitor 
Chiellini et al.201 designed two 19-nor-1-OH-vitamin D type analogues containing the 
azole VIMI or CPA1 (cyclopropylamine) in the side chain201 (Figure 17). Both VIMI 
and CPA1 are potent competitive inhibitors of CYP24A1. However, VIMI showed a 
4.3-fold moderate selectivity for the inhibition of CYP24A1 over CYP27B1 whereas 
CPA1 showed 80 times more selectivity in inhibiting CYP24A1 over CYP27B1201.  
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                                        VIMI                                      CPA1 
Figure 17: Vitamin D derivatives as CYP24A1 inhibitor 
 
Posner et al.202,203 reported sulfone and sulfoxime derivatives of calcitriol, CTA018 and 
CTA091, respectively (Figure 18). CTA091 is classified as a pure CYP24A1 inhibitor 
with low calcaemic activity and an IC50 of 6.5 ± 0.2 nM, which is 40-fold more potent 
than ketoconazole202. Studies with lung cancer cells have shown that CTA091 increases 
the stability of calcitriol by slowing its catabolism and enhancing the half-life of 
calcitriol. The antiproliferative effects of calcitriol were improved about 45-fold when 
it was co-administered with CTA091 in vitro, indicating that they can work 
synergistically106. Unlike CTA091, the sulfone analogue, CTA018, is a mixed 
CYP24A1 inhibitor/VDR agonist, as it binds to the VDR, although with a 15-fold lower 
affinity than that of calcitriol.204 CTA018 is also a low calcaemic inhibitor of CYP24A1 
and is ten times more potent than ketoconazole. When administered to rats with induced 
CKD, both CTA091 and CTA018 suppressed parathyroid hormone levels and increased 
serum calcitriol202. Thus, CTA018 is a selective drug candidate to treat CKD and 
hyperphosphatemia205 . 
 
                            CTA018                                   CTA091 
Figure 18: Sulfone and sulfoxime derivatives  
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1.7.5.2 Cyclopropylamine derivativas 
Hanzlik et al.206 reported cyclopropylamine derivatives can be used as CYP24A1 
inhibitors. N-benzyl-N-cyclopropylamine (Figure 19) is a suicide substrate for 
cytochrome P450 enzymes; in addition, a 1’-methyl-substituted analogue of 1,N-(1’
- methylcyclopropyl)amine lacking the hydrogen atom at the position of cyclopropyl 
group was also capable of inactivating CYP24A1207.  
 
Figure 19: N-benzyl-N-cyclopropylamine 
 
1.7.5.3 Azole derivatives as CYP24A1 inhibitor 
Azole-based compounds can inactivate a broad range of cytochrome P450 enzymes by 
binding to the haem moiety present in the enzyme active site. Azole compounds have 
a nitrogen heterocyclic ring, frequently an imidazole or triazole, and it is through a 
nitrogen of the heterocyclic ring that binding occurs with the haem iron. Ketoconazole 
and liarozole were shown to extend the half-life of calcitriol in prostate cancer cells in 
vitro and in vivo208,202. Nevertheless, azole compounds have the possibility to cause 
significant systemic side effects due to the poor selectivity among cytochrome P450 
enzymes. Thus, the development of novel CYP24A1 inhibitors with good selectivity 
and low toxicity are necessary209. Ketoconazole is an azole compound with CYP24A1 
inhibitory activity and is a nonselective inhibitor for CYP24A1 and CYP27B1210,211. 
Schuster et al.212 described the azole compounds (Table 2); which inhibit CYP24A1 
and CYP27B1. Chiellini et al.201 reviewed the non selective cytochrome inhibitor 
ketoconazole, which has been shown to inhibit CYP24A1 and act synergistically with 
vitamin D analogues in cell cultures. In addition, Peehl et al.213 reported that the 
combination of 0.1 µg/mL ketoconazole potentiated antitumor activity of calcitriol 50-
fold and EB 1089 ( vitamin D analogue) 10-fold.  Ly et al.214 showed that liarazole has 
also been shown to inhibit CYP24A1 and act synergistically with calcitriol in the 
treatment of prostate cancer. The development of azole type inhibitors of CYP24A1 
was started in Novartis in the early 1990s201. Around 400 different azole inhibitors have 
been evaluated, using primary human keratinocytes as a model system. R-(-)VID400 
displayed potent selective CYP24A1 inhibitor activity, and so it was chosen for 
development in the indication of psoriasis215,216. Aboraia et al.210 illustrated how N-(2-
N
H
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(1H-imidazol-1-yl)-2-phenylethyl)arylamides were evaluated for their inhibitory 
activity against human CYP24A1 and IC50 ranging from 0.3 to 0.72 µM compared with 
the standard ketoconazole 0.3 µM (Figure 20). 
 
Figure 20: N-(2-(1H-imidazol-1-yl)-2-phenylethyl)arylamides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
H
O
N
N
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Where R:
R1 = H, NO2
R2 = H, OCH3
R3 = H, F, Cl
R3
O
R1
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Table 2: Example of azole non selective and selective inhibitors of CYP24A1215 
 
1.7.5.3.1 Styryl azole derivatives as CYP24A1 inhibitor 
Aboraia et al.210 found that the styryl nucleus plays an important role in improving 
CYP24A1 inhibitor activity191. Ferla et al.211 synthesised the styryl indole imidazole 
derivatives and styryl indole sulphonyl derivatives (Table 3). The imidazole styryl 
indole derivatives were found to be potent inhibitors of CYP24A1 with IC50 ranging 
between 0.19 and 0.52 µM, which is more active than the standard ketoconazole (Figure 
20). In addition, the sulfonate and sulfonamides displayed only weak CYP24A1 
Compound Chemical structure IC50 (nM) 
CYP27B1 CYP24A1 
Ketoconazole 
 
28.3 126.0 
R-(-)VID400 
 
616.1 15.2 
SDZ-286907 
(R) 
 
1696.9 34.9 
SDZ-287871 
(R) 
 
1271.6 29.9 
VAB636 
(R) 
 
266.1 5.08 
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inhibitory activity, thus indicating the importance of the imidazole azole group in 
interacting with the active site haem moiety. In general, styryl indole imidazole 
derivatives and styryl indole sulphonyl derivatives displayed a small selectivity for 
CYP24A1 over CYP27B1, which was comparable with that of ketoconazole          
(Figure 21). 
Chemical structure Chemical structure 
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Table 3: styryl indole imidazole derivatives and styryl indole sulphonyl derivatives 
 
 
Figure 21: IC50 data for styryl indole imidazole derivatives and styryl indole sulphonyl 
derivative against CYP24A1 
 
 
Ferla et al.191 demonstrated that styryl derivatives had stronger inhibitory activity, 
(Figure 22) with an IC50 value of 0.11 µM, than ketoconazole (IC50 = 0.47 µM) against 
human CYP24A1 (Table 4). A structure-activity relationship study that investigated the 
reduction of the styrene double bond resulted in a reduced level of inhibitory (IC50 
= 0.51 µM), and changing the double bond for a sulfonamide group resulted in a more 
remarkable decrease in activity (IC50 = 1.3 µM).  
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Figure 22: Styryl imidazole derivatives 
 
 
 
 
 
 
 
 
 
 
 
Table 4: IC50 data for CYP24A1 and CY27B1 
 
1.7.5.4 Tetralone derivative as CYP24A1 inhibitor 
Non-azole compounds without the nitrogen heterocycle bind within the active site 
including hydrogen bonding and hydrophobic interactions. Nevertheless, the strength 
of these interactions is mostly less than that observed with azole compounds resulting 
in less potent inhibitors. The tetralone derivatives enhance the antiproliferative action 
of calcitriol. The ability of tetralones to inhibit the CYP24A1 enzyme is less than that 
of their azole. However, tetralone derivatives have more selectivity through their 
binding to the active site; the enzyme inhibitory effect of tetralone derivatives is 
mediated through hydrogen bonds and hydrophobic interactions with the active site of 
the enzyme. Yee and Simons217 reported that benzylidenetetralone derivatives were 
found to be very weak inhibitors (IC50 20 to >100 µM), whereas the 2-benzyltetralone 
derivatives showed promising inhibitory activity (IC50 0.9 µM for the most active 
derivative) compared with ketoconazole (IC50 20 µM). Also, Aboraia et al.218 
demonstrated that tetralone derivatives displayed potent inhibitory activity compared 
with ketoconazole (Figure 23).  
N
H
O
N
N
R1
R2
R3
Where R:
a = R1 = H,         R2 = H,        R3 = H
b = R1 = H,         R2 =  F,        R3 = H
c = R1 = H,         R2 = OCH3, R3 = H
d =  R1 = OCH3,  R2 = H,        R3 = OCH3
e = R1 = OCH3,  R2 = OCH3, R3 = OCH3
Cpd 
IC50 (μM) 
CYP24A1 CYP27B1 
a 0.40 0.50 
b 0.26 0.60 
c 0.34 0.24 
d 0.11 0.16 
e 0.14 0.33 
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Figure 23: Tetralone derivative 
 
 
Yee et al.219 illustrated that 2-(4-hydroxybenzyl)-6-methoxy- 3,4-dihydro-2H-
naphthalen-1-one (Figure 24) was found to be a potent inhibitor (IC50 3.5 µM); indeed, 
it was shown to be a more potent inhibitor than standard ketoconazole. 
 
Figure 24: 2-(4-hydroxybenzyl)-6-methoxy- 3,4-dihydro-2H-naphthalen-1-one 
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1.8 Aims and Objectives 
Therapy using calcitriol is limited owing to the short duration of action; 25OHD3 has a 
life of two weeks, and the half-life of calcitriol has been measured in hours220, due to 
CYP24A1, which metabolises calcitriol to inactive products. The aim of this research 
is to design and synthesise novel inhibitors of CYP24A1 to enhance the endogenous 
levels of circulating calcitriol. In addition, it is important to develop compounds that 
are selective for CYP24A1 over CYP27B1 so that the generation of calcitriol itself is 
not blocked (Figure 25).  
25-hydroxyvitamin D3       1𝜶,25-hydroxyvitamin D3           1𝜶,24,25-trihydroxyvitamin D3 
Figure 25: Site of CYP24A1 inhibitor action 
 
Although potent CYP24A1 inhibitors have been described, selectivity versus CY27B1 
has proved more challenging. In order to understand the requirements of inhibitor 
binding to the enzyme-active site, it would be useful to have a 3D structure of both 
human CYP24A1 and CYP27B1. However, to date, no human crystal structures are 
available for either of these enzymes. Therefore, a homology model for CYP24A1 has 
been developed and published191.  In this project, a homology model of CYP27B1 will 
be developed, validated, optimised, and subsequently analysed for both CYP24A1 and 
CYP27B1 enzyme active sites. Identification of the differences in both substrate 
binding and active site architecture will be used to assist in the design of selective 
inhibitors.  
Previously, screening of the SPECS database221 has identified some promising 
CYP24A1 inhibitors with moderate inhibitory activity222 (Figure 26). Two of these 
compounds (Lead 2 and 3) will be taken as lead compounds for further development. 
In addition, Ferla et al.191 investigated how the imidazole styrylbenzamide derivatives 
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(lead 3) furnished optimal activity (Figure 23). 
 
Lead 1 IC50 = 4.2 µM                        Lead 2 IC50 = 5.5 µM                             Lead 3 IC50 = 0.4 µM 
Figure 26: CYP24A1 inhibitors with moderate inhibitory activity 
 
Owing to the lack of potential CYP24A1 inhibitors in the market, the development of 
potent and selective inhibitors after the modification of Lead 1, Lead 2 and Lead 3 was 
investigated. 
Firstly, the study investigated the modification of lead 1222, specifically through (i) 
replacement of the dimethyl pyrazole with a basic heterocycle to enhance binding 
interaction with the haem moiety, (ii) substitution of the benzene rings to explore 
structure-activity relationship, and (iii) variation in the length of the linker to determine 
optimum length to allow complete filling of the hydrophobic pocket of the CYP24A1 
active site (Figure 27). 
 
Figure 27: Modifications of lead 1 compound 
 
Secondly, the study investigated the modification and development of Lead 2222, 
specifically through (i) replacement of the phenyl with a basic heterocycle to enhance 
the binding interaction with the haem moiety, (ii) simplifying of the bromophenyl with 
an unsubstituted phenyl ring, (iii) the addition of phenyl substituents to dipyrazole rings 
or replacement of the dipyrazole rings with a basic heterocycle to allow complete filling 
in the active site of the CYP24A1 active site, and (iv) variation of the ether position to 
allow complete filling in the active site of CYP24A1 (Figure 28). 
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Figure 28: Modification of lead 2 compound 
Finally, the study investigated the modification and development of Lead 3191, 
specifically through (i) substitution of the phenyl ring of imidazole to explore the 
structure-activity relationship, (ii) substitution of the phenyl ring of styrene to explore 
the structure-activity relationship, and (iii) alteration of the alkene position to allow 
complete filling of the active site of the CYP24A1 (Figure 29). 
Figure 29: Modification of lead 3 compound 
The main objective of the research can be summarised as follows: 
1. Development of a theoretical CYP27B1 homology model based on
homologous templates using Molecular Operating Environment
(MOE) and validation of the model using Verify 3D, Errat, ProSA
and Ramachandran plot
2. Optimisation of the model using molecular dynamics by using
Maestro software
3. Further validation of the optimised CYP27B1 model by docking
with the natural substrate (25-hydroxyvitamin D3); analysis of the
enzyme active sites of both CYP27B1 and CYP24A1 using
described inhibitors (both selective and non-selective) to identify
any differences in the two proteins
4. Chemical synthesis for modified Lead 1, 2 and 3 and evaluation in
vitro of the development of lead 1, lead 2 and lead 3 regarding their
inhibitory activities against CYP24A1 and CYP27B1 enzymes.
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2 Molecular modelling 
2.1 General consideration 
The improvement of new medications is undoubtedly a very complex and demanding 
interdisciplinary process. Driven by the joint endeavour of the pharmaceutical 
companies, biotech companies, and academia, the approaches and methodologies used 
in drug design have changed after some time, exploiting and driving new technological 
advances to solve the various bottlenecks found along the way. Today, the field of 
medication improvement might appear to be riper than any time in recent memory, with 
limitless measures of data made accessible from molecular modelling. There is no 
single answer for a drug design difficulty. The suitable test strategies or computational 
techniques to be utilised will rely upon the qualities of the framework itself and the data 
available223,224. 
Molecular modelling can be considered as a range of computerised procedures based 
on hypothetical science techniques and experimental data that can be utilised to analyse 
molecules to predict molecular and physicochemical properties225. Molecular 
modelling serves as a bridge between theory and experiment. In addition, molecular 
modelling and drug design are economical and save time. During the past two decades, 
research centres have changed the method of research to generate novel bioactive 
molecules by using advances in molecular modelling techniques through identification 
of enzymes using X-ray crystallography, after which, drugs were designed which could 
bind with enzymes as ligands. Moreover, molecular modelling helps to compare 
experimental results with theoretical predictions for the model.  Molecular modelling 
also helps to understand and to interpret experimental observations and provide data 
not available from genuine experiments. Therefore, molecular modelling can be 
characterised as the generation, manipulation, calculation, and expectation of 
reasonable molecular structures and associated physicochemical as well as biochemical 
properties using a computer. However, the traditional method of drug discovery is the 
experimental screening of huge quantities of chemicals to find out their biological 
action by enrolling hundreds of compounds. Unfortunately, it is an expensive and time-
consuming method. Furthermore, molecular modelling is a computational technique 
used in pharmaceutical research to design and discover potentially useful proteins, 
which are visualised as three dimensional structures. There are two types of molecular
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modelling studies in drug design: either the structure of the target is known or 
unknown226.  
Proteins are essential to life, as they play critical roles in most biological processes. X-
ray crystallography is the main method for determining the structure of proteins, 
including the ability to elucidate how they work based on their three dimensional 
structures to study active sites and the interaction between the protein and the ligand.  
Unfortunately, the majority of proteins are currently difficult to crystallise or are too 
large for NMR studies. This can be a time-consuming process, and it will succeed only 
if it is possible to find suitable conditions for growing crystals. This can therefore easily 
become a bottleneck in drug design projects227. The protein data bank (PDB) is an 
available source of protein crystal structures, but only 12 % of all known proteins are 
available as three dimensional structures228. Homology modelling is used for the 
determination of a protein structure based on the crystal structure of a protein 
(template), which has a similar amino acid sequence.  
Human CYP27B1 and CYP24A1 are part of the huge cytochrome P450 (CYP) 
superfamily; both enzymes are integrally placed in the inner mitochondrial membrane, 
and, as for almost all mammalian CYPs, structural data from X-ray crystallography or 
NMR analyses is even now inaccessibility. Currently, the aim of this chapter is to 
develop a human CYP27B1 homology model as a tool in the design of a selective 
inhibitor of vitamin D metabolism, specifically to aid in the design of chemical 
compounds with a selective inhibition of CYP24A1 and not the inhibition of CYP27B1, 
which inactivates the active form of vitamin D, calcitriol. A model of human CYP24A1 
using the rat CYP24A1 crystal structure as a template191 has previously been described 
by our group. To assist in the design of a selective CYP24A1 inhibitor, a CYP27B1 
homology model was required. 
2.2 Homology modelling 
Three-dimensional protein structures are of extraordinary value for the rational design 
of a wide range of biological experiments, for example, site-coordinated mutagenesis 
or the structure-based discovery of particular inhibitors. Nevertheless, the number of 
structurally characterised proteins is small compared with the number of known protein 
sequences. Different computational strategies for modelling three-dimensional 
structures of proteins have been produced to conquer this restriction. Since the number 
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of possible folds in nature appears to be limited, homology modelling has proven to be 
the method of choice to generate a reliable 3D model of a protein from its amino acid 
sequence229. Homology modelling mixes sequence investigation and molecular 
modelling to predict three-dimension structures. Homology modelling depends on the 
identification of known protein structures with sequences similar to the structure of the 
query protein. Ideally, the similarity between a query sequence and the template 
sequence should be above 20 %230. The sequence alignment and template structure are 
used to produce a homology model; several stages are involved in the homology 
process. First, one or more appropriate structural templates are identified from the 
PDB228. The second stage aligns the query sequence with the template sequence. The 
third stage develops the general skeleton from the alignment. Finally, the homology 
model is subject to validation. 
 
2.3 Identification of a template 
The (Expert Protein Analysis System) (ExPASy) was used to obtain the amino acid 
sequence of the target gene human CYP27B1. ExPASy was obtained from the Swiss 
Institute of Bioinformatics (SIB), which contains a variety of information regarding 
proteins223. Using the UniProt KB/TrEMBL tool from the ExPASy server and a search 
target of the protein CYP27B1 showed 79 hits for many different organisms. The 
complete human protein sequence (CYP27B1 human) was selected. 
The amino acid sequence for human CYP27B1 has entry number O15528, and it is also 
known as CYP 1α–hydroxylase223 (Table 5). CYP27B1 is compossed of 508 amino 
acids (Figure 30).   
Table 5: CYP27B1 Human (O15528) 
Entry name Accession number 
Entry state Entry history 
CP27B1 
Human 
O15528 
Reviewed 
(UniPortKB/Swiss-
Port) 
Integrated into UniPortKB/Swiss-Prot 
July 15, 1998. 
Last sequence update Jan. 1,1998 
Last modified February 19, 2014 
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>sp|O15528|CP27B_HUMAN 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial OS=Homo sapiens GN=CYP27B1 PE=1 SV=1 
MTQTLKYASRVFHRVRWAPELGASLGYREYHSARRSLADIPGPSTPSFLAELFCKGGLSR 
LHELQVQGAAHFGPVWLASFGTVRTVYVAAPALVEELLRQEGPRPERCSFSPWTEHRRCR 
QRACGLLTAEGEEWQRLRSLLAPLLLRPQAAARYAGTLNNVVCDLVRRLRRQRGRGTGPP 
ALVRDVAGEFYKFGLEGIAAVLLGSRLGCLEAQVPPDTETFIRAVGSVFVSTLLTMAMPH 
WLRHLVPGPWGRLCRDWDQMFAFAQRHVERREAEAAMRNGGQPEKDLESGAHLTHFLFRE 
ELPAQSILGNVTELLLAGVDTVSNTLSWALYELSRHPEVQTALHSEITAALSPGSSAYPS 
ATVLSQLPLLKAVVKEVLRLYPVVPGNSRVPDKDIHVGDYIIPKNTLVTLCHYATSRDPA 
QFPEPNSFRPARWLGEGPTPHPFASLPFGFGKRSCMGRRLAELELQMALAQILTHFEVQP 
EPGAAPVRPKTRTVLVPERSINLQFLDR 
Figure 30: The query sequence of the CYP7B1 protein in FASTA format 
 
The critical initial step in homology modelling is the determining of the best template 
structure. The least complex strategy of template identification depends on serial 
pairwise sequence alignments supported by database search systems, for example, 
BLAST. The BLAST231 tool from the ExPASy server was used to identify suitable 
crystal structures, which are similar to the query protein sequence by alignment of the 
query protein against crystal structures from the PDB. In addition, molecular computer 
techniques can be used to support the choice of the best homology model. The 
selections of templates depend on factors and parameters such as length alignment, E-
value (a better protein sequence when E-value < 0.005), % sequence identity, and 
BLAST score (Table 6). Nine different cytochrome enzymes that have various % 
sequence identities and E-values were identified. CYP24A1 (3K9V-A) for rat232, has 
the best E-value of 1e-54, and the % sequence identity was 30%. Human cytochrome 
enzymes might be more reliable and could take priority such as CYP11A1 (3N9Y-A), 
CYP11A1 (3NA0-A) and CYP11B2, which all have a sequence identity of 29%, and 
E-values of 6e-51, 6e-51 and 1e-42 respectively. This result agreed with the CYP27B1 
model, which was built by Zalewski et al.233 
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Table 6: Different selected protein crystal structures from BLAST search 
 
2.3.1 Multiple sequence alignments 
Running the Clustal omega tool234 from the European Bioinformatics Institute, part of 
the European Molecular Biology Laboratory (EMBL-EBI), alignment of the query 
amino acid sequence with other protein sequences of selected crystal structure (PDB) 
was performed.  Amino acids that have the same physicochemical properties appear 
with the same colour (Figure 31). 
 
 
 
 
 
 
 
 
 
 
PDB code BLAST 
score 
Sequence 
identity 
% 
Positive 
% Sequence 
identity 
Chain 
length 
E-value Accession 
number 
CYP24A1 (rat) 
3K9V-A 
210 144 44 30 482AA 1e-54 Q09128 
CYP11A1 
(human) 3N9Y-A 
198 142 44 29 487AA 6e-51 P05108 
CYP11A1 
(human) 3NA0-A 
198 142 44 29 471AA 6e-51 P05108 
CYP11A1 (bovine) 
3MZS-A 
197 141 43 29 486AA 1e-50 P00189 
CYP11B2 
(human) 4DVQ-A 
171 128 43 29 483AA 1e-42 P19099 
CYP3A4 (human) 
1W0E-A 
107 75 48 32 485AA 1e-23 P08684 
CYP3A4 (human) 
3UA1-A 
107 75 48 32 487AA 1e-23 P00191 
CYP21A (bovine) 
3QZ1-A 
90.1 65 47 33 496AA 3e-18 P00191 
CYP46A1 
(human) 2Q9F-A 
89.4 66 46 31 456AA 5e-18 Q9Y6A2 
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      H HELIX acid-alcohol I Helix        J Helix 
CYP11A1      LGDSKMSFEDIKANVTEMLAGGVDTTSMTLQWHLYEMARNLKVQDMLRAEVLAARHQ--
A 323 
CYP27B1      LFREELPAQSILGNVTELLLAGVDTVSNTLSWALYELSRHPEVQTALHSEITAALSPGSS 356 
CYP24A1      YQQDHLSKKELYAAVTELQLAAVETTANSLMWILYNLSRNPQAQRRLLQEVQSVLPD--N
 331 
                ..:  :.: . ***:  ..*:*.: :* * **:::*: :.*  *  *: :.      
  
        K HELIX        b1-4 b2-1     b1-3 
CYP11A1      QGDMATMLQLVPLLKASIKETLRLHPISVTLQRYLVNDLVLRDYMIPAKTLVQVAIYALG
 383 
CYP27B1      AYPSATVLSQLPLLKAVVKEVLRLYPVVPGNSRVPDKDIHVGDYIIPKNTLVTLCHYATS
 416 
CYP24A1      QTPRAEDLRNMPYLKACLKESMRLTPSVPFTTRTLDKPTVLGEYALPKGTVLTLNTQVLG
 391 
                 *  *  :* *** :** :** *      *   :   : :* :*  *:: :   . . 
          
          Haem pocket      L-HELIX 
CYP11A1      REPTFFFDPENFDPTRWLSKDKNITYFRNLGFGWGVRQCLGRRIAELEMTIFLINMLENF
 443 
CYP27B1      RDPAQFPEPNSFRPARWLGEGPTPHPFASLPFGFGKRSCMGRRLAELELQMALAQILTHF
 476 
CYP24A1      SSEDNFEDSHKFRPERWLQKEKKINPFAHLPFGIGKRMCIGRRLAELQLHLALCWIIQKY
 451 
              .   * : ..* * *** :  .   *  * ** * * *:***:***:: : *  :: :: 
 
Figure 31:  Illustration of multiple amino acid sequence alignment of the query protein. (*) means the residues 
are identical, (.) means the residues are similar, and (:) means the residues are highly conserved. The 
conserved cysteine in FXXGXXXCXG motif in each of these sequences is a crucial residue. The residues are 
coloured per their chemical properties: red small hydrophobic (AVFPMILWY), blue acidic (DE), magenta 
basic (RHK), green hydroxyl+ amine +basic (STYHCNGQ). 3K9V-A is CYP24A1 (rat), CYP11A1 human 
(3N9Y-A). 
                                                                                                                                                 
The phylogenetic tree result of twenty crystal structure proteins and the protein query 
(VIRT6852) placed the query protein in the same branch with 3N9Y-A, 3NA0-A, 
3MZS-A and 4DVQ-A and rat crystal structure (3K9V-A)235, (Figure 32). 
 
Figure 32: Phylogenetic tree for twenty-crystal structure proteins and query protein, CYP24A1 rat (3K9V-
A), CYP11A1 human (3N9Y-A and 3NA0-A), CYP11A1 bovine (3MZS-A), CYP11B2 human (4DVQ-A), 
CYP3A4 human (1W0E-A, 1TQN-A and 3UA1-A), CYP21A bovine (3QZ1-A), CYP46A1 (2Q9F-A), 
VIRT6852 is query, CYP17A1 human (3RUK-A), CYP2A6 human (3EBS-A, 2PG6-A, 2PG5-A, 2PQ7-A and 
1Z10-A), CYP2E1 human (3E4E-A), CYP2R1 human (3CZH-A), CYP2R1 human (3C6G-A ) and CYP2C8 
human (1PQ2-A) 
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The nine crystal structures were aligned with the query protein to find conserved 
regions by using PRATT236; 31 amino acids in each sequence were conserved which 
contained the FXXGXXXCXG) characteristic of the haem-binding motif (Table 7). 
 
Table 7: PRATT result illustrating the 31 amino acid residues of the conserved Motif 
 
In conclusion analysis confirmed rat CYP24A1 as the optimal template. 
 
 
2.4 Homology building 
Using the amino acid sequence of human CYP27B1 and CYP24A1 rat (3K9V-A) as 
templates, a homology model was built using Molecular Operating Environment 
(MOE) software237. Force-fields were used to construct the homology models including 
MMFF94. MOE generates ten intermediate models for each template, and the final 
model was taken as the Cartesian average of all the intermediate models. 
 
2.5 Homology validation 
Every homology model contains errors, with the number of errors depending on various 
factors: first, regarding the % sequence identity between template and target, if it is 
PDB code Sequence Conserved sequence Accession No 
CYP24A1rat 
3K9V-A 
455 - 485 FGiGkRmCIGrRLAelQLhLaLcwIIqkydI 
 
Q09128 
CYP11A1 human 
3N9Y-A 
455 - 485 FGwGvRqCLGrRIAelEMtIfLinMLenfrV P05108 
CYPA1 human 
3NA0-A 
455 - 485 FGwGvRqCLGrRIAelEMtIfLinMLenfrV 
 
P05108 
CYPA1 bovine 
3MZS-A 
454 - 484 FGwGvRqCVGrRIAelEMtLfLihILenfkI 
 
P00189 
CYP11B2 human 
4DVQ-A 
443 - 473 FGfGmRqCLGrRLAeaEMlLlLhhVLkhflV 
 
P19099 
CYP3A4 human 
1W0E-A 
435 - 465 FGsGpRnCIGmRFAlmNMkLaLirVLqnfsF 
 
P08684 
CYP3A4 human 
3UA1-A 
435 - 465 FGsGpRnCIGmRFAlmNMkLaLirVLqnfsF 
 
P00191 
CYP21A bovine 
3QZ1-A 
420 - 450 FGcGaRvCLGeSLArlELfVvLlrLLqaftL 
 
P00191 
CYP46A1 human 
3Q9F-A 
430 - 460 FSlGhRsCIGqQFAqmEVkVvMakLLqrleF 
 
Q9Y6A2 
Query 448 - 478 FGfGkRsCMGrRLAelELqMaLaqILthfeV O15528 
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greater than 90 %, the accuracy of the model can be compared with the crystal structure, 
except for a few individual side chains238. From 25 % to 90 % identity, the error will 
start. If the sequence identity is 25 % or less, the homology model will have very large 
errors. If errors in the template are located far from the active site, the error becomes 
less important. Once the homology modelling of the CYP27B1 model derived from 
CYP24A1 rat (3K9V-A) was finished, the templates and its model should be validated 
to evaluate the CYP27B1 model. Such validation considers the physicochemical quality 
to confirm that the stereochemistry and side chain environment of the model is 
correct238,239. 
 
2.5.1 Validation of active the site cysteine 
The distance between the thiolate of the cysteine residue at the active site and the haem 
for template CYP24A1 rat (3K9V-A) and the CYP27B1 model was determined (Table 
8). This shows the distance for the template was 2.36	Å. In the human CYP27B1 
model, the distance between the thiolate of the cysteine and the iron of the haem was 
found to be 2.41	Å, which is close to the template. As a result, the distance in the 
human CYP27B1 model was very suitable for interaction between the thiolate and the 
haem. 
 
 
Table 8:  The distance between the thiolate of the cysteine residue at the active site and haem iron 
for template and model 
 
2.5.2 Validation by Ramachandran plots 
Ramachandran plots were generated by using the RAMPAGE server240. A 
Ramachandran plot interprets phi-psi torsion angles for all residues in the structure. 
Importantly, glycine residues appear unique and separated from other residues in the 
plot region. In addition, glycine and proline residues are represented in different plots 
due to a difference in the phi-psi angles. 
 
Distance between thiolate of cysteine at the active site and haem iron 
PDB Template Homology model 
3K9V-A CYP24A1 rat 2.36	Å 2.41	Å 
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Table 9: Ramachandran plot evaluated the template and the corresponding model 
	
A Ramachandaran plot program was used to check the quality of the template and the 
corresponding model (Table 9). The template had no residue in the outlier region. The 
result of the Ramachandran plot for the CYP27B1 model showed 12 amino acid 
residues in the outlier region. Visualisation of the outlier amino acid residues in the 
CYP27B1 model by MOE, showed them to be far from the active site (Figure 33). As 
a result, the CYP27B1 model passed the Ramachandaran examination. 
 
Figure 33: Outlier amino acids (space filled) identified by Ramachandran plot for CYP27B1 
model 
 
 
2.5.3 Validation by ERRAT 
The ERRAT program works by analysing the statistics of non-bonded interactions 
between different atom types. The error is represented in the ERRAT diagram as a 
confidence limit that measures the structural error at each residue in the protein. 
Moreover, it calculates an overall score for the structure241. The ERRAT program is 
sensitive in detecting unusual atomic environments in protein molecules. In addition, 
this empirically derived atomic distribution was used as the basis for statistically 
PDB No of residues in 
favoured region 
No of residues in 
allowed region 
No of residues in 
outlier region 
Amino acid outlier 
3K9V-A 
CYP24A1 rat 
448 14 0 NIL 
CYP27B1 
model 
 
398 64 12 Phe48, Arg99, Gly176, 
Pro180, Ser205, Gly290, 
Pro359, Glu424, Thr439, 
His441, Leu446 and Ser454 
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discriminating between correctly and incorrectly modelled regions of a query protein 
structure. The overall ERRAT score given for a structure signifies the percentage of 
residues falling below the 95 % confidence limit. Most quality structures are 80 - 100 
% below the 95 % confidence limit. 
In this work, ERRAT validation outputs for the template gave an overall score of 96.48 
%. The CYP27B1 model, derived from rat CYP24A1 (3K9V-A) had the problematic 
areas appearing in residues around amino acids 200, 430, 440 and 460 (Figure 34). 
ERRAT showed them to be far from the active site. As a result, the CYP27B1 model 
passed the validation by ERRAT (Figure 35). 
 
 
Figure 34:  ERRAT validation for 3K9V-A CYP24A1 rat template 
 
 
Figure 35: ERRAT validation for the CYP27B1 model 
 
 
2.5.4 Validation by Verifiy 3D242 
Verify 3D is a program that examines the compatibility of a three dimensional atomic 
model with its own amino acid 1D sequence243. Three dimensional verification is an 
effective tool for detecting errors in a protein structure, such as the wrong folding. The 
program examines how compatible the three-dimensional structure is with the primary 
structure244. Each of the twenty amino acids is given three parameters describing its 
preference for: secondary structure, degree of buried surface area and the fraction of 
side-chain area that is covered by polar atoms. 
These three parameters are evaluated for each residue in the structure and a correlation 
is calculated between this set of observed parameters and the ideal parameters of the 
amino acid type to which it has been assigned. Verified 3D should stay above 0.2 and 
not fall under zero. The scores for the first 9 and the final 9 sequence positions have no 
meaning and are just for control. The rat CYP24A1 (3K9V-A) template and CYP27A1 
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model passed the validation without any residue below zero, and the residue percentage 
of amino acid is 94.5 % and 86 % above 0.20 respectively. 
 
2.5.5 ProSA validation 
ProSA (protein structure analysis) is a commonly used program to check faults in three-
dimensional protein structure based on statistical analysis. A major issue in structural 
biology is the recognition of errors in experimental and theoretical models of protein 
structures. The ProSA program, which invests the benefits of interactive web-based 
applications for the show of scores and energy, plots potential issues seen in the protein 
structures245. 
In this work, the template and CYP27B1 homology model was evaluated by ProSA, 
and the outcomes are represented in two diagrams, the first diagram for Z- score by X-
ray and NMR which measure the total Z-energy of the structures. The second diagram 
shows problematic residues in the template and CYP27B1 homology model. The 
ProSA-web service, which examines a PDB file and produces a score based on the 
quality of local structure surrounding each residue, based on the typical ranges of 
dihedral angles and side chain contacts observed in real protein. Also, ProSA calculates 
an overall for structural quality with Z score ≤ -10.  So, (Table 10) the template and 
the CYP27B1 model showed two green lines to be present on the error axis to indicate 
the confidence with which the residues exceed error value. In addition, ProSa displayed 
quite a similar overall Z-score for the template (-10.35) and the CYP27B1 model              
(-7.82). Indicating a good quality for the CYP27B1 homology model (Table 10). 
PDB  Z score Local model quality Overall model quality (X- ray, NMR) 
3K9V-A 
CYP24A1 
rat 
-10.53 
 
 
CYP27B1 
model  
-7.82 
  
Table 10: 3D proSA validation for templates and their models. 
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2.5.6 Superimpose 
 To further increase the confidence of the acceptability of the CYP27B1 model, the 
root-mean-square deviation (RMSD) was run by MOE to estimate the RMSD between 
3K9V-A CYP24A1 rat templates and the CYP27B1 homology model. The output for 
the RMSD homology model was superimposed with good RMSD below 2	Å (Table 
11). 
 
 
Table 11: RMSD data 
	
2.5.7 Prediction of secondary structure 
The secondary structure of the CYP27B1 model was generated to identify α helices, 
β sheets, coils, and loops. The secondary structure prediction showed a high similarity 
in helices and beta sheets between the template and its model. The first 30 amino acids 
at the N-terminal segment, which is the membrane anchor peptide, have many 
hydrophobic residues. The polyproline motif  follows the membrane anchor peptide246. 
As all of the selected sequences and query sequences of CYP27B1 were CYP 
subfamilies, the features common to all sequences revealed the presence of the haem-
binding motif, an essential part of all cytochromes by using PRATT236 and Psipred247. 
The patterns conserved over a set of sequences were identified, and it was found that 
31 amino acids were similar in every protein. These 31 amino acids contained the 
conserved cysteine in all proteins, and this was the haem-binding motif. The cysteine 
ligand loop of the FXXGXXXCXG motif is a conserved region, which is found either 
before or toward the beginning of the L helix. The motif also contains a phenylalanine 
residue, which has an important role in modulating the thermodynamic properties of 
the haem iron248 (Table 12). Another conserved region, the EXXR motif is believed to 
contribute to the catalytic activity of the cytochrome P450, and it helps to support 3D 
folding of the secondary structure.  
Most cytochrome enzymes have the important acid - alcohol pair situated in the I-helix 
with the conserved sequence (A/G) GX (E/D) (T/S). The CYP27B1 model has the 
alcohol pair as AGVDT, that is, Ala317, Gly318, Val319, Asp320, and Thr321. 
Using the nomenclature of Gotoh249,250 six Substrate Recognition Site (SRS) regions 
were identified in all selected sequence alignments based on a CYP2 family analysis. 
PDB RMSD 
3K9V-A CYP24A1 rat 0.956	Å 
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SRS-1 forms part of the B′-helix region followed by the inter helical loop region, 
SRS-2 is within the F-helix, SRS-3 lies in a region of the G-helix, SRS-4 lies at the 
centre of the I-helix, while SRS-5 (β1-4) and SRS-6 are just after the L-helix251. 
The haem is typically sandwiched between helix L on the side of the haem proximal to 
the surface of the protein and helix I in the inside of the protein. 
The 3K9V-A CYP24A1 rat template and CYP27B1 model232,251 were selected to run 
secondary structures by using the PSIPRED program252. The output result from 
PSIPRED is different from the MOE secondary structure result; this might result from 
a difference in calculations and logarithms between them.  
The observed secondary structures of both proteins using PSIPRED demonstrated a 
high degree of similarity in terms of helices and β sheets. There is good overlap 
between the template and CYP27B1 model especially the L and I helices. Noticeably, 
helix αI for the CYP27B1 model has 14 amino acid residues, which is too short to 
cover the haem binding site, requiring the combination of the α I and αH helices to 
cover the haem binding site (Figure 36 and 37). 
 
Table 12: Secondary structure data for the template and CYP27B1 model 
PDB Helix template Helix CYP27B1 
model 
Strand template Strand CYP27B1 
model 
3K9V-A 
CYP24A1 
(rat) 
Ser67 -Trp75 = αA’ 
Lys81-Lys92 = αA 
Pro112-Thr121 = αB 
Pro133 - His140 = αB
’ 
Gln153 - Phe162 = α
C 
Lys164 - Lys165 = αC 
Pro169 - Asp195 = α
D 
Leu203 - Tyr220 = αE 
Glu233 - Met253 = α
F 
Val257 - His260 = αG
’ 
Val267 - Ser294 = αG 
Phe301 - Gln307 = α
H 
Lys313 - Lue342 = αI 
Pro346 -Val359 = αJ 
Ala368 - 371Leu = α
K 
Tyr376 - Ser384 = αK 
Asn418 -Val420 = αK, 
αK’’ 
Cys462 - Lys482 = αL 
Ser47 - Lys55 = αA’ 
Arg60 - Phe72 = αA 
Pro91 - Gln100 = αB 
Trp113 - Cys119 = αB
’ 
Glu132 - Leu141 = α
C 
Pro148 - Arg173 = αD 
Val186 - Leu202 = αE 
Pro216 - Arg243 = αF 
Trp250 - Arg278 = α
G’ 
Ser289 - Phe298 = αG 
Ala304 - Ala317 = αH 
Asp320 - Leu333 = αI 
Pro337 - Ala350 = αJ 
Ala361 - Leu364 = α
K 
Leu369 - Val377 = αK 
His412-Thr415 = αK
’, αK’’ 
Met456 -His475 = αL 
Phe96 - Met99 = β1-1 
Asp106 - Leu109 = β1-
2 
Thr402 - Leu404 = β1-
4 
Tyr407 - Leu409 = β2-
1 
Val414 - Leu417 = β1-
3 
Leu422 - Met461 = Cys 
Loop 
Asp484 - Val486 = β3-1 
Leu496 - Ile500 = β4-1 
Ile509 - Arg512 = β3-2 
Trp76 - ala78 = β1-1 
Thr85 - Ala89 =B1-2 
Ile395 - Val397 = β1-4 
Tyr400 - Ile402 = β2-1 
Leu407 - Cys411 = β1-
3 
Ser416 - Cys455 = Loop 
Cys 
Glu477 - Gln479 = β3-
1 
Thr491 - Val496 = β4-1 
Leu503 - Asp507 = β3-
2 
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Figure 36: Haem binding site for template 3K9V-A 
 
 
Figure 37: Haem binding site for CYP27B1 model 3K9V-A 
 
2.6 Molecular dynamic studies 
2.6.1 Molecular dynamic for the CYP27B1 model at 300 K 
Molecular dynamics can be used to correct protein structure issues, for example, 
folding, conformational flexibility, and stability. The molecular dynamics simulations 
on CYP27B1. First used a 5 ns simulations carried out at two different temperatures, 
300 K and 312 K. Molecular dynamics simulation at 300 K and 312 K represent normal 
body temperature and elevated body temperature. 
The RMSD values of the backbone atoms were plotted as a time-dependent function of 
the molecular dynamics simulation. The outcomes support the CYP27B1 model 
structure, as they show time dependence of constant RMSD (Å) of the backbone atoms 
throughout the whole simulation process. This demonstrates that the model achieved 
equilibrium after some initial fluctuations. The chart plainly shows that there is an 
adjustment in the RMSD from 0.9 Å to 2.4 Å and that it reached the 2.02 Å at 1.39 ns 
and then declined to 1.83 Å at 1.83 ns, but after that, it reached a plateau from 2.25 ns 
(Figure 38).  
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Figure 38: Time-dependent RMSD (Å) of backbone atoms of the CYP27B1 model at 300 K 
 
Root mean square fluctuation (RMSF) showed the differences of structural behaviours 
and flexibilities in each residue for the CYP27B1 model; the amino acid residue 
(Pro440) was shown to be highly fluctuated (Figure 39). 
 
Figure 39: The RMSFs for the CYP27B1 model at 300 K. Root mean square fluctuation (RMSF) 
showed the differences of structural behaviours and flexibilities in each residue for the CYP27B1 
model; the amino acid residue Pro440 was shown to be highly fluctuated 
 
2.6.2 Molecular dynamic for the CYP27B1 model at 312 K 
The RMSD of the backbone atom values for CYP27B1 at 312 K simulations were not 
much different from the simulations at 300 K (Figure 37). However, the graph clearly 
indicates that there is a change in the RMSD from 0.9 Å to 2.5 Å, and it reaches a 
plateau from 2.48 ns. The RMSF showed the amino acid residue Gly281 to be highly 
fluctuated (Figure 40 and 41). 
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The results of the molecular dynamics simulation for 5 ns at temperatures 300 K and 
312 K showed that there are similar effects on the CYP27B1 model. Overall, it can be 
said that there is no significant difference in structure during molecular dynamics 
simulations at temperatures 300 K and 312 K. This means that at 312 K, the model still 
has activity, and no structural damage has happened. 
 
  Figure 40: Time-dependent RMSD (Å) of backbone atoms of the CYP27B1 model at 312 K 
 
 
Figure 41: The RMSFs for the CYP27B1 model at 312 K. Root mean square fluctuation (RMSF) 
showed the differences of structural behaviours and flexibilities in each residue for the CYP27B1 
model; the amino acid residue Gly281 was shown to be highly fluctuated. 
 
 
2.6.3 Ramachandran plot validation for CYP27B1 model after molecular 
dynamics simulation  
To validate the CYP27B1 model structure, Ramachandran plots were run before as well 
as after molecular dynamics simulation, and structures were analysed using 
RAMPAGE Ramachandran Plot Assessment (Table 13). After MD and it shows that 
the phi/psi angles of 90.9 % are in the most favoured regions, with 8.1 % in additional 
allowed regions, and 1.1 % amino acid residues were in disallowed regions. Therefore, 
the CYP27B1 model had improved after molecular dynamics simulation. However, the 
1.1 % disallowed region might be attributed to the fact that the human CYP27B1 
sequence has a low similarity to any of the crystal structures in the protein database 
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(PDB), and the modelling server utilised the only available template with reasonable 
resemblance. 
Table 13: Ramachandran plot evaluated the CYP27A1 model before and after molecular 
dynamics simulations 
 
2.6.4 Molecular dynamic for the CYP27B1 model - SDZ-88357 at 300 K 
SDZ-88357 is a selective inhibitor of the CYP27B1 enzyme and prevents the formation 
of calcitriol (Table 15). Molecular dynamics simulations were carried out on the 
CYP27B1 model-SDZ-88357 docking complex system to improve the understanding 
of the binding mode obtained from molecular docking. The dynamic stabilities of the 
complex system were predicted using RMSD changes during the molecular dynamics 
simulations.  
Firstly, a molecular dynamics simulation for the CYP27B1 model-SDZ-88357 complex 
system was run for 5 ns (Figure 42). RMSDs increased progressively, fluctuations were 
observed until 5 ns, and the curve did not reach a plateau. Therefore, a molecular 
dynamics simulation for 5 ns was not enough to optimise the CYP27B1 model-SDZ-
88357 complex system. 
 
Figure 42: Time-dependent RMSD (Å) of backbone atoms of the CYP27B1 model - SDZ-88357 at 
5 ns 
 
Secondly, molecular dynamics simulations were carried out on the CYP27B1 model-
SDZ-88357 complex system for 50 ns.  The RMSD changed from 1.37 Å at zero time 
to 3.57 Å at 33.44 ns; then the protein was equilibrated with no evident RMSD 
fluctuations observed after 33.44 ns. The stability of the CYP27B1 model-SDZ-88357 
complex structure during the molecular dynamics simulation was measured by its 
PDB No of residues in 
favoured region 
No of residues in allowed 
region 
No of residues in 
outlier region 
% Amino acid 
outlier 
Post-MD 428 38 5 1.1 
Pre-MD 398 64 12 2.5 
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deviation from the initial structure in terms of RMSD. This indicates that, after an initial 
increase in the magnitude of the fluctuation of the ligand atoms, the ligand reached a 
state of equilibrium characterised by the RMSD profile (Figure 43), showing that the 
complex has attained equilibration and is stable. 
 
Figure 43: Time-dependent RMSD (Å) of backbone atoms of the CYP27B1 model - SDZ-88357 
complex at 50 ns 
 
Ligand RMSD (right Y- axis, Figure 44) demonstrates how stable the ligand is 
regarding the protein and its binding pocket. The red line indicates the RMSD of a 
ligand when the CYP27B1 model-SDZ-88357 complex is initially aligned on the 
protein backbone of the reference and then the RMSD of the ligand heavy atoms is 
measured. If the values observed are significantly larger than the RMSD of the protein, 
then it is likely that the ligand has diffused far from its initial binding site253. A pink 
line (Lig fit Lig) indicates the RMSD of a ligand that is aligned and measured just on 
its reference conformation. This RMSD value measures the internal fluctuations of the 
ligand atoms. 
 
Figure 44: Protein and ligand root mean square fluctuation (RMSD). The above plot indicates the 
RMSD evolution of a protein (left Y-axis). All protein frames are first aligned on the reference 
frame backbone, and then the RMSD is calculated based on the atom selection. Ligand RMSD 
(right Y-axis) demonstrates how stable the ligand is with respect to the protein and its binding 
pocket, A pink line indicates the RMSD of a ligand when the protein–ligand complex is first 
aligned on the protein backbone of the reference, and then the RMSD of the ligand heavy atoms is 
measured. 
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The RMSF of all the CYP27B1 model-SDZ-88357 complex structure generated during 
the MD simulation were calculated to characterise the mobility of the individual 
residues. The side chain residues from Met277 to Gly280 had high peaks during the 
MD simulations of the CYP27B1 model-SDZ-88357 complex and showed remarkable 
fluctuation events in the RMSF plot (Figure 45), indicating large fluctuations of those 
residues. The protein RMSF is useful for characterising local changes along the protein 
chain. On this plot, the peaks show the ranges of the protein that fluctuate the most 
during the simulation. Ordinarily, the tails (N- and C-terminal) fluctuate more than any 
other sequence of the protein. Secondary structure components, such as alpha helices 
and beta strands, are typically more inflexible than the unstructured part of the protein, 
and do not fluctuate as much as the loop regions. From the diagram, it is apparent that 
the vast majority of residue fluctuations were localised in the loop areas.  
 
Figure 45: The RMSF for the CYP27B1 model-SDZ-88357 graph showed secondary structure 
elements, alpha-helical and beta-strand regions are highlighted in red and blue backgrounds, 
respectively. Ligand contacts and protein residues that interact with the ligand are marked with 
green coloured vertical bars. 
  
Protein ligand interaction for the CYP27B1 model-SDZ-88357 complex is showed in 
(Figure 46). Protein interactions with the ligand were checked all through the 
simulation and interactions are ordered by their sort shown specifically hydrogen 
bonds, hydrophobic, ionic, and water bridges.  
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Figure 46:  Illustration of protein interactions with the ligand. The red column means ionic bond, 
green column means a hydrogen bond, blue column means water bridges, and a purple column 
means a hydrophobic bond. The stacked bar charts are normalised over the course of the 
trajectory: for example, a value of 0.5 suggests that for 50% of the simulation time, the specific 
interaction is maintained. 
  
The influence of SDZ-88357 on the dynamical properties of the CYP27B1 model active 
site has been clarified by analysing the trajectory data obtained from the molecular 
dynamics simulations. The CYP27B1 model-SDZ-88357 docking interactions were 
reproduced during the entire simulations period. The analysis revealed the crucial role 
of water molecules in the CYP27B1 model-SDZ-88357 docking interactions. In most 
of the trajectories, active site residues of the CYP27B1 model-SDZ-88357 complex 
were involved in H-bonding through water bridges. The hydrogen bonds observed for 
Ser388 and Thr493 in the CYP27B1 model-SDZ-88357 docking complex remained 
stable throughout the simulation period. Ser388 and Thr493 formed a H-bond with one 
water bridge  
 
2.7 Docking the natural substrate in the optimised CYP27B1 model 
Yamamoto et al.254 reported the substrate binding pocket for the CYP27B1 model based 
on rabbit CYP2C5 to be Leu61, His62, Gln65, Phe80, Trp113, Leu127, Val225, 
Val228, Leu316, Ala317, Thr321, Pro385, Gly386, Asn387, Ser388, Thr409, Val496, 
and Pro497. In addition, Yamamoto et al.255 showed that the side chain of 25-(OH)D3 
was situated to close Gln65 and Thr409, and the distances between the 25-hydroxyl 
group and Gln65 and the 25-hydroxyl group and Thr409 are 2.83 and 2.82 Å, 
respectively. This suggests that the 25-hydroxyl group forms pincer-type hydrogen 
bonds with Gln65 and Thr409. The 1𝛼-hydrogen of 25-(OH)D3, which will be 
subjected to hydroxylation, orients to the haem iron atom. Conformation of 25-(OH)D3 
accommodated in CYP27B1, 25-(OH)D3 is docked with a stable conformation in which 
the A-ring adopts the chair form, and the side chain adopts the gauche(+) conformation 
(43°) at C16-17-20-22 and the following anti-conformation from C20 to the terminal 
 Chapter two                                                                                  Molecular modelling 
	
	
65 
	
methyl group. The A-ring adopts the 𝛽-form. In this conformation, the distance between 
C1 and iron is 4.3 Å and between hydrogen at the 1𝛼-position and iron is 3.3 Å. 
In this chapter, the CYP27B1 model was optimised before undergoing docking studies. 
The docking was performed using LeadIT 2.1.2 for the CYP27B1 model derived from 
rat CYP24A1. The natural substrate (25-hydroxyvitamin D3) (Figure 47) was docked 
in the CYP27B1 model to see how it interacted with the model and to identify the amino 
acids which interacted with the substrate. The docking result for the CYP27B1 model 
are given in Table 14. Docking was run for 10 conformations. The distance between 
the haem iron of the CYP27B1 model and carbon number 1 in the 25-hydroxyvitamin 
D3 was 4.58 Å, which had interactions between 16 amino acid residues and the ligand. 
This result agreed with Yamamoto et al.255 
 
Figure 47: 3D and 2D for 25-hydroxyvitamin D3 
 
A B C 
25-hydroxyvitamin D3 4.58	Å Gln65, Tyr87, Cys108, Thr321, Val384, Asn387, 
Thr409, Leu410, Cys411, Thr493 and Val494. 
Table 14: (A) Docking output for the CYP27B1 model, (B) distance between carbon number 1 
and the haem iron and (C) amino acids in the active site making interactions with the ligand. 
 
2.7.1 Selective inhibitors of CYP27B1 model and the CYP24A1 model after 
molecular dynamics simulations 
Powerful inhibitors of cytochrome P450 enzymes are found in azole compounds, which 
directly bind to the prosthetic haem iron through a pair of electron from heterocyclic 
nitrogen. Moreover, they interact with other amino acids in the binding site. Azole 
compounds block both oxygen binding and activation at the haem iron as well as 
substrate accommodation in the active site. The antifungals ketoconazole and 
clotrimazole are examples of azole drugs, which inhibit CYP24A1 and CYP27B1. 
OH
HO
2
3
7 8
24
25
1
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More selective inhibitors of vitamin D metabolism have been designed. For example, 
(R)-(-)VID400 has good selectivity for CYP24A1; however, SDZ-284971 and SDZ-
88357 have more effect on CYP27B1 (Table 15). 
 
Table 15: Example of selective inhibitors of CYP24A1 and CYP27B1215 
 
2.7.1.1 Docking (R)-(-)VID400 inhibitor in the CYP27B1 model 
(R)-(-)VID400 was a weak inhibitor of CYP27B1 based on the docking distance 
between the nitrogen of the imidazole ring and the haem iron, which was 4.16	Å (Table 
16). This agrees with the literature IC50 data (Table 15). In addition, there were some 
poses of compound (R)- (-)VID400 that form different interactions with the haem. e.g. 
the chloro substituent of the phenyl ring interacts with the iron.  
Compound Chemical structure IC50 (nM) 
CYP27B1 CYP24A1 
R-(-)VID400 
 
616.1 15.2 
SDZ-284971 
 
78.8 10000 
SDZ-88357 
 
60.2 >10000 
Cl
NH
O
N N
N
O
N
N N
N S N
OH
N
Cl
Cl
N
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Table 16: 3D and 2D for (R)-(-)VID400 inhibitor in the CYP27B1 model 
 
2.7.1.2 Docking (R)-(-)VID400 inhibitor in the CYP24A1 model 
On the other hand, when (R)-(-)VID400 was docked inside the pocket of the CYP24A1 
model191, the distance between the nitrogen of imidazole and the haem iron was 2.31	Å. 
(R)-(-) VID400 interacted with amino acid residues from the active site by hydrophobic 
interaction (Leu148, Met246, Phe249, Thr330, Ala326) (Figure 48). 
 
Figure 48: 3D and 2D for (R)-(-) VID400 inhibitor on the CYP24A1 model 
N
H
O
NN
Cl
Fe3+Fe5201
Thr330
Ser247
Phe249
Met246
Leu148
Hem520
Ala326
 
  
 
N
H
O
NN
Cl
Val384
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Fe6011
Ala317
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Overall, the docking output showed that (R)-(-)VID400 was more selective for the 
CYP24A1 model than the CYP27B1 model. 
 
2.7.1.3 Docking SDZ-88357 selective inhibitor in the CYP27B1 model 
SDZ-88357 is a selective inhibitor of the CYP27B1 enzyme and prevents the formation 
of calcitriol. Docking results showed the interaction between the nitrogen lone pair of 
tetrazole ring and the haem iron at a distance of 2.25	Å. There were hydrophobic 
interactions between the inhibitor with amino acid residues in the active site (Phe110, 
Leu127, Pro385 and Gly386) (Figure 49). In addition, SDZ-88357 was observed 
making three additional hydrogen bonds with amino acids Arg107, Asn387 and Asp320 
(Table 17).  
 Distance Hydrogen bond 
1 2.07	Å Between imidazole of SDZ-88357 and Arg107 
2 2.80 Å Between hydroxyl group of SDZ-88357 and Asn387 
3 3.42	Å Between tertiary amine of SDZ-88357 and Asp320 
Table 17: Hydrogen bonds between SDZ-88357 and amino acid residues of CYP27B1 model 
 
 
Figure 49: 3D and 2D for SDZ-88357 selective inhibitor on the CYP27B1 model 
 
Noticeably, Asp320 was part of the αI helix for the CYP27B1 model, which covers 
the haem binding site and contains SRS-4, and plays a key role in orientating the ligand 
at the active site by electrostatic interactions166. Asp320 has the important acid - alcohol 
pair situated in the I-helix with the conserved sequence (A/G) GX (E/D) (T/S), which 
assumes an essential role in the binding of an oxygen molecule for catalysis. 
 
2.7.1.4 Docking SDZ-88357 selective inhibitor in the CYP24A1 model 
Schuster et al.215 showed SDZ-88357 was a weak inhibitor of the CYP24A1 enzyme 
(> 1000 nM). Docking results showed the interaction between the nitrogen lone pair of 
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tetrazole and the haem iron at a distance of 5.56	Å. There were hydrophobic 
interactions between the inhibitor with amino acid residues in the active site (Arg128, 
Leu129, Ile131, Trp134, Leu148, Met246, Phe249, Leu325, ala326, Val391, Pro392, 
Phe393, Thr395, His497, Gly499 and Thr500) (Figure 50). There was no hydrogen 
bond between SDZ-88357 and the CYP24A1 model. Overall the selectivity of DZ-
88357 for CYP27B1 rather than CYP24A1 can be explains from docking experiments.  
 
Figure 50: Docking output for SDZ-88357 inhibitor on the CYP24A1 model 
 
2.7.1.5 Docking SDZ-88357 selective inhibitor in the mutant CYP24A1 model 
The observation from the docking output for the SDZ-88357 inhibitor on the CYP27B1 
model showed the hydrogen bonds between amino acid residues in CYP27B1 model 
Arg107, Asn387 and Asp320, which play an important role in fixing the SDZ-88357 
inhibitor in the active site close to the haem iron of the CYP27B1 model.   
Furthermore, to confirm the role of Arg107, Asn387 and Asp320 in CYP27B1, 
mutations were introduced in CYP24A1 by changing the amino acid residues Leu148, 
His497 and Gly499 in mutant for amino acid residues Asp148, Arg497 and Asn499. 
The docking results showed the interaction between SDZ-88357 and the mutant 
CYP24A1 model was the same as the docking output result of SDZ-88357 complexed 
with the CYP27B1 model. In addition, the distance between the lone pair of electrons 
of terazole and the haem iron was 2.38	Å. There were hydrophobic interactions between 
the inhibitor with amino acid residues in the active site (Ile131, Ala326, Val391, Pro392 
and Thr500) (Figure 51). In addition, SDZ-88357 making three additional hydrogen 
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bonds with amino acids Asp148, Arg497 and Asn499, the length of the hydrogen bonds 
in mutant CYP24A1 were the same as in the CYP27B1 model (Table 18) 
 
Figure 51: 3D and 2D for SDZ-88357 selective inhibitor on the mutant CYP24A1 model 
 
 Distance Hydrogen bond 
1 2.90	Å Between imidazole of SDZ-88357 and Arg497 
2 2.74 Å Between hydroxyl group of SDZ-88357 and Asn499 
3 3.03	Å Between tertiary amine of SDZ-88357 and Asp148 
Table 18: Hydrogen bonds between SDZ-88357 and amino acids residues of CYP27B1 model 
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2.8 Conclusions 
A homology model of CYP27B1 was built using MOE and was approved for 
stereochemical and amino acid environment quality using appropriate programmes, 
with further optimisation of the active site architecture achieved by molecular dynamics 
simulations. Understanding protein-ligand interactions is essential for designing more 
selective and potent CYP24A1 inhibitors. This chapter uses a combination of homology 
modelling, molecular dynamics simulations, and molecular docking to understand the 
satisfactory explanation of the binding selectivity of the CYP27B1 model with a natural 
substrate and with selective inhibitor complexes. Monitoring RMSD during simulations 
indicated that it is a structurally stable homology model. Docking results for CYP27B1 
showed amino acids Arg107, Asn387 and Asp320 have an important role in binding 
interaction to form hydrogen bonds with inhibitors. Asp320 was part of the αI helix 
for the CYP27B1 model, which covers the haem binding site and contains SRS-4, and 
plays a key role in orientating the ligand at the active site by electrostatic interactions. 
Asp320 has the important acid - alcohol pair situated in the I-helix with the conserved 
sequence (A/G) GX (E/D) (T/S), which assumes an essential role in the binding of an 
oxygen molecule for catalysis. 
 The main strategy that can be used to build an inhibitor selective for CYP24A1 over 
CYP27B1, is to design compound unable to form hydrogen bonding interactions with 
CYP27B1 especially with Arg107, Asn387 and Asp320. Although additional H-bonds 
can improve binding and potentially inhibitory activity of hCYP24A1 this is at the 
expense of selectivity. Incorporating larger hydrophic pharmacophores capable of 
filling the active site cavity and formation of multiple hydrophic interactions with active 
site amino acids would result in CYP24A1 inhibitory activity and crucially selectivity 
with respect to CYP27B1. 
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2.9 Experimental 
2.9.1  Docking method 
The important amino acid residues of the active pocket Gln82, Ile131, Trp134, Met246, 
Ala326, Glu329, Thr330, Val391, Phe393, Thr394, Ser498, Gly499 and Tyr500191,190 
were selected, and then the selection was extended to 12.5 Å in order to include in the 
docking site the haem and the access tunnel to the catalytic site. Ligand database in mol 
2 format, prepared using MOE237, was used as input for the docking calculations. The 
iron atom of the catalytic site was set as an essential pharmacophoric feature. Ligand 
docking was performed using the default values, configured with flexible torsion, 
external formal charges, Corina for generation, volume overlap factor 2.9, and ligand 
clash factor 0.6, and no water molecules were considered. 100 output solutions were 
obtained from each compound, and visual inspection in MOE was used to identify the 
interaction between ligand and protein. 
2.9.2 Method of Molecular dynamic  
A molecular dynamics simulation was run on the CYP27B1 model alone and the 
CYP27B1 model in complex with SDZ-88357. Both PDB files were first optimised 
with protein preparation wizard in Maestro, version 11.0.015256  by assigning bond 
orders, adding hydrogen, and correcting incorrect bond types. A default quick 
relaxation protocol was used to minimise the MD systems with the Desmond 
program256. In Desmond, the volume of space in which the simulation takes place (the 
global cell) is built up by regular 3D simulation boxes, which was utilised as part in 
this system for protein interactions. The orthorhombic water box (volume = 501882 
Å3) allowed for a 10	Å buffer region between protein atoms and box sides. 
Overlapping water molecules were deleted, and the systems were neutralised with 
Na+ ions and salt concentration 0.15 M. 
Force-field parameters for the CYP27B1 model and the CYP27B1 model-SDZ-88357 
complex were assigned using the OPLS_ 2005 force-field, that is, a 5 ns or 50 ns 
molecular dynamic run in the NPT ensemble (T = 300 K) at a constant pressure of 1 
bar. Energy and trajectory atomic coordinate data were recorded at each 1.2 ns.  
Molecular dynamics simulation for drug design is ideally conducted at a temperature 
range of 300 -314 K. In this study, molecular dynamics simulation was done at 300 K 
and 312 K. 
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3 Lead compounds 
Previous screening of the SPECS database221 identified some promising CYP24A1 
inhibitors with moderate inhibitory activity222. The most potent CYP24A1 inhibitors 
were selected as lead compounds (lead 1 and lead 2) for further development. In 
addition, lead 3 was synthesised in our laboratory191 and showed potent CYP24A1 
inhibitory activity (Figure 52).   
LEAD1  LEAD 2  LEAD 3 
IC50 = 4.2	μM 222 IC50 = 5.5 μM  222 IC50 = 0.40 μM191 
Figure 52:  CYP24A1 inhibitors with moderate inhibitory activity 
Firstly, docking of lead 1 into its binding site of the CYP24A1 model191 was performed. 
Lead 1 was able to access the channel of the active site, and the nitrogen atom of 
heterocycle of lead 1 interacted perpendicularly with the haem iron with a distance of 
2.35 Å. In addition, there were hydrophobic interactions between lead 1 and the amino 
acids of the active site of the human CYP24A1 model191 (Arg128, Leu148, Ala326, 
Thr330, Val391, Phe393 and Thr394). Furthermore, docking studies showed there was 
no hydrogen bond between lead 1 and the active site of the CYP24A1 model (Figure 
53). 
Figure 53: Docking data for lead 1 
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This chapter is concerned with the modification and development of lead 1, specifically 
through (i) replacement of the dimethyl pyrazole with basic heterocyclic rings to 
enhance binding interaction with the haem moiety (ii) substitution of the benzene rings 
to explore structure-activity relationship, and (iii) variation in the length of the linker 
to determine the optimum length to allow complete filling of the hydrophobic channel 
of the CYP24A1 active site (Figure 54). 
 
Figure 54: The modification of lead 1 
 
This chapter is divided into 8 parts as follows: 
1. Development of lead 1 by replacement with pyridine (pyridine pyrazole 
derivatives) 
 
Figure 55: 3-(substituted/ unsubstituted phenyl)-1-phenyl-N-(pyridin-4-ylmethyl)-1H-
pyrazole-4-carboxamide derivatives
N
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optimise fit in active site
N
N
R1
R2
O
HN
N
Where R
5a = R1 = H,    R2 = H
5b = R1 = F,     R2 = H
5c = R1 = Cl,    R2 = H
5d = R1 = H,     R2 = OCH3
5e = R1 = CH3, R2 = H
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2. Development of lead 1 by variation of the liker and replacement with imidazole
Figure 56: N-(2-(1H-imidazol-1-yl) ethyl)-3-(substituted/ unsubstituted phenyl)-1-
phenyl-1H-pyrazole-4-carboxamide derivatives 
3. Development of lead 1 by variation of the liker and replacement with triazole
Figure 57: N-(2-(1H-1,2,4-triazol-1-yl)ethyl)-1-phenyl-3-(substituted/ unsubstituted 
phenyl)-1H-pyrazole-4-carboxamide derivatives 
4. Development of lead 1 by changing the heterocycle
Figure 58: 1-(1,3-diphenyl-1H-pyrazol-4-yl)-2-(1H-imidazol-1-yl)ethan-1-one 
5. Molecular modelling
6. Biological assay
7. Conclusions
8. Experimental
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Scheme 4: Synthetic pathway of pyridine pyrazole derivatives 
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3.1 Synthetic pathway of pyridine pyrazole derivatives 
Literature methodology was searched using SciFinder® to determine the appropriate 
methods for the synthesis of the pyridine series. A four-step synthetic pathway was 
devised and is shown in (Scheme 4). 
 
3.1.1 Synthesis of imines (2) 
 
 
Scheme 5: Synthesis of imines 
 
Acetophenone derivatives were reacted with phenyl hydrazine and acetic acid as the 
catalyst and solvent at room temperature, which provided the corresponding imines 2a 
- 2e. The yield for N-[1-(4-fluorophenyl)ethylidene]-N’-phenyl-hydrazine (2b) was 
much lower than the theoretical yield and also lower than the literature yield257 with 
loss during filtration (Scheme 5). 
Compounds 2a - 2e were synthesised with yields ranging from 20 - 100 %. 
Unfortunately, this method did not work particularly well with the 3-
methoxyacetophenone 2d, as the expected product 2d did not precipitate out in acetic 
acid. This could be due to the polar nature of the methoxy group, as compound 2d was 
very soluble in acetic acid preventing it from precipitating out.  
Furthermore, this was also supported by a lower Log P (2.86) compared with 2a, 2b, 
2c and 2e where Log P was between 2.98 and 3.54. As a result, the procedure for 3-
methoxyacetophenone derivatives 2d was attempted using ethanol as the solvent and 
acetic acid as the catalyst. Evaporation under vacuum was performed to remove the 
ethanol resulting in a precipitate. TLC was performed for all the imine reactions and 
the same Rf value was obtained for the products and their corresponding acetophenone, 
suggesting that both were the same compound.  However, different colours were 
observed due to discolouration on light exposure. Therefore, storing the compounds 
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wrapped in foil was very important (Table 19). Owing to the light and air sensitivity of 
the compounds, they were not stable enough to perform NMR (rapid discolouration and 
decomposition), therefore they were used immediately in the next reaction step. 
Table 19: Synthesis data for step (1) 
3.1.2 Synthesis of pyrazole-4-carbaldehyde derivatives (3) 
The Vilsmeier-Haack reaction is an important method for the synthesis of various 
aromatic aldehydes261; in 1927 Vilsmeier and Haack observed that N-
dimethylformamide in the presence of POCl3. Furthermore, the reaction of carbonyl 
compounds with the Vilsmeier reagent, N,N-dimethylformamide, and phosphorus 
oxychloride (DMF/POCl3) is also used in a variety of cyclisation and cyclo 
aromatisation reactions262. The Vilsmeier reagent serves not only as a formylating 
agent, but also as an activating reagent for carboxylic acids to give esters, amides, and 
acid chlorides and for alcohols to give alkyl chlorides. Overall, the Vilsmeier reagent 
is used to generate a halomethyleneiminium salt used in the production of many 
heterocyclic compounds. Phosphorus oxychloride reacts with tertiary amides to give an 
adduct that exhibits salt-like properties, as shown in (Figure 59). 
Initial electrophilic attack of Vilsmeier-Haack reagent on hydrazone yielded the 
intermediate I which subsequently looses a molecule of HCl to provide intermediate II. 
The nucleophilic attack by N-H group initiates the cyclisation and the resulting pyrazole 
intermediate losses (CH3)2NH to give the more stable pyrazole derivative. The 
pyrazole formed reacts with another molecule of Vilsmeier-Haack reagent in an 
electrophilic substitution process giving an iminium salt (Intermediate III), which is 
hydrolysed to corresponding 4-formyl pyrazole262. The electrophilic attack of first 
Vilsmeier-Haack complex at the probable attacking site of hydrazones results into 
cyclisation. While 
cpd 
Yield 
% 
m.p. Colour and 
appearance Practical Lit. 
2a 100 80 - 82℃ 108 ℃258 White solid 
2b 20 88 – 90℃ 134 - 136℃257 light yellow crystals 
2c 89 109 - 111℃ 102℃259 light yellow crystals 
2d 78 61 - 62 ℃ Unrecorded light yellow solid 
2e 100 80 - 82 ℃ 80℃260 light yellow solid 
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electrophilic attack of second Vilsmeier-Haack complex forms formyl product after 
hydrolysis.  
The optimum reaction temperature was 60 °C; at lower temperatures, the reaction did 
not reach completion. Hydrolysis was done by pouring the reaction mixture on crushed 
ice (100 mL), and was made basic (pH 8.0) using 10% NaOH (Figure 59). 
Figure 59:  Vilsmeier-Haack reaction mechanism 
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Scheme 6: Synthesis of pyrazole-4-carbaldehyde (3) 
 
The method used by Yadlapalli et al.263 was followed to prepare compounds 3a - 3e. 
This method began with the imines 2a - 2e being dissolved in dry DMF, then POCl3 
was added slowly dropwise at 0	℃ as a catalyst, and the mixture was stirred for 2 h at 
90	℃. 10 % aqueous NaOH solution was added to neutralise the solution to form the 
corresponding pyrazole-4-carbaldehyde; 3a - 3e were obtained in yields ranging from 
39 to 60 % (Scheme 6). 
This method was straightforward and successful although flash column 
chromatography was performed on 3d to purify the product. Good yields were obtained 
for all the aldehydes (Table 20). 
1H NMR confirmed the presence of the CHO group with a peak at approximately δ ≅	10.07 for 3a - 3e as a singlet. In addition, the H group for pyrazole appeared as a 
singlet at δ	≅ 8.5 for all the compounds, thus confirming the presence of pyrazole.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 20: Synthesis data for step (2) 
 
 
 
 
POCl3 NN
R1
R2
O
H
3a = R1 = H,    R2 = H
3b = R1 = F,     R2 = H
3c = R1 = Cl,    R2 = H
3d = R1 = H,     R2 = OCH3
3e = R1 = CH3, R2 = H
N
H
N
R1
R2
2
cpd 
Yield 
% 
m.p. Colour and appearance 
Practical Lit. 
3a 66 128 - 130℃ 144 -146℃258 light yellow solid 
3b 44 150 - 154℃ 173 -175℃257 light yellow crystals 
3c 61 139 - 142℃ 138 - 140℃1 light yellow crystals 
3d 69 70 - 74℃ 102℃6,7 light yellow crystals 
3e 39 125 - 128℃ 120℃8 light yellow solid 
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3.1.3 Synthesis of 1H-pyrazole-4-carboxylic acid derivatives (4)   
Aldehydes can be oxidised to carboxylic acids with both mild and strong oxidising 
agents. Typical oxidising agents for aldehydes include potassium permanganate and 
potassium dichromate in acid solution and Tollens reagent264. 
Potassium permanganate, which is an inexpensive oxidant that has been widely used in 
organic synthesis and is a highly efficient and effective nonselective oxidant when used 
in aqueous solutions265. Potassium permanganate is preferred when an organic 
compound contains only one site for oxidation. In addition, when the aqueous solution 
is made acidic by the addition of mineral acid, the rate of reaction increases. Under 
acidic conditions, permanganate is reduced to soluble manganese (II) or (III) salts; in 
addition, the rate of the reaction is also accelerated by the addition of sodium or 
potassium hydroxide as a basic medium266. 
The oxidation of aldehydes to carboxylic acids occurs in two steps. In the first step, one 
molecule of H2O is added in the presence of an acid catalyst to generate a hydrate 
(Scheme 7). 
 
Scheme 7: Formation hydrate ion 
	
In the second step, the hydrate is oxidised to the carboxylic acid, thus formally 
eliminating H2O. 
The method of Pandey et al.258 was followed to synthesise compounds 4a - 4e. This 
procedure involved compounds 3a - 3e, which were dissolved in a mixture of t-
butanol/H2O, and then, a solution of KMnO4 was added dropwise with stirring at 75	
℃. Aqueous KOH solution was then added until alkaline pH to dissolve the product in 
water (as salts). The mixture was filtered to produce a dark paste-like solid, and the 
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filtrate was acidified with conc. HCl to release the carboxylic acid group. Next, the 
product was recrystallised to give the corresponding compounds 4a - 4e.   
 
Scheme 8: Synthesis of 1H-pyrazole-4-carboxylic acid derivatives (4) 
 
Pyrazole carboxylic acids were obtained in yields ranging from 54 to 80% for 
compounds 4a, 4c, 4d and 4e. These compounds precipitated as a white solid and 
appeared as one spot in TLC (CH2Cl2: CH3OH, 9:1 v/v). Compound 4b contained 
impurities and required two recrystallisations, the first using ethanol, and then the 
second with acetonitrile; subsequently, a lower yield of 37 % was obtained (Scheme 9). 
1H NMR confirmed the presence of the COOH group with a peak at δ	≅ 12.59 for 4a 
- 4e as a singlet. In addition, the H group for pyrazole appeared as a singlet at δ 9.03 
to 9.08, thus confirming the presence of pyrazole. The compound 3-(3-
methoxyphenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid 4d was a novel compound, 
so was further characterised by the 13C NMR spectra, which confirmed the COOH 
group at δ 163.74. Finally, 3-(3-methoxyphenyl)-1-phenyl-1H-pyrazole-4-carboxylic 
acid 4d was analysed with microanalysis, which confirmed C17H14N2O3 and M. Wt. 
294.30 by calculation of the % of C, H and N (Table 21). 
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Table 21: Synthesis data for step (3) 
 
 
3.1.4 Synthesis of 1H-pyrazole-4-carboxamide derivatives (5) 
N,N′-Carbonyldiimidazole (CDI) is one of several commonly used reagents for 
coupling carboxylic acids with aliphatic or aromatic amines to form an amide267. The 
mechanism involves a nucleophilic attack of the carboxylate to the carbonyl carbon of 
CDI, resulting in the formation of the active imidazolide and the liberation of carbon 
dioxide. The aliphatic amine then attacks the intermediate structure leading to coupling 
of the amine with the carboxylic acid to form an amide group.  
 
Scheme 9: Synthesis of 1H-pyrazole-4-carboxamide derivatives
N
N
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R2
O
OH
N
NH2
CDI
N
N
R1
R2
O
HN
N
5a = R1 = H,    R2 = H
5b = R1 = F,     R2 = H
5c = R1 = Cl,    R2 = H
5d = R1 = H,     R2 = OCH3
5e = R1 = CH3, R2 = H
4
Cpd 
Yield 
% 
m.p. Microanalysis 
 
Colour and 
appearance Practical Lit. 
4a 83 198 - 200 ℃ 200 - 202℃258 - pale yellow solid 
4b 37 222 - 223℃ 229 - 230℃257 white crystals 
4c 80 238 - 240 ℃ 240 - 242℃257 white solid 
4d 
70 139 - 140℃ Novel Anal. Calcd for C17H14N2O3 
(294.30): C 69.38%, H 4.79%, 
N 9.51%. Found C 69.40%, H 
4.66%, N 9.51% 
white solid 
4e 54 235 – 238℃ 191 - 193℃258 - white solid 
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The procedure of Aboraia et al.210 was used to synthesise the final compounds 5a - 5e. 
This was achieved by reaction of carboxylic acids 4a - 4e with in N,N′-
carbonyldiimidazole for 1 h at 0	℃ to form the intermediate compound, followed by a 
solution of 4-aminomethylpyridine. After 20 h at room temperature, the product was 
obtained in a yield ranging from 4 to 58 %. Compound 5e did not precipitate and 
required further purification (Scheme 9). 
1H NMR confirmed the presence of the amide group with a peak at δ	≅ 8.80 for 5a - 
5e as a triplet except for compound 5b, which was found as a pseudo triplet.13C NMR 
spectra confirmed the amide group (CONH), which was observed at δ	≅ 162.7 for 5a 
- 5e (Table 22).  
 
Table 22: 1H-pyrazole-4-carboxamide derivatives 
 
 
 
 
 
 
 
cpd 
Yield 
% 
m.p. 
 
Microanalysis/ HRMS 
 
Colour and 
appearance 
5a 
39 188 - 190℃ 
 
Anal. Calcd for C22H18N4O (354.40): C 74.56%, H 
5.12%, N 15.80%. Found C 74.36%, H 5.04%, N 
15.84% 
White solid 
5b 
58 199 - 200℃ 
 
Calculated mass: 373.1459 [M + H]+, measured 
mass: 374.1493 [M + H]+ 
White 
crystals 
5c 
37 222 - 223℃ 
 
Anal. Calcd for C22H17ClN4O (388.85): C 67.95%, 
H 4.41%, N 14.41%.  Found C 67.87%, H 4.31%, N 
14.58% 
White solid 
5d 
33 143 - 144℃ 
 
Anal. Calcd for C17H14N2O3 (294.30): C 69.38%, H 
4.79%, N 9.51%. Found C 69.40%, H 4.66%, N 
9.51% 
White solid 
5e 
4 191 - 193℃ 
 
Anal. Calcd for C23H20N4O	∙ 0.3 H2O (373.85): C 
73.89%, H 5.47%, N 14.98%. Found C 73.72%, 
H 5.40%, N 14.59% 
White solid 
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3.2 Development of lead 1 by replacement with imidazole 
This involved the coupling of the carboxylic acid with aminoethylimidazole 
dihydrochloride salt (9), which was synthesised as shown in Scheme 11. 
 
Scheme 10: Synthetic pathway of imidazole-pyrazole derivatives 
 
 
3.2.1 Synthesis of N-(2-(1H-imidazol-1-yl)ethyl)-3-(substituted/ unsubstituted 
phenyl)-1-phenyl-1H-pyrazole-4-carboxamide (10) 
3.2.1.1 Synthesis of 2-(2-(1H-imidazol-1-yl)ethyl) isoindoline-1,3-dione (8) 
 
6                               7                                                           8 
Scheme 11: 2-(2-(1H-imidazol-1-yl)ethyl) isoindoline-1,3-dione (8) 
N
Br
O O NHN
KI
N
N
O O
N
HCl
N N
NH2Cl
N
N
O
HO
R1
R2
CDI
N
N
O
H
N N
N
R1
R2
a = R1 = H,    R2 = H
b = R1 = F,     R2 = H
c = R1 = Cl,    R2 = H
d = R1 = H,    R2 = OCH3
e = R1 = CH3, R2 = H
(10)
(4)
+
(6) (7) (8)
(9)
N
Br
O
O
NHN N
N
O
O
N
+ NaHX
 Chapter three                                                                                                       Lead 1 
 
	
	
86 
	
Many methods were attempted to prepare compound 8. The first method followed the 
procedure of Buchhoiz et al.268; this method involved a reaction between 2-(2-
bromoethyl)isoindoline-1,3-dione 6 and imidazole 7 in the presence of NaH  (Scheme 
12) as a base catalyst to form compound 8, which gave a yellow viscous liquid that was 
recrystallised with isopropanol (Scheme 11). The resulting white precipitate was 
analysed by 1H NMR. However, this confirmed that a carboxylic acid rather than the 
product was obtained. The reported carboxylic acid resulted from ring opening of 
imidazolylethylphthalamide, as reported by Ye et al.269 where the presence of imidazole 
can enhance the rate of hydrolysis of the adjacent amide in a basic medium. As a result, 
the method of Buchhoiz et al.268 was unsuccessful for producing compound 8       
(Scheme 12) 
 
Scheme 12: Ring opening of imidazolylethylphthalamide 
 
A second method followed the procedure of Hay et al.270; this used another base catalyst 
(potassium carbonate) rather than NaH in an attempt to synthesise 2-(2-(1H-imidazol-
1-yl)ethyl)isoindoline-1,3-dione 8.  
 
6                               7                                                          8 
Scheme 13: Unsuccessful method to produce compound 8 
 
This method was unsuccessful for producing compound 8 (Scheme 13), and the 
resulting product on analysis by 1H NMR shows that carboxylic acid rather than the 
product was obtained271 (Scheme 14). 
 
Scheme 14: Effect of K2CO3 on bromoethylphthalamide 
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Lastly, the method of Popkov and Skvortsova272 was attempted, in which melted 
imidazole 7 was refluxed with bromoethylphthalamide 6, and potassium iodide was 
added to convert bromide into iodide, as it is a better leaving group (Scheme 15).  
 
6                               7                                                          8 
Scheme 15: Using the imidazole as both reactant and solvent 
 
The reaction was refluxed for 3 h, after which toluene was added, and the reflux 
continued for a further 20 h. The product was obtained in a yield of 49 % after 
recrystallisation with isopropanol (Table 23).  
 
 
 
 
 
Table 23: Identification data for compound 8 
 
 
3.2.1.2 Synthesis of 1-(2-ammonioethyl)-1H-imidazol-3-ium chloride (9) 
The Gabriel synthesis273, for converting halides to primary amines, involves two major 
steps: the first step is the synthesis of alkylphthalimide.  The second step is a synthesis 
of primary amines from N-alkylphthalimide. The formation of a primary amine from 
the N-substituted phthalimide involves either hydrolysis, by using an acid or a base, or 
hydrazine, and is called the Ing-Manske procedure274 (Scheme 16).  
Treatment of 8 with 1 N aqueous HCl and hydrazine monohydrate gave the product 9 
in a yield of 82%. 1H NMR confirmed the amine as a singlet at 8.61 (Table 24).  
 
8                                                                      9 
Scheme 16: 1-(2-Ammonioethyl)-1H-imidazol-3-ium chloride (9) 
 
 
 
 
 
N
Br
O
O
NHN N
N
O
O
N
+ KI
N
N
O
O
N
HCl
N
+HN
NH3+
Cl-
Cl-
Cpd 
Yield 
% 
m.p. Colour and 
appearance Practical Lit. 
8 83 126 - 130℃ 155 – 157 ℃272 White solid 
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Table 24: Identification data for compound 9 
 
 
3.2.1.3 Synthesis of: N-(2-(1H-imidazol-1-yl) ethyl)-3-(substituted/unsubstituted 
phenyl)-1-phenyl-1H-pyrazole-4-carboxamide (10) 
 
Scheme 17: N-(2-(1H-imidazol-1-yl) ethyl)-3-(substituted/unsubstituted phenyl)-1-phenyl-1H-
pyrazole-4-carboxamide derivatives (10) 
 
The procedure of Aboraia et al.210 was used to synthesise the final sproducts of 10a - 
10e, achieved by reacting 4a - 4e, with CDI as previously described (section 3.1.4). The 
carboxamide compounds 10a - 10e were obtained in yields ranging from 6% to 40 % 
(Scheme 18).  The methoxy derivative 10d was an incomplete reaction after 20 h and 
an additional 2 eq of CDI was added and heated overnight at 60 ℃. The methyl 
derivative 10e was obtained in a low yield because of impurities, as noted by TLC 
(EtOAc-CH3OH 9:1 v/v) where three spots were observed (Table 25). 
 
 
 
 
 
 
 
NN
O OH
R1
R2
NN
O
NH
N
N
R1
R2
10a = R1 = H,    R2 = H
10b = R1 = F,     R2 = H
10c = R1 = Cl,    R2 = H
10d = R1 = H,    R2 = OCH3
10e = R1 =CH3, R2 = H
CDIN
+HN
NH3+
Cl-
Cl-
+
94
Cpd 
Yield 
% 
m.p. Colour and 
appearance Practical Lit. 
9 82 170 - 175℃ 217 - 220℃272 Pale yellow solid 
 Chapter three                                                                                                       Lead 1 
 
	
	
89 
	
 
Table 25: N-(2-(1H-imidazol-1-yl) ethyl)-3-(substituted/unsubstituted phenyl)-1-phenyl-1H-
pyrazole-4-carboxamide derivatives (10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cpd 
Yield 
% 
m.p. 
 
Microanalysis/ HRMS 
 
Colour and 
appearance 
10a 
40 136 - 138℃ Anal. Calcd for C21H19N5O (357.42): C 70.57%, H 
5.36%, N 19.59%. Found: C 70.28%, H 5.19%, N 
19.29% 
White solid 
10b 
29 158 - 160 ℃ ): C 380.81( O20.3 H 	∙O5FN18H21Anal. Calcd for C
66.60%, H 4.90%, N 18.31%. Found: C 66.57%, H 
4.82%, N 17.99% 
White 
crystals 
10c 
19 184 - 186 ℃ 
 
Anal. Calcd for C21H18ClN5O	∙ 0.1 H2O (393.66): C 
64.07%, H, 4.65% N 17.79%. Found: C 63.92% H 
4.33% N, 17.76% 
White 
crystals 
10d 
32 108 - 112℃ 
 
Anal. Calcd for C22H21N5O2∙ 0.2 H2O (391.04): C 
67.57% H 5.51% N 17.91%. Found: C 67.21%, H 
5.25% N 17.56% 
Bright 
yellow 
crystals 
10e 
6 76 - 80℃ 
 
Anal. Calcd for C22H21N5O (371.44): C 71.14%. H 
5.70%, N, 18.85%. Found: C 70.87%, H 5.74%, N 
18.67% 
White solid 
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3.3 Development of lead 1 by replacement with triazole 
The method of synthesis for triazole derivatives was the same as described for 
imidazole derivatives (10) involving the reaction of the carboxylic acid (4) with 
corresponding aminoethyltriazole dihydrochloride salt (Scheme 18 and Figure 58). 
 
Scheme 18: Synthetic pathway of triazole-pyrazole derivatives 
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3.3.1 Synthesis of N-(2-(1H-1,2,4-triazol-1-yl)ethyl)-1-phenyl-3-(substituted/ 
unsubstituted phenyl)-1H-pyrazole-4-carboxamide derivatives (15) 
 
Figure 60: N-(2-(1H-1,2,4-triazol-1-yl)ethyl)-1-phenyl-3-(substituted/unsubstituted 
phenyl)-1H-pyrazole-4-carboxamide derivatives 
 
3.3.1.1  Synthesis of 2-(2-(1H-1,2,4-triazol-1-yl)ethyl)isoindoline-1,3-dione (12) 
Preparation of compound 12 followed the same procedure as described for 8 
(see 3.2.1.1) where triazole 11 instead of imidazole 7 was refluxed for 3 h, after which 
toluene was added and reflux continued for 20 h. The product was obtained in a yield 
of 46% after recrystallisation with isopropanol (Scheme 19). 
 
6                               11                                                           12 
Scheme 19: 2-(2-(1H-1,2,4-triazol-1-yl)ethyl)isoindoline-1,3-dione (12) 
 
1H NMR confirmed the presence of triazole with peaks at δ 8.5 and 7.90. In addition, 
the ethyl linker appeared as triplets at δ 4.57 and δ 4.12 (Table 26). 
 
 
 
 
 
Table 26: Identification data for compound 12 
 
 
3.3.1.2 Synthesis of 1-(2-ammonioethyl)-1H-1, 2,4-triazol-4-ium chloride (13) 
Preparation of compound 13 followed the same procedure as described for 9 (see 3.1.4) 
where 12 was used instead of 8. 1 N aqueous HCl and hydrazine monohydrate was 
added to help the breakdown of 12. The product was obtained in a yield of 85 %. 1H 
NMR confirmed the presence of the amine with peaks at δ 8.85. 13C NMR spectra, 
NN
O
NH
N
NN
 R1 = H, F, Cl,OCH3 and CH3
R
N
Br
O
O
N
NHN KI N
N
O
O
N
N
+
Cpd 
Yield 
% 
m.p. Colour and appearance 
Practical Lit. 
12 46 152 - 156℃ 166 - 169℃272 Yellow crystals 
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confirming the ethyl linker (CH2), were observed at δ 46.7 and 37.7 (Table 27 and 
Scheme 20).  
 
(12)                                                     (13) 
Scheme 20: 1-(2-Ammonioethyl)-1H-1, 2,4-triazol-4-ium chloride (13) 
 
 
 
 
 
 
Table 27: Identification data for compound 13 
 
 
3.3.1.3 Synthesis of N-(2-(1H-1,2,4-triazol-1-yl)ethyl)-1-phenyl-3-(substituted/ 
unsubstituted phenyl)-1H-pyrazole-4-carboxamide derivatives (15) 
The method followed was according to the procedure of Aboraia et al.210, as previous 
described (see 3.1.4). The triazole-pyrazole series was difficult to synthesise by using 
coupling reagent CDI (Scheme 22). The carboxylic acids 4a - 4d reacted with the 
coupling reagent rather than with 1-(2-ammonioethyl)-1H-1,2,4-triazol-4-ium chloride 
13 and produced the imidazole-pyrazole compound. As a result, this method was 
unsuccessful for synthesising 15a - 15e (Scheme 21). 
 
Scheme 21: The procedure of Aboraia et al.210 which was used with the triazole-pyrazole series 
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Yield 
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m.p. Colour and 
appearance Practical Lit. 
13 85 162 - 166℃ 182 - 183℃272 Pale yellow crystals 
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Scheme 22: Reacting the CDI with carboxylic acid instead of triazole 
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3.3.1.4 Synthesis of (3-(unsubstituted/substituted)-1-phenyl-1H-pyrazol-4-
yl)(1H-imidazol-1-yl)methanone (16) 
 
1                                                                                        16 
Scheme 23: Synthesis of (3-(unsubstituted/ substituted)-1-phenyl-1H-pyrazol-4-yl)(1H-imidazol-
1-yl)methanone (16) 
 
These compounds were produced by reacting the CDI with a carboxylic acid instead of 
with triazole (Scheme 23). The intermediate products had a yield of 42 and 39% 
respectively. 1H NMR confirmed the presence of the imidazole, and there was no ethyl 
group in the aliphatic region (Table 28 and Scheme 22). 
Table 28:  Reacting of CDI with carboxylic acid 
 
A second method followed the procedure of Khan et al.275 In this method, a two-step 
strategy for the preparation of 15a - 15e was initiated using the acid chlorides 14b, 14d 
and 14e rather than carboxylic acids 4 (Scheme 24).  
 
Scheme 24: Acid chloride derivatives 
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O OH
R
NN
ON
N
R
Where R
16a = R1 = H
16b = R1 = F
CDINN
+HN
NH3+
Cl-
Cl-+
NN
O OH
R1
R2
N
N
R1
R2
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Cl
14b = R1 = F,      R2 = H
14d = R1 = H,     R2 = OCH3
14e = R1 = CH3, R2 = H
Cl S Cl
O
4
Cpd 
Yield 
% 
m.p. 
 
HRMS 
 
Colour and 
appearance 
16a 
42 118 - 120℃ Calculated mass: 314.1217 [M + H]+, 
measured mass: 314.1209 [M + H]+ 
White solid 
16b 
39 130 - 134℃ Calculated mass: 333.1152 [M + H]+, 
measured mass: 333.1146 [M + H]+ 
White solid 
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Carboxylic acid derivatives 4b, 4d and 4e were reacted with thionyl chloride. The 
reaction was refluxed for 6 h, which provided the corresponding acid chlorides, and the 
product was obtained in a yield ranging from 57 to 78 %. 1H NMR confirmed the 
disappearance of the carboxylic acid (Table 29). The acid chlorides 14b, 14d and 14e 
were coupled with 13 using CDI.  
 
 
 
 
 
 
	
Table 29: Identification data for compound 14 
 
                 4e                                                                                            15e 
Scheme 25: N-((1H-1, 2, 4-triazol-1-yl) methyl)-3-phenyl-1-(p-tolyl)-1H-pyrazole-4-carboxamide 
15e 
 
The reaction was successful for one derivative N-((1H-1, 2, 4-triazol-1-yl) methyl)-3-
phenyl-1-(p-tolyl)-1H-pyrazole-4-carboxamide 15e with a yield of 6 % (Scheme 26). 
The reaction resulted in a complex mixture (five spots on TLC), resulting in a very low 
yield after recrystallisation with methanol. However, it was unsuccessful for other 
derivatives (Table 30 and Scheme 25) 
Table 30: Identification data for compound 15e 
 
 
 
 
 
 
NN
+HN
NH3+
Cl-
Cl-
NN
O Cl N
N
O
NH
N
NN
+ CDI
Cpd 
Yield 
% 
m.p. Colour and 
appearance Practical Lit. 
14b 57 112 - 166℃ 140 - 141℃276 White solid 
14d 74 98 - 100℃ Unrecorded White solid 
14e 78 92 - 94℃ Unrecorded White solid 
Cpd Yield% m.p. HRMS Colour and appearance 
15e 
6 142 - 148℃ Calculated mass: 373.1771 
[M + H]+, measured mass: 
373.1772 [M + H]+ 
White solid 
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3.4 Development of lead 1 by changing heterocycle 
Variation in the length of the linker from two carbons to one carbon was investigated 
(Scheme 26) 
Scheme 26: Development of lead 1 by variation the linker 
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3.4.1 Synthesis of 2-((1H-imidazol-1-yl)methyl)isoindoline-1,3-dione (18) 
The method of  Popkov and Skvortsova272 was followed, which used melted imidazole 
7 refluxed with bromomethylphthalamide 17, and potassium iodide was added. The 
reaction was refluxed for 3 h, after which time toluene was added and reflux continued 
for a further 20 h. The product was then recrystallised with methanol, and the product 
was obtained in a yield of 38% (Scheme 27).  
 
17                                 7                                         18 
Scheme 27: 2-((1H-imidazol-1-yl)methyl)isoindoline-1,3-dione (18) 
 
 
3.4.1.1 Synthesis of 2-((1H-1, 2, 4-triazol-1-yl) methyl)isoindoline-1,3-dione (19) 
The method of Popkov and Skvortsova272 was followed, which used melted triazole 11 
refluxed with bromomethylphthalamide 17, and potassium iodide was added (Scheme 
28). The reaction was refluxed for 3 h, after which toluene was added and reflux 
continued for a further 20 h. The product was obtained in a yield of 57 % (Table 31). 
 
 
 
 
 
 
Table 31: Identification data for 18 1and 19 
 
 
17                     11                                          19 
Scheme 28: 2-((1H-1, 2, 4-triazol-1-yl) methyl)isoindoline-1,3-dione (19) 
 
Hydrolysis of compounds 18 and 19 was unsuccessful using hydrazine monohydrate 
and HCl, and instead produced an unknown compound was obtained (Scheme 29). 
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appearance Practical Lit. 
18 38 168 - 172℃ 185 -187℃277 White crystals 
19 57 164 - 168℃ 169 - 170℃
272 White crystals 
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Scheme 29: Unsuccessful hydrolysis 18 and 19 
 
This could be because compounds 18 and 19 have a self-destruct feature. The CH2 linker was 
made stable by steric electronic effects, and imidazole has a catabolic effect leading to the 
hydrolysis of 18 and 19 to produce imidazolylmethylphthalamic acid. As a result, synthesis of 
18 and 19 was unsuccessful, which led to the pathway of synthesis of the final compounds 
being blocked. 
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3.5 Molecular modelling 
Our aim was to design inhibitors of CYP24A1 that are highly potent compared with 
ketoconazole and that would inhibit the catabolism of calcitriol while avoiding impairment of 
its synthesis. Furthermore, the designed compounds should be easily synthesised in our 
laboratory facilities. Crystal structures for human CYP24A1 and CYP27B1 are not available; 
therefore, the human CYP24A1 homology model was built in our laboratory191 (the CYP27B1 
model is detailed in Chapter 2). Ligands were designed and energy minimised using MOE237, 
and then these were saved as a database file (mdb). Docking studies were performed using 
LeadIT 2.1.2 by BioSolve.IT278; this was used as it is one of the most suitable software 
programmes to perform docking studies. 
 
3.5.1 Docking studies on the human CYP24A1 model with development of lead 1 by 
replacement with pyridine 
To design new selective CYP24A1 inhibitors, the objective in this chapter was to create a new 
library of compounds and to dock them in the active site of the human CYP24A1 model191. 
The compounds were designed based on the structure of lead1222, which has IC50 = 4.2	μM. 
Introducing the pyridine ring instead of the pyrazole ring in lead 1 gave compounds 5a - 5e, 
which accessed the CYP24A1 enzyme channel and reached the active site, and they were able 
to carry out hydrophobic interaction with amino acid residues in the active site (Table 32). 5a 
- 5e interacted perpendicularly with the haem iron of the CYP24A1 model with a distance 
ranging between 2.19 Å and 2.87 Å (Figure 61). Furthermore, 5a and 5e could make a hydrogen 
bond between the amide group and Glu329. However, there were poses for compound 5d, 
where the methoxy group bonded perpendicularly with the haem iron with a distance of 2.35 
Å. In addition, there were two extra hydrogen bonds – the first one between the amide group 
and Ala326 and the second bond between the pair of electron on the nitrogen atom of pyrazole 
and Glu329 (Figure 62).  
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Figure 61: Example of some poses of compound 5d interacting with the haem iron via the methoxy group 
 
 
Figure 62: docking data for 5c 
 
 
Table 32: (A) Distance between N of pyridine and iron of haem, (B) 3D and (C) 2D with binding 
interaction 
 
NN
N
H
O
N O
R
N
H
R O
Ala326
R
ON
R
H
Glu329
Fe3+Fe5201
Val391
Val328
Thr330
Met246
Leu325
Hem520
Glu329
Fe5201
Ala327
Ala326
cpd A 
Key amino acids making interaction 
B C 
5a 2.35 Å Glu329 - CONH Met246, Phe249, Ala326, Ala327, Thr330, and Thr500 
5b 2.87 Å - Ile131, Met246, Phe249, Leu325, Ala326, Glu329 and Thr330 
5c 
2.19 Å - Arg128, Ala327, Glu329, Val391, Thr394, Leu325, Ala326, 
Val328, Thr330 and Thr500 
5d 
2.33 Å - Arg128, Leu148, Glu329, Val391, Phe393, Thr394, Ala326, 
Thr330 and Thr500 
5e 2.34 Å Glu329 - CONH Met246, Phe249, Leu325, Ala326, Ala327, Thr330 and Val391 
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3.5.2 Docking studies on the human CYP24A1 model with the development of lead 1 by 
replacement with imidazole  
Inhibitor compounds have been designed by modification of lead 1, introducing the imidazole 
ring instead of the pyrazole ring and changing the linker to the two carbons. The designed 
compounds 10a - 10e interacted perpendicularly with the haem iron of the human CYP24A1 
model with a distance ranging between 2.02 Å and 2.40 Å. All the designed compounds showed 
hydrophobic interaction with the amino acid residues (Table 33, Figure 63, 64 and 65). 
Furthermore, 10a, 10c and 10e formed additional hydrogen bonds. However, there were poses 
for compound 10d, where the methoxy group bonded perpendicularly with the haem iron with 
a distance of 2.13 Å. In addition, the amide 10e interacted perpendicularly with the haem iron 
(Figure 66).  
 
Figure 63: docking data for 10a 
 
 
 
 
Figure 64: docking data for 10e 
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Table 33: (A) Distance between N of imidazole and iron of haem, (B) 3D and (C) 2D with binding 
interaction 
 
 
Figure 65: Example of some poses of compound 10d interacting with the haem iron via methoxy group 
 
 
 
 
Figure 66: Example of some poses of compound 10e interacting with the haem iron via the carbonyl 
groups 
O N
H
N N
N N
O
Fe3+
Fe5201
Val391
Thr395 Thr394
Thr330
Phe393
Leu148
Hem520
Arg128
Ala326
O N
H
N N
N N
Fe3+Fe5201 Val391
Thr500
Thr330 Leu148
Ile131 Hem520
Glu329
Arg128
Ala326
cpd A 
Key amino acids making interaction 
B C 
10a 
2.02 Å Glu329 - CONH 
Thr330 -  CONH 
Leu148, Ile242, Met246, Leu325, Ala326, Ala327, Val328, Val391 
and Thr500 
10b 2.33 Å - Arg128, Ile131, Leu148, Ala326, Glu329 andThr330 
10c 
2.27 Å Val328 - CONH Phe212, Ile239, Ile242, Met246, Leu325, Ala326, Ala327, Glu329 
and Thr330 
10d 
2.32 Å - Arg128, Leu148, Ala326, Thr330, Val391, phe393, Thr394 and 
Thr500 
10e 2.40 Å Glu329 - pyrazole Ile242, Leu325, Ala326, Ala327, Val328, Thr330 and Val391 
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3.5.3 Docking studies on the human CYP24A1 model with the development of lead 1 by 
replacement with triazole 
The modification of lead 1 was achieved by introducing the triazole ring instead of the pyrazole 
ring and changing the linker to the two carbons. The designed compound 15e interacted 
perpendicularly with the haem iron of human CYP24A1 with a distance of 2.15 Å. 15e showed 
hydrophobic interactions with the amino acid residues (Ile242, Met246, Phe249, Ala326, 
Val328 Glu329 and Thr330, and Thr500) (Figure 67). Hydrogen bonds were observed between 
the amide group of 15e, through the nitrogen atom and amino acid Leu325 
 
Figure 67: Example of some poses of compound 15e interacting with the haem iron via nitrogen of amide 
group 
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3.6 Biological assay 
3.6.1 CYP24A1 inhibitor  enzymatic assay279 
All the final compounds 5a - 5e, 10a - 10e, 15e and 16a were evaluated by enzymatic assay to 
determine CYP24A1 inhibitory activity. The assay was performed according to the method of 
Zhu et al.279 in general, the compounds displayed weak inhibition of CYP24A1 activity when 
compared with the ketoconazole standard, and were less active than lead 1 (IC50 4.1 μM)222. 
The IC50 values ranged between 10.2 and 28.4 μM, and the best IC50 value was obtained for 
compound 10b (10.2 µM). The IC50 values are the average (± 10 %) of two independent 
experiments (n = 2), which followed published paper methods191,280, 281,282,283 The limit of two 
experiments is owing to the high cost of enzyme isolation and the appropriate vitamin D 
substrates. 
 
 
Figure 68: 3-(substituted/unsubstituted phenyl)-1-phenyl-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-
carboxamide derivatives 
 
 
Figure 69: N-(2-(1H-imidazol-1-yl) ethyl)-3-(substituted/unsubstituted phenyl)-1-phenyl-1H-
pyrazole-4-carboxamide derivatives 
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Figure 70: N-(2-(1H-1,2,4-triazol-1-yl)ethyl)-1-phenyl-3-(substituted/unsubstituted phenyl)-1H-
pyrazole-4-carboxamide derivatives 
 
The main difference between modified lead 1 compounds (5a – 5e), (10a – 10e) and 15e was 
the variation in the length of the linker with different heterocyclic groups (pyridine, imidazole 
and triazole), where (5a – 5e) have one carbon linker attached to pyridine, (10a – 10e) have a 
two carbon linker to the imidazole group, and 15e has a two carbon linker attached to the 
triazole group, to allow the complete filling of the hydrophobic channel of the CYP24A1 active 
site. The results of all designed compounds were less active than ketoconazole (0.51µM) and 
lead 1 (4.2 µM) (Figures 68 and 69). The best inhibitory activity was observed for the 
imidazole-pyrazole series with 4-fluoro substitution on the phenyl ring 10b (Figure 70 and 71) 
that might be due to the two carbon linker, which leads to a reduction in the distance between 
the imidazole group and the haem iron of CYP24A1. In addition, Saberi et al.281  reviewed how 
dependence on the basicity of the nitrogen heterocycle with inhibitory activity decreased with 
decreasing basicity (pKa: imidazole 14.5 >  triazole  10 >  pyridine 5.2), which correlates well 
with protein affinity (PA) (imidazole, PA =  247 kJmol-1 > triazole, PA =  231kJmol-
1 >  pyridine, PA =  206 kJmol-1). Furthermore, Vinh et al.280 showed that the imidazole 
interacts optimally through a N:-FeIII-haem coordinate link, through the N3 of imidazole, 
however introducing an additional nitrogen in the heterocyclic ring (triazole) reduces the 
coordination potential through the N: due to the electron withdrawing effect of the additional 
electronegative nitrogen, this effect is increased with two additional nitrogens (tetrazole) 
drawing electron density from both sides of the coordinating nitrogen. Moreover, the inhibitor 
activity for 10b was slightly greater than for 5b; this might be because fluorine is more 
electronegative and much smaller in size than chlorine and has a greater ability than chlorine 
to attract electrons. It was found that 5d (13.1µM) had the best inhibitory activity in the pyridine 
series, which could be related to computational molecular docking of 5d in the human 
CYP24A1 homology model; this would predict some poses interacting with the haem iron via 
NN
O
NH
N
NN
Where R R = H, F, Cl,OCH3 and CH3
R
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the methoxy group and enable it to make two additional hydrogen bonds with Ala326 and 
Glu329.   
 
 
Figure 71: CYP24A1 inhibitor enzymatic assay 
 
 
 
3.7 Conclusions 
Previous screening for lead 1 from the SPECS database identified some promising CYP24A1 
inhibitors with moderate inhibitory activity,  
Development of lead 1 by replacement with pyridine and imidazole was synthesised 
successfully. Replacement with triazole was also synthesised by the same methods, however, 
intermediate compounds ware produced due to the carboxylic group reacting with CDI rather 
than with triazolylethylamine salt. All the compounds accessed the vitamin D channel and 
interacted with the active site of CYP24A1. The compounds exhibited weak potency and IC50 
ranging between 10.2 to 28.4 µM against CYP24A1. Owing to the low CYP24A1 inhibitory 
activity the compounds were not evaluated against CYP27B1. 
However, computational molecular docking of two exemplar compounds 5d and 10b in the 
CYP27B1 homology model would predict 10b may have some inhibitory activity of this 
enzyme. Both compounds were found to be at a distance too far for the imidazole to interact 
with the haem iron, however the amide nitrogen of 10b forms a H-bonding interaction with 
Asp320, one of the amino acids identified as important for CYP27B1 inhibitory activity (Figure 
72 and 73). 
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Figure 72: 3D and 2d models showing key binding interactions of 5d with CYP27B1 model 
 
Figure 73: 3D and 2d models showing key binding interactions of 10b with CYP27B1 mode
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3.8 Experimental 
 
Chemistry general information 
All chemicals, reagents, and solvents were purchased from Sigma-Aldrich and Fisher Scientific 
and, where required, solvents were dried and stored over 4	Å	molecular sieves under nitrogen. 
Flash column chromatography was performed with silica gel 60 nm (230 - 400) (Merck), and 
TLC was formed on precoated silica gel plates (Merck Kiesegel 60F254) and preparative TLC 
plates with 254 UV and dimension 20 ×20 cm (Analtech, Inc.). Melting points were 
determined on an electrothermal instrument (Gallenkamp) and are uncorrected. Compounds 
were visualised by irradiation with UV light at 254 nm and 366 nm. 1H and 13C NMR spectra 
were recorded on a Bruker Advance DPX500 spectrometer operating at 500 MHz and 125 
MHz respectively and autocalibrated to deuterated solvent reference peak. Chemical shifts are 
given in	δ relative to tetramethylsilane (TMS); the coupling constant (J) is given in Hertz. 
TMS was used as an internal standard (δ = 0) for 1H NMR, and CDCl3 served as an internal 
standard (δ = 77.0) for 13C NMR. Multiplicity is denoted as s (singlet), d (doublet), t (triplet), 
m (multiplet) or combinations. Mass spectra were performed on a Bruker Daltonics microTof-
LC, (atmospheric pressure ionisation and electron spray mass spectroscopy) in either positive 
mode. Mass spectroscopy and microanalysis were performed by Medac Ltd, Alpha 319, 
Chobham Business Centre, Surrey and EPSRS Swansea. 
 
3.8.1 Molecular modelling 
All molecular modelling method information is reported in Chapter 2. 
 
3.8.2 CYP24A1 inhibitor  enzymatic assay279 
All the final compounds 5a - 5e, 10a - 10e, 15e and 16a were evaluated by enzymatic assay to 
determine CYP24A1 inhibitory activity. The assay was performed according to the method of 
Zhu et al,279 and required a buffer solution containing (Adx + AdxR + CYP24A1 + calcitriol 
+ inhibitors + NADPH) 279 with concentrations and volumes detailed in Table 34. The assay 
was performed in a buffer solution containing 20 mM Tris (pH = 7.6 - 7.7) and 125 mM NaCl. 
The inhibitor compounds were prepared by serial dilution (control with zero time, control, 
0.125 μM, 0.25 μM, 0.5 μM, 1 μM, and 2 μM). 
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Table 34: The concentration and volumes required in the CYP24A1 inhibition assay 
 
The reaction was initiated by the addition of NADPH at a final concentration of 0.5 mM and 
the mixture kept for 25 min at 37 ℃ to keep calcitriol conversion at less than 25 %. Then the 
reaction was quenched by adding four volumes of dichloromethane. After centrifugation, the 
dichloromethane layer was collected and kept overnight to dry. The assay for each compound 
was performed in duplicate (n =2).  The reaction was conducted and analysed by HPLC with 
an eluent of 15 % isopropanol and 85 % hexane; the reaction mixture was injected into HPLC 
on the silica column (Waters Sherisorb S5W, 25 cm x 4.6 mm, 5	μm, SUPELCO Analytical) 
and monitored at 265 nm. 
 
3.8.3 Chemistry 
 
Synthesis of 3-(substituted/unsubstituted phenyl)-1-phenyl-N-(pyridin-4-ylmethyl)-1H-
pyrazole-4-carboxamide derivatives  
 
 
N
N
R1
R2
O
HN
N
Where R
5a = R1 = H,    R2 = H
5b = R1 = F,     R2 = H
5c = R1 = Cl,    R2 = H
5d = R1 = H,     R2 = OCH3
5e = R1 = CH3, R2 = H
Material 
CYP24A1 
Concentration Volume 
Adx 0.1	𝛍𝐌 0.35	𝛍𝐋 
AdxR 0.1	𝛍𝐌 2	𝛍𝐋 
CYP24A1 0.1	𝛍𝐌 5.7	𝛍𝐋 
Calcitriol 2.5	𝛍𝐌 2	𝛍𝐋 
Inhibitor 0 - 2	𝛍𝐌 2	𝛍𝐋 
NADPH 0.5	𝐦𝐌 2	𝛍𝐋 
Buffer solution 186	𝛍𝐋 
Total volume 200 𝛍𝐋 
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3.8.3.1  (E)-1-phenyl-2-(1-phenylethylidene)hydrazine (2a) 
 
 
                           
Method:  
Acetophenone 1a (4.8 g, 40 mmol) was mixed with acetic acid (40 mL), then, phenylhydrazine 
(4 mL, 40 mmol.) was added slowly with stirring for 15 min. The resulting yellow solid was 
collected by filtration and washed with cold ethanol to remove acetic acid263. 
TLC. Petroleum ether-EtOAc 4: 1 v/v, Rf = 0.35 
m. p. = 80 - 82 ℃ (Lit. m. p. 108	℃)258 
Yield = 8.46 g (100 %), white solid 
 
3.8.3.2 (E)-1-(1-(4-fluorophenyl)ethylidene)-2-phenylhydrazine (2b) 
 
                              
Method: See 3.8.3.1 
Reagent: 4-Fluoroacetophenone (5.5 g, 40 mmol) 1b 
TLC: Petroleum ether-EtOAc 3:1 v/v, Rf = 0.53 
m. p. = 88 - 90 ℃ (Lit. m. p. 134 -136	℃)257 
Yield = 1.86 g (20 %), light yellow crystals 
 
3.8.3.3 (E)-1-(1-(4-chlorophenyl)ethylidene)-2-phenylhydrazine (2c) 
 
O
PhNHNH2 N
H
N
Chemical Formula: C14H14N2
Molecular Weight: 210.28
1a 2a
O
F
PhNHNH2 N
H
N
F
Chemical Formula: C14H13FN2
Molecular Weight: 228.27
1b 2b
O
Cl
PhNHNH2 N
H
N
Cl
Chemical Formula: C14H13ClN2
Molecular Weight: 244.72
1c 2c
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Method: See 3.8.3.1  
Reagent: 4-chloroacetophenone (6.2 g, 40 mmol) 1c 
TLC: Petroleum ether-EtOAc 3:1 v/v, Rf = 0.63 
m. p. = 109 - 111℃	(Lit. m. p. 102	℃)259 
Yield = 8.78 g (89 %), light yellow crystals  
  
3.8.3.4 (E)-1-(1-(3-methoxyphenyl)ethylidene)-2-phenylhydrazine (2d) 
 
Method: 
3-Methoxyacetophenone 1d (6 g, 40 mmol) was mixed with acetic acid (4 mL) then, 
phenylhydrazine (4 mL) was added slowly with stirring for 15 min. After stirring for 15 min, 
no precipitate formed. Methanol was added, followed by ice water (100 mL) to give a yellow 
gum. This was extracted with CH2Cl2 (100 mL), and then the organic layer was washed with 
H2O (100 mL ×	2), dried (MgSO4) and concentrated under reduced pressure to give a thick 
dark brown syrup. To this syrup was added ethanol (50 mL) and on standing, the product 
precipitated. The product was collected by vacuum filtration, washed with cold ethanol and 
dried under vacuum to give a light yellow solid263. 
TLC: Petroleum ether-EtOAc 4:1 v/v, Rf = 0.29 
m. p. = 61 - 62 ℃ 
Yield = 7.5 g (78 %), light yellow solid 
 
3.8.3.5  (E)-1-phenyl-2-(1-(P-tolyl)ethylidene)hydrazine (2e) 
 
 
 
 
 
O
PhNHNH2 N
H
N
Chemical Formula: C15H16N2O
Molecular Weight: 240.31
O
O 1d 2d
O
PhNHNH2 N
H
N
Chemical Formula: C15H16N2
Molecular Weight: 224.31
1e 2e
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Method: 
Phenylhydrazine (1.08 g, 10 mmol) was mixed with acetic acid (1mL) and a solution of 4-
methylacetophenone 1e (1.34 g, 0.01 mmol) in ethanol (30 mL) added. The reaction mixture 
was refluxed for 1 h at 83 ℃. Once complete the reaction was cooled and the solvent removed 
under vacuum. Precipitation of product was achieved in ethanol and the resulting precipitate 
was filtered and washed with cold ethanol followed by drying under vacuum257. 
TLC: Petroleum ether-EtOAc 4:1 v/v, Rf = 0.48 
m. p. = 80 - 82 ℃ (Lit. m. p 80	℃)260 
Yield = 2.24 g (100 %), light yellow solid 
 
3.8.3.6 1,3-Diphenyl-1H-pyrazole-4-carbaldehyde (3a) 
 
Method:  
(E)-1-phenyl-2-(1-phenylethylidene) hydrazine 2a (5.8 g, 28 mmol) was dissolved in dry DMF 
(15 mL), then POCl3 (8.5 mL, 91.1 mmol) was added slowly dropwise at 0	℃ and after 
complete addition of POCl3, the mixture was stirred for 2 h at 90	℃. The mixture was then 
poured into ice (50 mL) and 10 % aqueous NaOH solution (10 mL) was added to neutralise the 
solution. The resulting mixture was extracted with CH2Cl2 (2 ×50 mL), washed with water (2 
×50 mL) to remove excess DMF, then organic layer was dried (MgSO4) and evaporated under 
reduced pressure. To the crude product petroleum ether (10 mL/ mmol) was added and the 
mixture stirred for 30 min. The resulting solid was collected by filtration and dried263. 
TLC: Petroleum ether-EtOAc 2:1 v/v, Rf = 0.57 
m. p. =128 - 130	℃ (Lit. m. p. 144 -146	℃)258 
Yield = 4.5 g (66 %), light yellow solid 
1H NMR (CDCl3): 
δ: 10.08 (s, 1H, CHO), 8.57 (s, 1H, pyrazole), 7.81(m, 4H, Ar), 7.48 (m, 5H, Ar), 7.42 (t, J = 
7.5 Hz, 1H, Ar).  
POCl3 NN
O
H
N N
H
Chemical Formula: C16H12N2O
Molecular Weight: 248.29
2a 3a
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3.8.3.7 3-(4-Fluorophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (3b) 
 
 
Method: See 3.8.3.6 
Reagent: (E)-1-(1-(4-fluorophenyl)ethylidene)-2-phenylhydrazine (1.9  g, 8 mmol) 2b 
TLC: Petroleum ether-EtOAc 3:1v/v, Rf = 0.48 
m. p. =150 - 154℃ (Lit. m. p. 173 - 175	℃)257 
Yield = 0.97 g (44 %), light yellow crystals 
1H NMR (CDCl3): 	δ:	10.06 (s, 1H, CHO), 8.56 (s, 1H, pyrazole), 7.90 (dd, J = 5.4, 8.9 Hz, 2H, Ar), 7.82 (d, J = 
8.1 Hz, 2H, Ar), 7.55 (𝜑t, J = 7.6, 8.1 Hz, 2H, Ar), 7.43 (t, J= 7.5 Hz, 1H, Ar), 7.22 (t, J = 8.5 
Hz, 2H, Ar). 
 
3.8.3.8 3-(4-Chlorophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (3c) 
 
Method: See 3.8.3.6 
Reagent: (E)-1-(1-(4-chlorophenyl)ethylidene)-2-phenylhydrazine (2 g, 8 mmol) 2c 
TLC: Petroleum ether-EtOAc 3:1 v/v, Rf = 0.42 
m. p. = 139 -142	℃  (Lit. m. p. 138 - 140	℃)263 
Yield = 1.4 g (61 %), light yellow crystals 
1H NMR (CDCl3): 
δ: 10.06 (s, 1H, CHO), 8.55 (s, 1H, pyrazole), 7.86 (d, J = 8.6 Hz, 2H, Ar), 7.81(d, J = 7.7 Hz, 
2H, Ar), 7.55 (𝜑t, J = 8.1, 8.5 Hz, 2H, Ar), 7.5 (d, J = 8.5 Hz, 2H, Ar), 7.43 (t, J = 7.0 Hz, 1H, 
Ar). 
POCl3 NN
F
O
H
N N
H
F
Chemical Formula: C16H11FN2O
Molecular Weight: 266.28
2b 3b
POCl3 NN
Cl
O
H
N N
H
Cl
Chemical Formula: C16H11ClN2O
Molecular Weight: 282.73
2c 3c
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3.8.3.9 3-(3-Methoxyphenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (3d) 
 
Method: See 3.8.3.6 
Reagent: (E)-1-(1-(3-methoxyphenyl)ethylidene)-2-phenylhydrazine (4.3 g, 18 mmol) 2d 
TLC: Petroleum ether-EtOAc 3:1 v/v, Rf = 0.46 
m. p. = 70 - 74	℃	(Lit. m.p 102	℃ )284,285 
Yield = 3.49 g (69 %), light yellow crystals 
1H NMR (CDCl3): 
δ: 10.09 (s, 1H, CHO), 8.56 (s, 1H, pyrazole), 7.53 (t, J = 7.9 Hz, 2H, Ar), 7.82 (dd, J = 1.1, 
8.6 Hz, 2H, Ar), 7.40 (m, 4H, Ar), 7.04 (m, 1H, Ar), 3.91 (s, 3H, OCH3). 
 
3.8.3.10     1-Phenyl-3-(p-tolyl)-1H-pyrazole-4-carbaldehyde (3e) 
           
 
Method: See 3.8.3.6 
Reagent: (E)-1-phenyl-2-(1-(p-tolyl)ethylidene)hydrazine (2.24 g, 10 mmol) 2e 
TLC: Petroleum ether-EtOAc 3:1 v/v, Rf = 0.63 
m. p. = 125 - 128	℃	(Lit. m. p. 120	℃) 286 
Yield = 2.6 g (39 %), light yellow solid 
1H NMR (CDCl3) 
δ: 10.07 (s, 1H, CHO), 8.56 (s, 1H, pyrazole), 7.81 (d, J = 7.6 Hz, 2H, Ar), 7.74 (d, J = 8.1 
Hz, 2H, Ar), 7.53 (𝜑t, J = 7.6, 8.4 Hz, 2H, Ar), 7.41 (t, J = 7.4 Hz, 1H, Ar), 7.34 (d, J = 7.9 Hz, 
2H, Ar), 2.45 (s, 3H, CH3). 
POCl3 NN
O
H
N N
H
Chemical Formula: C17H14N2O2
Molecular Weight: 278.31
O
O
2d 3d
POCl3 NN
O
H
N
H
N
Chemical Formula: C17H14N2O
Molecular Weight: 262.31
2e 3e
Chapter three                                                                                                       Lead 1 
	
	
115	
3.8.3.11 3-Diphenyl-1H-pyrazole-4-carboxylic acid (4a) 
 
Method:  
1,3-Diphenyl-1H-pyrazole-4-carbaldehyde 3a (1g, 4 mmol) was dissolved in a mixture of t-
butanol/H2O 1:1 (10 mL/10 mL), then, an aqueous solution of KMnO4 (0.7 g in 20 mL H2O, 
4.1 mmol) was added dropwise over 45 min with stirring at 75	℃. 10 % aqueous KOH solution 
(15 mL) was then added until alkaline pH. The mixture was filtered and the filtrate was 
acidified with conc. HCl to pH 2. The precipitated solid was collected by filtration and washed 
with H2O258.  
TLC: CH2Cl2-CH3OH 9: 1 v/v, Rf = 0.73 
m. p. = 198 - 200	℃	 (Lit. m. p. 200 - 202℃)258 
Yield = 0.91 g (83 %), pale yellow solid recrystallised with methanol 
1H NMR (DMSO-d6): 
δ: 12.59 (s, 1H, COOH), 9.06 (s, 1H, pyrazole), 7.98 (d, J = 7.6 Hz, 2H, Ar), 7.98 (d, J = 8.4 
Hz, 2H, Ar), 7.85 (d, J = 7.9 Hz, 2H, Ar), 7.55 (𝜑t, J = 7.0, 9.0 Hz, 2H, Ar), 7.47 (m, 2H, Ar). 
    
3.8.3.12  3-(4-Fluorophenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid (4b) 
 
Method: See 3.8.3.11 
Reagent: 3-(4-Fluorophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (1 g, 3.8 mmol) 3b 
TLC: CH2Cl2-CH3OH 9: 1 v/v, Rf = 0.53 
m. p. = 222 - 223	℃ (Lit. m. p. 229 - 230	℃) 276 
Yield = 0.35 g, (37 %), a white crystals recrystallised with methanol 
 
N
N
O
OH
KMnO4NN
O
H
Chemical Formula: C16H12N2O2
Molecular Weight: 264.28
3a 4a
N
N
O
OH
KMnO4NN
O
H
Chemical Formula: C16H11FN2O2
Molecular Weight: 282.27
F F
3b 4b
Chapter three                                                                                                       Lead 1 
	
	
116	
1H NMR (DMSO-d6) 
δ: 12.60 (s, 1H, COOH), 9.07 (s, 1H, pyrazole), 7.98 (d, J = 7.4 Hz, 2H, Ar), 7.93 (dd, J = 
5.6, 88 Hz, 2H, Ar), 7.55 (t, J = 7.8 Hz, 2H, Ar), 7.40 (𝜑t, J = 7.0, 8.5 Hz, 1H, Ar), 7.39 (t, J = 
8.5Hz, 2H, Ar) 
 
3.8.3.13   3-(4-Chlorophenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid (4c) 
  
Method: See 3.8.3.11  
Reagent: 3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (1g, 3.5mmol) 3c 
TLC: CH2Cl2-CH3OH 9: 1 v/v, Rf = 0.23 
m. p. = 238 - 240	℃ (Lit. m. p. 240 - 242	℃)276 
 Yield = 0.85 g (80 %), white solid recrystallised with methanol 
1H NMR (DMSO-d6) 
δ: 12.68 (s, 1H, COOH), 9.08 (s, 1H, pyrazole), 7.98 (d, J = 7.9 Hz, 2H, Ar), 7.90 (d, J = 8.4 
Hz, 2H, Ar), 7.86 (m, 4H, Ar), 7.40 (t, J = 7.4 Hz, 1H, Ar). 
  
3.8.3.14 3-(3-Methoxyphenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid (4d) 
 
Method: See 3.8.3.11 
Reagent: 3-(3-methoxyphenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (1 g, 3.4 mmol) 3d 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.77 
m. p. = 139 - 140	℃ 
Yield = 0.71 g (70 %), white solid, recrystallised with methanol 
N
N
O
OH
KMnO4NN
O
H
Chemical Formula: C16H11ClN2O2
Molecular Weight: 298.73
Cl Cl
3c 4c
N
N
O
OH
KMnO4NN
O
H
Chemical Formula: C17H14N2O3
Molecular Weight: 294.31
OO
3d 4d
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1H NMR (DMSO-d6): 
δ: 12.55 (s, 1H, COOH), 9.06 (s, 1H, pyrazole), 7.98 (d, J = 7.6 Hz, 2H, Ar), 7.55 (t, J = 8.0 
Hz, 3H, Ar), 7.35 (m, 4H, Ar), 3.85 (s,1H, OCH3). 
13C NMR (DMSO-d6): 
δ: 163.7 (COOH), 158.7, 152.5, 138.8, 113.9, 133.3 (5 × C, Ar), 133.6 (pyrazole), 129.6, 
128.8, 127.2, 121.3, 119.2, 119.0, 114.8, 114.0 (9 × CH, Ar), 55.1 (OCH3). 
 Microanalysis: 
Anal. Calcd for C17H14N2O3 (294.30): C 69.38 %, H 4.79 %, N 9.51, %. Found C 69.40 %, H 
4.66 %, N 9.51 %. 
 
3.8.3.15   1-Phenyl-3-(p-tolyl)-1H-pyrazole-4-carboxylic acid(4e) 
                          
Method: See 3.8.3.11 
Reagent: 1-phenyl-3-(p-tolyl)-1H-pyrazole-4-carbaldehyde (0.8g, 3mmol) 3e 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf  = 0.26 
m. p. = 235 - 238	℃ (Lit. m. p. 191 - 193	℃)287 
Yield = 0.47 g, (54 %) white solid 
1H NMR (DMSO-d6): 
δ: 12.64 (s, 1H, COOH), 9.03 (s, 1H, pyrazole), 8.03 (m, 2H, Ar), 7.74 (d, 2H, J = 8.1 Hz, 
Ar), 7.57 (m, 2H, Ar), 7.43 (m, 1H, Ar), 7.26 (d, J = 8.2 Hz, 2H, Ar), 2.37 (s, 3H, CH3). 
 
N
N
O
OH
KMnO4NN
O
H
Chemical Formula: C17H14N2O2
Molecular Weight: 278.31
3e 4e
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3.8.3.16 1,3-Diphenyl-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-carboxamide derivatives 
(5a) 
 
Method:  
1,3-Diphenyl-1H-pyrazole-4-carboxylic acid 4a (0.3 g, 1.1 mmol) was dissolved in anhydrous 
DMF (5 mL), then a solution of N,N′-carbonyldiimidazole (0.2 g, 1.2 mmol) in dry DMF (3 
mL) added and the reaction stirred for 1 h. The reaction was cooled to 0	℃, and a solution of 
4-aminomethylpyridine (0.16 g, 1.5 mmol) in dry DMF (4 mL) was added and the mixture 
stirred at room temperature for 20 h. Once complete, ice - H2O (50 mL) was added and the 
resulting white precipitate collected by filtration and washed with cold water and dried210. 
TLC: CH2Cl2-CH3OH 9:1v/v, Rf = 0.79 
m. p. = 188 - 190	℃ 
Yield = 0.16 g (39 %), white solid, recrystallised with methanol 
1H NMR (DMSO-d6): 
δ: 9.01 (s, 1H, pyrazole), 8.84 (t, J = 5.8 Hz, 1H, NH), 8.53 (d, J = 5.6 Hz, 2H, pyridine), 7.93 
(d, J = 7.7 Hz, 2H, Ar), 7.86 (dd, J = 1.3, 7.6 Hz, 2H, Ar), 7.58 (𝜑t, J = 7.5, 8.3 Hz, 2H), 7.44 
(m, 6H, Ar), 4.48 (d, J = 5.9 Hz, 2H, CH2). 
13C NMR (DMSO-d6): 
δ: 163.0 (CO), 150.9, 148.4, 139.0 (3 × C), 132.2 (CH, pyrazole), 130.3 (C), 129.6, 128.7, 
128.3, 127.9, 126.9, 122.2, 118.6 (14 × CH, Ar), 117.4 (C), 41.5 (CH2) 
 Microanalysis: 
 Anal. Calcd for C22H18N4O (354.40): C 74.56 %, H 45.12 %, N 15.80 %. Found C 74.36 %, 
H 5.04 %, N 15.84 %.  
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3.8.3.17 3-(4-Fluorophenyl)-1-phenyl-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-
carboxamide (5b) 
 
Method: See 3.8.3.16 
Reagent: 3-(4-fluorophenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid (0.3 g, 1.1 mmol) 4b  
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.58 
m. p. = 199 - 200	℃ 
Yield = 0.24 g (58 %), white crystals, recrystallised with methanol 
1H NMR (DMSO-d6): 
δ: 9.03 (s, 1H, pyrazole), 8.54 (𝜑t, J = 1.5, 4.5 Hz, 1H, NH), 8.54 (dd, 2H, J = 1.5, 4.5 Hz, 
pyridine), 7.94 (m, 4H, Ar), 7.57 (𝜑t, 2H, J = 8.5, 7.5 Hz, Ar), 7.41 (m, 3H, Ar), 7.25 (t, 2H, J 
= 9.0 Hz, pyridine), 4.49 (d, 2H, J = 6.0 Hz, CH2). 
13C NMR (DMSO-d6): 
δ: 163.2 (CO), 162.9 (F-C), 161.2, 150.2 (2 × CH, Ar), 149.5, 148.4, 138.9, 130.6, 130.5 (5 
× C), 130.4 (CH, pyrazole), 130.1, 129.7, 128.8, 128.7, 127.1, 122, 117.1, 118.7, 114.9, 114.8 
(11 × CH, Ar), 41.4 (CH2). 
LRMS (ES-TOF) 
m/z: 373 [M + H]+ 
HRMS (ES-TOF) 
Calculated mass: 373.1459 [M + H]+, measured mass: 373.1493 [M + H]+ 
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3.8.3.18  3-(4-Chlorophenyl)-1-phenyl-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-
carboxamide (5c) 
 
Method: See 3.8.3.16 
Reagent: 3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid (0.5 g, 3.3 mmol) 4c. 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.58 
m. p. = 222 - 223	℃ 
 Yield = 0.24 g (37 %), white crystals, recrystallised with methanol 
1H NMR (DMSO-d6): 
δ: 9.04 (s, 1H, pyrazole), 8.87 (t, J = 5.6 Hz, 1H, NH), 8.53 (dd , J = 1.4, 4.6 Hz, 2H, pyridine), 
7.91 (t, J = 8.7 Hz, 4H,  Ar), 7.60 (𝜑t, J = 8.2, 7.5 Hz, 2H, Ar), 7.48 (d, J = 8.6 Hz, 2H, Ar), 
7.41 (t , J = 7.3 Hz, 1H, Ar), 7.36 (d, J = 5.7 Hz, 2H, pyridine), 4.48 (d, J = 5.7 Hz, 2H, CH2). 
13C NMR (DMSO-d6): 
δ: 162.8 (CO), 149.9, 148.3, 138.9, 133.0, 131.2 (5 × C), 130.48 (CH, pyrazole), 130.1, 
129.7, 128.0, 127.1, 122.2, 118.7 (13 × CH, Ar), 117.3 (C), 41.5 (CH2). 
 Microanalysis: 
Anal. Calcd for C22H17ClN4O (388.85): C 67.95 %, H 4.41 %, N 14.41 %. Found C 67.87 %, 
H 4.31 %, N 14.58 %.  
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3.8.3.19 3-(3-Methoxyphenyl)-1-phenyl-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-
carboxamide (5d) 
 
 
Method: See 3.8.3.16 
Reagent: 3-(3-methoxyphenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid (0.5 g, 1.7 mmol) 4d 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.67 
m. p. = 143 - 144	℃ 
Yield = 0.22 g (33 %), white crystals, recrystallised with methanol 
1H NMR (DMSO-d6): 
δ: 8.99 (s, 1H, pyrazole), 8.87 (t, J = 5.9 Hz, 1H, NH), 8.53 (d, J = 5.8 Hz, 2H, pyridine), 7.93 
(d, J = 7.8 Hz, 2H, Ar), 7.57 (t, J = 7.9, 2H, Ar), 7.47 (m, 2H, Ar), 7.47 (m, 4H, Ar), 6.98 (dd, 
J = 2, 8, Hz, 2H, Ar), 4.48 (d, J = 5.9 Hz, 2H, CH2), 3.77 (s, 3H, OCH3). 
13C NMR (DMSO-d6): 
δ: 163.1 (CO), 158.9, 150.6, 148.3, 139.0, 133.5, (5 × C), 130.2 (CH, pyrazole), 129.7, 129.1, 
126.9, 122.2, 120.6, 118.7, (11 × CH, Ar), 117.6 (C), 113.8, 113.9 (2 × CH, Ar), 41.5 (CH2), 
54.9 (OCH3). 
 Microanalysis: 
Anal. Calcd for C23H20N4O2 (384.43): 71.86 %, H 5.24 %, N 14.57 %. Found C 71.90 %, H 
5.12 %, N 14.73 %. 
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3.8.3.20   1-Phenyl-N-(pyridin-4-ylmethyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide (5e) 
 
Method: See 3.8.3.16 
Reagent: 1-phenyl-3-(p-tolyl)-1H-pyrazole-4-carboxylic acid (0.47 g, 1.7 mmol) 4e 
TLC: CH2Cl2-CH3OH 9:1 v/v Rf = 0.48 
m. p. = 191 - 193	℃ 
Yield = 0.026 g (4 %), white solid, recrystallised with methanol 
1H NMR (DMSO-d6): 
δ: 8.97 (s, 1H, pyrazole), 8.80 (t, J = 6 Hz,1H, NH), 8.53 (d, J = 5.6 Hz, 2H, pyridine), 7.91 
(d, J = 7.7 Hz, 2H, pyridine), 7.75 (d, J = 8 Hz, 2H, Ar), 7.57 (t, J = 8 Hz, 2H, Ar), 7.40 (m, 
3H, Ar), 7.22 (d, J = 7.8 Hz, 2H), 4.47 (d, J = 6 Hz, 2H, CH2), 2.35 (s, 3H, CH3). 
13C NMR (DMSO–d6): 
δ: 163.1 (CO), 150.9, 148.4, 139.0, 137.6, (4 × C), 131.1 (CH, pyrazole), 131.0, 130.1, 129.7, 
128.6, 128.2, 126.9, 122.2, 118.6 (13 × CH, Ar), 117.3 (C), 41.5 (CH2), 20.8 (CH3). 
Microanalysis: 
Anal. Calcd for C23H20N4O	∙	0.3 H2O (373.85): C 73.89 %, H 5.47 %, N 14.98 %. Found C 
73.72 %, H 5.40 %, N 14.59 %. 
 
3.8.3.21      2-(2-(1H-imidazol-1-yl)ethyl)isoindoline-1,3-dione272 (8)  
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Method:  
Potassium iodide (0.2 g, 0.07 mmol) was added to melted imidazole 7 (5.7 g, 84 mmol). Then 
N-(2-bromoethyl)phthalimide 6 (7.1 g, 28 mmol) was added. The mixture was stirred at 100 
℃ for 3 h. Toluene (25 mL) was added, the reaction stirred at 115 ℃	for 20 h. The solvent was 
reduced under vacuum to give a thick syrup.  The syrup was recrystallised with isopropanol272.  
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.57 
m. p. = 126 - 130	℃	(Lit. m. p. 155 - 157	℃)272 
Yield = 3.3 g (49 %), white solid, recrystallised with isopropanol 
1H NMR (DMSO-d6): 
δ: 7.85 (d, J = 1.7 Hz, 4H, Ar), 7.55 (s, 1H, imid), 7.13 (s, H, imid), 6.82 (s, 1H, imid), 4.26 
(t, J = 6.1 Hz, 2H, CH2), 3.92 (t, J = 6.2 Hz, 2H, CH2) 
 
3.8.3.22 1-(2-Ammonioethyl)-1H-imidazol-3-ium chloride (9) 270,288 
 
Method:  
2-(2-(1H-imidazol-1-ylethyl)isoindoline-1,3-dione 8 (2.75 g, 11.4 mmol) and                                                         
hydrazine monohydrate (1.2 g, 22.8 mmol) dissolved in ethanol (25 mL) was heated under 
reflux for 4 h. The resulting mixture was cooled to 0 ℃ and filtered, and the filtrate was 
evaporated to dryness under reduced pressure. The residue was dissolved in aqueous 1 N HCl 
(50 mL) and filtered, and the solvent was removed under reduced pressure to give a pale yellow 
solid270.  
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.00 
m. p. = 170 - 175 ℃	(Lit. m. p. 217 - 220	℃)288 
Yield = 1.73 g (82 %), pale yellow solid 
1H NMR (D2O) 
δ: 8.88 (s, 1H, imid), 7.60 (s, 1H, imid), 7.54 (s, 1H, imid), 4.63 (t, J = 6.2 Hz, 2H, CH2), 3.57 
(t, J = 6.2 Hz, 2H, CH2). 
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3.8.3.23 N-(2-(1H-imidazol-1-yl)ethyl)-1, 3-diphenyl-1H-pyrazole-4-carboxamide (10a) 
 
Method:  
1,3-Diphenyl-1H-pyrazole-4-carboxylic acid 4a (0.42 g, 1.6 mmol) was dissolved in 
anhydrous DMF (8 mL), then a solution of N,N′-carbonyldiimidazole (0.26 g, 1.6 mmol) in 
dry DMF (2 mL) added and the reaction stirred for 1 h. The reaction was cooled to 0 ℃, and a 
mixture of 1-(2-ammonioethyl)-1H-imidazol-3-ium chloride 9 (0.3 g, 1.6 mmol) with 
triethylamine (0.5 mL, 3.2 mmol) in dry DMF (4 mL) was added and the mixture stirred at 
room temperature for 20 h. Once complete, ice-H2O (50 mL) was added and the resulting 
yellow precipitate collected by filtration and washed with cold water and dried.  The product 
was purified by gradient flash column chromatography, product was eluted with EtOAc- 
CH3OH 9:1 v/v210. 
TLC: EtOAc-CH3OH 9:1 v/v Rf = 0.42 
m. p. = 136 - 138 ℃ 
Yield = 0.24 g (40 %), white solid 
1H NMR (DMSO-d6):  
δ: 8.90 (s, 1H, pyrazole), 8.37 (s, 1H, NH), 7.88 (d, J = 7.3 Hz, 2H, Ar), 7.79 (d, J = 6.5 Hz, 
2H, Ar), 7.65 (s, 1H, imid), 7.58 (t, J = 6.8 Hz, 2H, Ar), 7.43 (t, J = 8.2 Hz, 4H, Ar), 7.21 (s, 
1H, imid), 6.92 (s, 1H, imid), 4.16 (s, 2H, CH2), 3.57 (d, J = 4.6 Hz, 2H, CH2) 
13C NMR (DMSO-d6): 
δ: 162.9 (CO), 150.9, 138.9, 132.2 (3 × C), 129.9 (CH, pyrazole), 129.7, 129.6, 129.1, 128.4, 
128.2, 128.2, 128.0, 127.9, 127.7, 126.9, 126.6, 118.8 (13 × CH, Ar), 117.4 (C), 45.3, 40.0 
(CH2). 
Microanalysis: 
C21H19N5O (357.42): C 70.57%, H 5.36 %, N 19.59 %. Found: C 70.28 %, H 5.19 %, N 
19.29%. 
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3.8.3.24 N-(2-(1H-imidazol-1-yl) ethyl)-3-(4-fluorophenyl)-1-phenyl-1H-pyrazole-4-
carboxamide (10b) 
 
Method: See 3.8.3.23 
The product was purified by gradient flash column chromatography; product was eluted with 
EtOAc- CH3OH 9:1 v/v.  
Reagent: 3-(4-Fluorophenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid (0.25 g, 1.4 mmol) 4b 
TLC: EtOAc-CH3OH 9: 1 v/v, Rf = 0.2 
m. p. = 158 -160	℃ 
Yield = 0.18 g (29 %), white crystals 
1H NMR (CD3OD):  
δ: 8.49 (s, 1H, pyrazole), 7.83 (d, J = 7.7 Hz, 2H, Ar), 7.85 (m, 3H, Ar), 7.56 (𝜑t, J = 7.6, 8.4 
Hz, 2H, Ar), 7.41 (t, J = 7 Hz, 1H, imid), 7.20 (s, 1H, imid), 7.19 (m, 2H, Ar), 7.05 (s, 1H, 
imid), 4.28 (t, 2H, J = 6.0 Hz, CH2), 3.72 (t, J = 6.0 Hz, 2H, CH2). 
13C NMR (CD3OD): 
δ: 166.1 (CO), 165.4 (F-C), 163.5 (C), 152.4 (C), 140.7 (C), 131.8, 131.7, 131.1, 129.9, 130.7, 
128.9, 128.5 (13 × CH, Ar), 129.8 (C), 118.1 (C), 47.2 (CH2), 41.4 (CH2). 
Microanalysis: 
Calculation for C21H18FN5O	∙ 0.3 H2O (380.81): C, 66.60, H, 4.90, N, 18.31. Found: C, 66.57; 
H, 4.82; N, 17.99. 
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3.8.3.25 N-(2-(1H-imidazol-1-yl) ethyl)-3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-
carboxamide (10c) 
 
Method: See 3.8.3.23 
Reagent: 3-(4-Chlorophenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid (0.42 g, 1.4 mmol) 4c 
TLC: EtOAc-CH3OH 9: 1v/v, Rf = 0.125 
m. p. = 184 - 186	℃ 
 Yield = 0.12 g (19 %), white crystal, recrystallised from acetonitrile 
1H NMR (CD3OD): 
δ: 8.53 (s, 1H, pyrazole), 7.83 (d, J = 7.7 Hz, 2H, Ar), 7.72 (d, J = 8.5 Hz, 2H, Ar), 7.68 (s, 
1H, imid), 7.55 (𝜑t, J = 7.6, 8.4 Hz, 2H, Ar), 7.44 (m, 3H, Ar), 7.18 (s, 1H, imid), 7.03 (s, 1H, 
imid), 4.25 (t, J = 6.0 Hz, 2H, CH2), 3.71 (t, J = 6.0 Hz, 2H, CH2). 
13C NMR (CD3OD): 
δ: 166.1 (CO), 152.2 (C), 140.7 (C), 135.6 (C), 132.3 (C), 131.2 (CH, pyrazole), 131.1, 130.8, 
129.4, 128.6, 120.5 (12 × CH, Ar), 118.3 (C), 47.1 (CH2), 41.4 (CH2). 
Microanalysis: 
Calculated for C21H18ClN5O	∙ 0.1 H2O (393.66): C, 64.07, H, 4.65, N, 17.79. Found: C, 63.92, 
H, 4.33, N, 17.76. 
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3.8.3.26 N-(2-(1H-imidazol-1-yl) ethyl)-3-(3-methoxyphenyl)-1-phenyl-1H-pyrazole-4-
carboxamide (10d) 
 
Method: See 3.8.3.23 
After 20 h the reaction was incomplete. Additional CDI (about 2 eq.)  and 1-(2-ammonioethyl)-
1H-imidazol-3-ium chloride 9 (1eq.) added and the reaction heated at 60 ℃ overnight.  The 
product was purified by gradient flash column chromatography, product was eluted with 
EtOAc- CH3OH 9:1 v/v.  
Reagent: 3-(3-Methoxyphenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid (0.4 g, 1.4 mmol) 4d 
TLC:  EtOAc-CH3OH 2:1 v/v, Rf = 0.6 
m. p. = 108 - 112 ℃ 
 Yield = 0.18 g (32 %), bright yellow crystals 
1H NMR (CD3OD):	 
δ: 8.51 (s, 1H, pyrazole), 7.83 (d, J = 7.7 Hz, 2H, Ar), 7.66 (s, 1H, imid), 7.55 (𝜑t, J = 7.6, 
8.4 Hz 2H, Ar), 7.42 (m, 4H, Ar), 7.16 (s, 1H, imid), 7.01(m, 2H, Ar), 4.25 (t, J = 6.0 Hz, 2H, 
CH2), 3.86 (s, 3H, OCH3), 3.71 (t, J = 6.0 Hz, 2H, CH2). 
13C NMR (CD3OD): 
δ: 166.3 (CO), 161.1, 152, 9, 140.8, 134.8 (4 × C), 131.2 (CH, pyrazole), 130.7, 130.5, 129.2, 
128.5, 122.1, 120.9, 115.4, 115.2 (12 × CH, Ar), 118.5 (C), 55.8 (OCH3), 47.1 (CH2), 41.5 
(CH2). 
Microanalysis: 
Calculated for C22H21N5O2	∙ 0.2 H2O (391.04): C, 67.57, H, 5.51, N, 17.91. Found: C, 67.21, 
H, 5.25, N, 17.56. 
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3.8.3.27 N-(2-(1H-imidazol-1-yl)ethyl)-1-phenyl-3-(p-tolyl)-1H-pyrazole-4-carboxamide 
(10e)   
 
Method: See 3.8.3.23 
The product was purified by gradient flash column chromatography, product was eluted with 
EtOAc- CH3OH 9:1 v/v.  
Reagent: 1-phenyl-3-(p-tolyl)-1H-pyrazole-4-carboxylic acid (0.47 g, 1.7 mmol) 4e 
TLC: EtOAc-CH3OH 9: 1 v/v, Rf =0.20 
m. p. = 76 - 80	℃ 
Yield = 0.034 g (6 %), white solid 
1H NMR (CD3OD):  
δ: 8.5 (s, 1H, pyrazole), 7.81 (d, J = 7.7 Hz, 2H, Ar), 7.69 (s, 1H, imid), 7.59 (d, J = 8.1 Hz, 
2H, Ar), 7.53 (𝜑t, J = 7.7, 8.3 Hz, 2H, Ar), 7.39 (t, J = 7.5 Hz, 1H, Ar), 7.24(d, J = 8 Hz, 2H, 
Ar), 7.17 (s, 1H, imid), 7.03 (s, 1H, imid), 4.23 (t, 2H, J = 6.0 Hz, CH2), 3.68 (t, J = 6 Hz, 2H, 
CH2), 2.45 (s, 3H, CH3). 
13C NMR (CD3OD): 
δ: 165.6 (CO), 152.50 (C), 139.98 (C), 139.1 (C), 130.4 (CH, pyrazole), 129.9, 129.2, 128.3, 
119.7 (12 × CH, Ar), 129.8 (C), 117.4 (C), 46.4 (CH2), 40.6 (CH2), 20.6 (CH3). 
Microanalysis: 
Calculation for C22H21N5O (371.44): C, 71.14; H, 5.70; N, 18.85. Found: C, 70.87, H, 5.74, N, 
18.67. 
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3.8.3.28  2-(2-(1H-1, 2,4-triazol-1-yl)ethyl)isoindoline-1,3-dione (12) 272 
 
 
 
Method:  
Potassium iodide (60.3 g, 1.8 mmol) was added to melted triazole 11 (6.5 g, 94 mmol). Then 
N-(2-bromoethyl)phthalimide 6 (6 g, 24 mmol) was added . The mixture was stirred at 100 ℃ 
for 3 h. Petroleum ether (20 mL) was added to give a waxy orange precipitate that was 
recrystallised  with isopropanol272.  
TLC: CH2Cl2-CH3OH 9.9: 0.1 v/v, Rf = 0.64 
m. p. = 152 - 156	℃	(lit. m. p. 166 - 169	℃)272 
Yield = 2.3 g (46 %), yellow crystals 
1H NMR (CD3OD):  
δ: 8.50 (s, 1H, triazole), 7.90 (s, H, triazole), 7.85 (m, 4H, Ar), 4.57 (𝜑t, J = 5.5, 5.9 Hz, 2H, 
CH2), 4.12 (t, J = 5.7 Hz, 2H, CH2) 
 
3.8.3.29 1-(2-Ammonioethyl)-1H-1,2,4-triazol-4-ium chloride (13)272 
 
Method: See 3.8.3.22 
Reagent: 2-(2-(1H-1, 2,4-triazol-1-yl)ethyl)isoindoline-1,3-dione (1.2 g, 5 mmol) 12                                                                     
TLC: CH2Cl2-CH3OH 9: 1 v/v, Rf = 0.00 
m. p. = 162 -166 ℃	(lit. m. p. 182 - 183 ℃)272 
Yield = 1.0 g (85 %), pale yellow solid 
1H NMR (DMSO-d6): 
δ: 9.48 (s, 1H, triazole), 8.66 (s, 1H, triazole), 8.56 (br. s, 3H, NH3+), 4.65 (t, J = 6 Hz, 2H, 
CH2), 3.32 (t, J = 6 Hz, 2H, CH2). 
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13C NMR (DMSO-d6): 
δ: 167.4, 131.4 (4 × C, Ar), 151.4, 144.3, 134.4, 123.1 (6 × CH, Ar) 46.7, 37.7 (2 × CH2, 
CH2). 
 
3.8.3.30 1-(4-Fluorophenyl)-3-phenyl-1H-pyrazole-4-carbonyl chloride (14b) 
 
Method:  
3-(4-Fluorophenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid 4b (0.17 g, 0.58                           
mmol) was suspended in dry toluene (15 mL) then thionyl chloride (0.13 mL, 1.8 mmol) was 
added dropwise. The mixture was refluxed for 6 h, then cooled to room temperature. The 
solvent was removed under reduced pressure to give a solid compound which  was washed 
with petroleum ether to give a white solid275 
Yield = 0.10 g (57 %), white solid 
m. p. = 122 -126 ℃	(lit. m. p. 140 - 141 ℃)276 
TLC: Petroleum ether-EtOAc 3: 1, Rf = 0.42 
1H NMR (DMSO-d6): 
δ: 9.07 (s, 1H, pyrazole), 7.99 (d, J = 7.7 Hz, 2H, Ar), 7.92 (m, 2H, Ar), 7.55 (t, J = 7.7 Hz, 
2H, Ar), 7.39 (t, J = 7.4 Hz, 1H, Ar), 7.29 (t, J = 8.9 Hz, 2H, Ar).  
 
3.8.3.31 3-Phenyl-1-(p-tolyl)-1H-pyrazole-4-carbonylchloride (14b) 
 
Method: See 3.8.3.30 
Reagent: 1-phenyl-3-(p-tolyl)-1H-pyrazole-4-carboxylic acid (0.35 g, 1.3 mmol) 4e 
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Molecular Weight: 300.72
4b 14b
NN
O OH
N
N
O
Cl
Cl S Cl
O
Chemical Formula: C17H13ClN2O
Molecular Weight: 296.75
4e
14e
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m. p. = 92 - 94	℃ 
TLC: Petroleum ether-EtOAc 3: 1, Rf = 0.58 
Yield = 0.291 g (78 %), white solid. 
1H NMR (DMSO-d6): 
δ: 9.06 (s, 1H, pyrazole), 7.97 (d, J = 8.0 Hz, 2H, Ar), 7.56 (t, J = 7.5 Hz, 3H, Ar), 7.42 (m, 
4H, Ar), 2.33 (s, 3H, CH3). 
 
3.8.3.32 N-(2-(1H-1,2,4-triazol-1-yl)ethyl)-1-phenyl-3-(p-tolyl)-1H-pyrazole-4-
carboxamide (15e) 
 
 
Method: See 3.8.3.23 
 The product was purified by gradient flash column chromatography; the product was eluted 
with EtOAc- CH3OH 9:1 v/v.  
Reagent: 3-phenyl-1-(p-tolyl)-1H-pyrazole-4-carbonylchloride (0.245 g, 1.3 mmol) 14e                    
TLC: EtOAc-CH3OH 9: 1, Rf = 0.29 
m. p. = 142 - 148	℃	 
Yield = 0.023 g (6 %) 
1H NMR (CDCl3):  
δ: 8.41 (s, 1H, NH), 7.95 (s, 1H, triazole), 7.80 (s, 1H, triazole), 7.66 (d, J = 7.8 Hz, 2H, Ar), 
7.38 (𝜑t, J = 7.7, 8.2 Hz, 3H, Ar), 7.32 (d, J = 7.8 Hz, 3H, Ar), 7.25 (t, J = 7.5, Hz, 1H, Ar), 
7.15 (d, J = 7.7, 1H, Ar), 4.25 (t, 2H, J = 5.4, Hz, CH2), 3.68 (q, J = 5.4 Hz, 2H, CH2), 2.25 (s, 
3H, CH3). 
13C NMR (CDCl3): 
δ: 163.2 (CO), 151.1 (C), 139.4 (C), 139.3 (C), 131.1 (CH, pyrazole), 129.7, 129.6, 128.9, 
127.4, 119.4 (11 × CH, Ar), 128.9 (C), 117.3 (C), 48.6 (CH2), 39.0 (CH2), 21.4 (CH3). 
 
NN
O Cl NN
O
NH
N
NN
CDINN
+HN
NH3+
Cl-
Cl-
+
Chemical Formula: C21H20N6O
Molecular Weight: 372.43
14e 13 15e
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LRMS (ES-TOF) 
m/z: 373 [ M + H]+, 319 [M - triazole]+ 
HRMS (ES-TOF) 
Calculated mass: 373.1771 [M + H]+, measured mass: 373.1772 [M + H]+
3.8.3.33 (1,3-Diphenyl-1H-pyrazol-4-yl)(1H-imidazol-1-yl)methanone  (16a) 
Method: See 3.8.3.23 
Reagent: 1,3-diphenyl-1H-pyrazole-4-carboxylic acid (0.13 g, 0.7 mmol) 4a 
TLC: Petroleum ether-EtOAc 1:9 v/v, Rf = 61 
m. p. = 118 - 120	℃
Yield = 0.75 g (42 %), white solid
1H NMR (DMSO–d6):
δ: 9.21 (s, 1H, pyrazole), 8.42 (s, 1H, imid), 8.02 (d, J = 8.0 Hz, 3H, 1×imid, 2×Ar), 7.71
(m, 4H, Ar), 7.59 (t, J = 7.5 Hz, 3H, Ar), 7.44 (s, 1H, imid), 7.14 (s, 1H, Ar)
13C NMR (DMSO-d6):
δ: 167.2 (CO), 160.5, 153.2, 138.7, 138.6 (4 × C, Ar), 135.8, 134.3, 133.1, 129.8, 127.5,
120.4 (14 × CH, Ar).
LRMS (ES-TOF)
m/z: 314 [ M + H]+
HRMS (ES-TOF)
Calculated mass: 314.1217 [M + H]+, measured mass: 314.1209 [M + H]+
NN
O OH
NN
ON
N
CDINN
+HN
NH3+
Cl-
Cl-
Chemical Formula: C19H14N4O
Molecular Weight: 314.35
4a 13 16a
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3.8.3.34  (3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)(1H-imidazol-1-yl) methanone  
(16b) 
 
Method: See 3.8.3.23 
Reagent: 3-(4-fluorophenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid (0.17 g, 0.58                           
mmol) 4b 
TLC: Petroleum ether-EtOAc 3:1 v/v, Rf = 62 
m. p. = 130 - 134	℃	 
Yield = 0.80 g (39 %), white solid 
1H NMR (DMSO-d6): 
δ: 9.24 (s, 1H, pyrazole), 8.45 (s, 1H, Ar), 8.03 (d, J = 7.9 Hz, 2H, Ar), 7.81 (𝜑t, J = 5.8, 7.9 
Hz, 3H, Ar), 7.59 (t, J = 7.7 Hz, 2H, Ar), 7.45 (t, J = 7.3 Hz, 1H, Ar), 7.33 (s, 1H, imid) 7.28 
(t, J = 8.7 Hz, 1H, imid), 7.17 (s, 1H, imid). 
13C NMR (DMSO-d6): 
δ: 165.5 (CO), 163.5 (C), 154.2 (C), 140.7 (C), 130.1 (5 × C), 134.4, 132.6, 130.1, 128.8, 
120.9, 115.6 (13 × CH, Ar). 
LRMS (ES-TOF) 
m/z: 333 [ M + H]+ 
HRMS (ES-TOF) 
Calculated mass: 333.1152 [M + H]+, measured mass: 333.1146 [M + H]+ 
 
3.8.3.35 2-((1H-Imidazol-1-yl)methyl)isoindoline-1,3-dione (18) 277 
 
NN
O OH
NN
ON
N
CDINN
+HN
NH3+
Cl-
Cl-
Chemical Formula: C19H13FN4O
Molecular Weight: 332.34
F
F
+
4b 13 16b
N
Br
O
O
NHN KI
N
N
O
O
N
+
Chemical Formula: C12H9N3O2
Molecular Weight: 227.22
17 7 18
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Method:  
Potassium iodide (0.4 g, 2.4 mmol) was added to melted imidazole 7 (5.7 g, 83 mmol). Then 
N-(2-bromomethyl)phthalimide 17 (5 g, 21 mmol) was added. The mixture was stirred at 100 
℃ for 3 h. The mixture was diluted with EtOAc (20 mL), washed with brine (2 ×	50	mL) 
Extracted with EtOAc (150) and washed with water (100 mL ×3). The organic layer was dried 
(MgSO4) and concentrated in vacuo to give a white solid which was recrystallised with 
methanol 272.   
Reagent: N-(2-bromomethyl)phthalimide (5 g, 20.8 mmol) 17                                                                     
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.96 
m. p. = 168 - 172	℃	(Lit. m. p. 185 - 187	℃)277 
Yield = 1.8 g (38 %), white crystals 
1H NMR (DMSO-d6): 
δ: 7.94 (m, 2H, Ar), 7.89 (m, 2H, Ar), 7.77 (s, 1H, imid), 7.19 (s, 2H, imid), 6.91 (s, 1H, 
imid), 5.97 (s, 2H, CH2). 
 
3.8.3.36 2-((1H-1, 2, 4-triazol-1-yl)methyl)isoindoline-1,3-dione (19)272 
 
Method: See 3.8.3.35 
Reagent: N-(2-bromomethyl)phthalimide (5 g, 20.8 mmol) 12                                                                      
TLC: Petroleum ether-EtOAc 3:1 v/v, Rf = 0.44 
m. p. = 164 - 168	℃		(Lit. m. p. 169 - 170	℃)272. 
Yield = 2.7 g (57 %), white crystal, recrystallised with acetonitrile 
1H NMR (DMSO-d6): 
δ: 8.72 (s, 1H, triazole), 7.99 (s, 1H, traizole), 7.94 (m, 2H, Ar), 7.90 (m, 2H, Ar), 5.96 (s, 
2H, CH2). 
 
 
 
 
N
Br
O
O
N
NHN KI
N
N
O
O
N
N
+
Chemical Formula: C11H8N4O2
Molecular Weight: 228.21
17 11 19
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Development of lead 2 
Previous screening of the SPECS database221 identified  lead 2 with promising CYP24A1 
inhibitor activity IC50 5.5 μM. Lead 2  was able to access the enzyme channel and reach the 
CYP24A1 active site with one polar  head group ( pyrazole ) interacting perpendicularly with 
iron haem at a distance of 2.39 Å (Figure 74) . In addition, lead 2 formed hydrogen bonds with 
amino acid residues Glu329, Thr330 and Gly499 (Table 35). Leu148, Met246, Gln324, 
Leu325, Val328, Val391 and Thr500 interacted with lead 2 by hydrophobic bonds.  
Figure 74: 3D and 2D models showing key binding interactions with lead 2 with CYP24A1 
Distance Hydrogen bond 
1 3.13	Å Between hydroxyl group of lead 2 and Gly499 
2 2.47 Å Between hydroxyl group of lead 2 and Ala326 
3 3.97	Å Between methoxy group of lead 2 and Thr330 
4 2.27	Å Between ether group of lead 2 and Glu329 
5 2.45	Å Between methoxy group of lead 2 and Glu329 
Table 35: Hydrogen bonds between lead 2 and amino acids residues of the CYP24A1 model 
Lead 2222 was modified and developed, specifically through (i) replacement of the phenyl with 
a nitrogen containing heterocycle to enhance the binding interaction with the haem moiety, (ii) 
simplifying of the bromomethoxyphenyl with an unsubstituted phenyl ring, (iii) addition of 
phenyl substituents on the dipyrazole rings or replacement of the dipyrazole rings with a basic 
heterocycle to allow complete filling in the active site of  CYP24A1, and (iv) variation of the 
ether group position to allow complete filling in of the active site of  CYP24A1. 
O
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O H
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This chapter is divided into five parts as follows: 
1. Results and discussion  
2. Molecular modelling  
3. Biological assay 
4. Conclusions 
5. Experimental 
 
3.9 Results and discussion  
A two steps synthetic pathway was devised and is shown in Scheme 30 
 
Scheme 30: synthetic pathway of the modified lead 2 compounds 
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3.9.1 2-Hydroxyethanaminium propionate289 (2-HEAP) (21) 
2-Hydroxy ethylammonium propionate (2-HEAP) was a relatively good catalyst for the 
synthesis of compounds 26 and 27. In addition, 2-HEAP can be easily and cheaply synthesised 
from a simple acid-base neutralisation reaction. Recently, Sobhani et al.290 reported the 
reaction of aldehydes with 3-methyl-1-phenyl-5-pyrazolone in ethanol in the presence of 2-
hydroxy ethylammonium acetate as a recyclable catalyst. Here it was used to help prepare 26 
and 27 by starting directly from aldehydes, phenylhydrazine/hydrazine hydrate, and ethyl 
acetoacetate, and using 2-HEAP as an efficient, cost effective, and recyclable catalyst. The 
product was a yellow viscous liquid with a yield of 81% (Scheme 31).     
 
20                                                                   21 
Scheme 31: 2-HEAP 
	
3.9.2 Synthesis of aldehyde derivatives (24b and 24c) 
Having determined the method using benzaldehyde 24a as the model, the required pyridine 
derivatives, 24b and 24c (Scheme 32 and Table 36), were prepared by mixing 4-
hydroxylbenzaldehyde 22a or 3-hydroxylbenzaldehyde 22b with 4-(chloromethyl)pyridine 
hydrochloride and K2CO3, which was stirred at 80	℃ for 7 h.  The obtained yields were in the 
range of 55 and 61 % for 24b and 24c respectively (Table 2).  
 
22                               23                                                        24 
Scheme 32: 4/3-(Pyridin-4-ylmethoxy)benzaldehyde (24b) and (24c) 
 
 
 
 
 
	
Table 36: Formation of aldehydes 24 
HO
+HN
Cl
Cl-
K2CO3 N
O
+
O
H
3
4
O
H
3
4
cpd 
Yield 
% 
m.p. Colour and 
appearance Practical Lit. 
24a Sigma-Aldrich 
24b 
61 102 - 104℃ 57 - 58℃291 Tan 
crystals 
24c 55 94 - 96℃ 74 - 75℃291 White solid 
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3.9.3 Synthesis of 4-((4-(1H-pyrazol-3-yl)phenoxy)methyl)pyridine (25) 
The synthesis of pyrazoles remains of great interest due to the various applications in the 
biological and pharmaceutical industry. The best method for the preparation of pyrazoles 
involves the double condensation of 1,3-diketones with hydrazine or its derivatives. 
The method of Varinder et al.292 was followed to prepare 25b with two head groups (pyridine 
and pyrazole). Benzaldehyde 24a and p-toluenesulfonyl hydrazide were stirred for 3 h at room 
temperature in the presence of 5 N aqueous NaOH and finally vinyl imidazole was added, and 
mixture was stirred at 50 °C for 48 h (Scheme 33). 
 
24a                                                                                                         25a 
Scheme 33: 3-Phenyl-1H-pyrazole292 
 
 
The formation of the diazo compound might be produced in situ from aldehydes in a one- pot 
process. Condensation of tosylhydrazine with benzaldehyde in the presence of an aqueous 
solution of sodium hydroxide led to the formation of benzaldehyde tosylhydrazone sodium salt, 
which on warming to 50 °C gave a reddish solution of phenyldiazomethane. Prior to warming 
the reaction mixture, 1-vinyl-1H-imidazole was added (Scheme 34). 
 
Scheme 34: Formation of 3-phenyl-1H-pyrazole292 
 
The yield of 25a was 20 % as a yellow liquid, which was purified by flash column 
chromatography. 25a was used as a model to confirm that the method of Aggarwal et al.292  
can be used to synthesise 25b (Scheme 35).   
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24b                                                                                                         25b 
Scheme 35: 4-((4-(1H-pyrazol-3-yl)phenoxy)methyl)pyridine 
 
Pyrazole 25b was obtained in a yield of 28 % as a yellow viscous liquid, produced by using 
24b as starting material and following the procedure of Varinder et al.292 Column 
chromatography was used for purification (Table 37). 
 
3.9.4 Synthesis of 1H-pyrazol-3-ol derivatives (26) 
 
                                   24                                                                                    26 
Scheme 36: Synthesis of 1H-pyrazol-3-ol derivatives (26) 
 
 
The method of Zhou et al.293 was used to synthesise compound 26. In this procedure, aldehydes, 
phenylhydrazine/hydrazine hydrate, and ethyl acetoacetate were reacted using 2-hydroxy 
ethylammonium propionate (2-HEAP) as the catalyst. 
The products 26a and 26b were prepared with hydrazine monohydrate with a yield of 36 % 
and 25 % respectively. These compounds were purified by recrystallisation from methanol 
(Scheme 36). 1H NMR confirmed the presence of the aliphatic CH with a peak δ 4.56 for 26a 
and δ 4.72 for 26b as a singlet. 13CNMR spectra confirmed an aliphatic CH at δ 32.9 and 
two CH3 groups at δ12.1 
The method of Zhou et al.293 was used to synthesise compound 27. In this procedure, aldehydes, 
phenylhydrazine/hydrazine hydrate, and ethyl acetoacetate were reacted using 2-hydroxy 
ethylammonium propionate (2-HEAP) as the catalyst. 
Benzaldehyde 24a was used as a model to confirm that the 2-HEAP reagent can help the 
reaction of aldehyde with phenylhydrazine (Scheme 37).  
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                              24a                                                                                          27a 
Scheme 37: 4,4'-(phenylmethylene)bis(3-methyl-1-phenyl-1H-pyrazol-5-ol) (27a) 
 
The procedure of Zhou et al.293 had a mistake in the order of the addition of the starting 
material, as benzaldehyde was used and mixed with phenylhydrazine and ethyl acetoacetate 
for 40 min and then 2-HEAP was added, which produced an imine compound. As a result, the 
addition of the starting material was changed by adding phenylhydrazine, ethyl acetoacetate 
and then adding 2-HEAP; the mixture was refluxed for 40 min. Then benzaldehyde 24a was 
added and refluxed further. The product was obtained after recrystallisation with methanol 
(Scheme 38).  
1H NMR confirmed the presence of the aliphatic CH with a peak at δ4.98 as a singlet and the 
two CH3 groups as a singlet at δ2.23.  
 
24                                                                                            27 
                 
Scheme 38: 4,4'-((3/4-(pyridin-4-ylmethoxy)phenyl)methylene)bis(3-methyl-1-phenyl-1H-pyrazol-5-ol) 
(27b) and (27c) 
 
The reaction of the aldehydes 24b and 24c with phenylhydrazine, ethyl acetoacetate and 2-
HEAP at reflux for 1 h gave compounds 27b and 27c in yields of 35 % and 10 % respectively. 
27c required purification by column chromatography using EtOAc as the mobile phase 
followed by recrystallisation with methanol. 27b was purified by recrystallisation with 
methanol (Table 37). 
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Table 37: Identification data for 25, 26 and 27 
	
3.10 Molecular modelling 
 
Figure 75: Compound 25b 
 
In this chapter, compounds were designed by taking lead 2 and using different substitutions to 
explore SAR. 25b was designed by using a simplified polar head group to one pyrazole group 
(Figure75). The compounds were docked using the LeadIT 2.1.2 programme, and the results 
were visualised using MOE (Figure 76). 25b displayed the ether group perpendicular to the 
haem iron with a distance of 2.20 Å and hydrophobic interactions with Trp134, Leu148, 
Glu322, leu325, Ala326, Thr330 and Val391(Table 38). 
 
N
O
HN
N
cpd. 
Yield 
% 
m.p. HRMS Colour and 
appearance Practical Lit. 
25b 
28 - - Calculated mass: 252.1145 [M 
+ H]+, measured mass: 
252.1155 [M + H]+ 
Yellow viscous 
liquid 
26a 
36 194 - 198 ℃ Novel Calculated mass: 392.1717 [M 
+ H]+, measured mass: 
392.1720 [M + H]+ 
Tan solid 
26b 
25 264 - 268℃ Novel Calculated mass: 392.1717 [M 
+ H]+, measured mass: 
392.1707 [M + H]+ 
Tan solid 
27a 55 152 - 154℃ 169℃293 - Yellow solid 
27b 35 
210 - 214℃ Novel Calculated mass: 544.2343 [M 
+ H]+, measured mass: 
544.2348 [M + H]+ 
Brown crystals 
27c 10 
180 - 186℃ Novel Calculated mass: 544.2343 [M 
+ H]+, measured mass: 
544.23031 [M + H]+ 
Brown solid 
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Figure 76: 3D and 2D models showing key binding interactions 25b with CYP24A1 model 
 
Table 38: Key bind interactions between 25b 
 
Figure 77: Compound 26 
 
26a and 26b were designed without a phenyl substitution on bis(3-methyl-1H-pyrazol-5-ol) 
and changing the position of the ether group from the 4 to 3 position (Figure 77). 26a and 26b 
were designed without phenyl substitution on bis(3-methyl-1H-pyrazol-5-ol) by changing the 
position of the ether group from the 4 to the 3 position. The compounds were docked using the 
LeadIT 2.1.2 programme, and the results were visualized on MOE. 26a and 26b were observed 
making hydrogen bonds between amino acids as shown (Table 39) and the nitrogen atom of 
pyridine for 26a and 26b interacted perpendicularly with the haem iron with a distance of 2.25 
Å and 1.89 Å respectively (Figure 78). In addition, the length hydrogen bonds between 26a 
NHN
ON
Fe3+
Fe5201
Val391
Trp134
Thr330
Leu325
Leu148
Hem520
Glu322
Fe5201
Ala326
N
N
NH
NHN
HO
OH
O
4
3
cpd Distance 
Key binding interactions 
Hydrogen bond interaction Hydrophobic interaction 
25b 
2.20 Å - Trp134, Leu148, Glu322, Leu325, Ala326, Thr330 
and Val391 
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and 26b and amino acid residues was ranging between 1.60 Å to 2.95 Å, which was slightly 
shorter than the length hydrogen bonds (2.27 Å to 3.14 Å) between lead 2 and amino acid 
residues (Table 39). 
 
Figure 78: 3D and 2D models showing key binding interactions 26b with CYP24A1 model 
 
 
 
 
 
 
 
 
 
 
 
 
Table 39: Hydrogen bond interaction 26a, 26b and amino acid residues of the CYP24A1 model 
 
N
O
N
N
H
O H
N N
H
O
H
H2N
N
H
NH2Arg128
R
O
N
R
H Leu129
R
O
HNR
Leu148
H O
Thr395
Fe3+
Fe5201
Val391
Thr395
Thr330
Leu148
Ile131
Efa*
Arg128
Ala326
cpd Length HB Hydrogen bonds 
 
26a 
 
2.31 Å Between hydroxyl group of 26a and Glu130 
1.65 Å Between hydroxyl group of 26a and Thr395 
1.85 Å Between hydroxyl group of 26a and Leu129 
26b 
1.60 Å Between hydroxyl group of 26b and Leu129 
2.38 Å Between hydroxyl group of 26b and Leu129 
2.26 Å Between pyrazole of 26b and Leu129 
2.95 Å Between methoxy group of 26b and Arg128 
1.91 Å Between pyrazole of 26b and Leu148 
2.14 Å Between pyrazole of l26b and Thr395 
Chapter four                                                                                                            Lead 2 
	
	
	
144	
 
Figure 79: Compound 27 
Compounds 27b and 27c have two phenyl rings on bis(3-methyl-1H-pyrazol-5-ol) (Figure 79); 
these were modified by changing the position of the ether group from the 4 to the 3 position. 
For compounds 27b and 27c the hydroxyl group interacted perpendicularly with the haem iron 
with a distance of 2.63 Å and 2.05 Å for 27b and 27c respectively rather than interaction 
through any heterocycle rings present in 27b and 27c (Figure 80 and Table 40). 
 
Figure 80: 3D and 2D models showing key binding interactions with 27b on CYP24A1 model 
 
Table 40: (A) Distance hydroxyl group of 27a, 27b and iron of haem, (B) Hydrogen bond interaction (C) 
hydrophobic key binding interactions 
 
3.10.1 Docking studies of compounds 26a and 26b using a CYP27B1 homology model 
Both compounds 26a and 26b reached the active site through the access channel and were 
exposed to multiple hydrophobic residues Phe110, Leu127, Ala317, Thr321, Gly386, Val387 
and Thr493 for 26a (Figure 81), and Phe110, Leu127, Ala317, Thr321, Val387 and Thr493 for 
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Key binding interactions 
B C 
27b 
2.63 Å Glu329 - ether Leu148, Leu325, Ala326, Val328, Glu329, Thr330, Val391, 
Ile463 and Thr500 
27c 
2.05 Å Arg128 - ether Leu148, Met246, Ala327, Val391, Phe393, Thr395 and 
Thr330 
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26b (Figure 77). Both 26a and 26b formed hydrogen bonds between the nitrogen of pyrazole 
with Asp320 additionally 26b formed hydrogen binding interaction with Asn387 (Figure 82). 
Both these amino acids Asp320 and Asn387 have been identified as important amino acids for 
CYP27B1 inhibitory activity (see Chapter 2). The nitrogen atom of the pyrazole for both 
compounds was perpendicular on the haem iron with a distance of 2.20 Å for 26a and 2.23 Å 
for 26b. 
 
 
Figure 81: 3D and 2D models showing key binding interactions of 26a with CYP27B1 model 
 
 
 
Figure 82: 3D and 2D models showing key binding interactions of 26b with CYP27B1 model 
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3.11 Biological assay 
3.11.1 CYP24A1 inhibitor enzymatic assay 
The final compounds 25b, 26a, 26b, 27b were evaluated by enzymatic assay to determine 
CYP24A1 inhibitory activity as previously described (see 3.6.1).  
Generally, compounds 25b, 26a, 26b and 27b displayed weak inhibition of CYP24A1 activity 
when compared with the ketoconazole standard. 26a and 26b were  more active than lead 2 
(IC50 5.5 μM)191. The IC50 values ranged between 2.5 to 25.5 μM, and the best IC50 values 
were obtained for compounds 26a and 26b, which were twice as active as lead 2 (Figure 83). 
  
 
Figure 83: Biological assay for modified lead 2 compounds on CYP24A1 
 
The structure of compound 25b was different from that of the other compounds. This a 
compound with a simple pyrazole ring and lacking hydroxyl substituents on the pyrazole ring. 
The less of inhibitory activity compared with lead 2 might be owing to the structure, which is 
straight and without branching to give a T shaped or Shaped structure, which are often more 
efficient at filling the active site and enhancing competitive inhibition. Complete filling of the 
binding cavity has shown to be important for improved IC50191. 
The main difference between 26a and 26b was changing the position of the ether group from 
the para position to the meta position on the phenyl ring, but it resulted in no notable 
improvement in the activity. 26a and 26b (IC50 = 2.5 μM and 2.6 μM). displayed activity 
twice as active as lead 2. The activity 26a and 26b, may be owing to the presence of a pyridine 
ring instead of a phenyl ring, which interacted with haem iron leaving the two pyrazole rings 
free to make hydrogen bonds with amino acid residues. In addition, the polar nature of 26a and 
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26b, which was also supported by a lower Log P of 0.56 compared with 27b and 27c where 
Log P was 4.35. The main difference between 26a and 26b was changing the position of the 
ether group from the para position to the meta position on the phenyl 
ring, but this result did not notable an improvement in the inhibitory activity. 
Compound 27b displayed poor inhibitory activity (IC50 = 11.7 μM) compared with lead 2 
(IC50 = 5.5 μM). This effect is perhaps due to the presence of two phenyl-ring substituents on 
two pyrazole rings resulting a very bulky compound preventing the nitrogen of the pyrazole 
from interacting efficiently with the haem iron 
 
3.11.2 CYP27B1 inhibitor enzymatic assay 
Compounds 26a and 26b showed inhibitory activity against CYP24A1 that was twice as active 
as lead 2. So, 26a and 26b were subject to further evaluation against CYP27B1. The IC50 values 
are the average (± 10 %) of two independent experiments (n = 2), which followed published 
paper methods191,280, 281,282,283 The limit of two experiments is owing to the high cost of enzyme 
isolation and the appropriate vitamin D substrates. However, both compounds showed 
inhibition (IC50 = 0.57 μM and 0.41 μM respectively) against CYP27B1 that was greater 
than that against CYP24A1. As a result, 26a and 26b have selectivity for CYP27B1 that is five 
times greater than CYP24A1. The selectivity of 26a and 26b could be related to better fit and 
binding in the CYP27B1 active site, where the pyrazole ring interacted with the haem iron 
instead pyridine as in the lead 2. Also, formation of hydrogen bond with Asp320 and Asn387, 
which are important amino acids in CYP27B1(see Chapter 2) (Figure 84). 
 
Figure 84: Biological assay for 26a and 26b compounds on CYP27B1 
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3.12 Conclusion 
Lead 2 has promising CYP24A1 inhibitory activity (IC50 5.5 μM) with a pyrazole nitrogen 
interacting perpendicularly with the iron haem at a distance 2.39 Å. In addition, lead 2 formed 
hydrogen bonds with amino acid residues Glu329, Thr330 and Gly499. The modified lead 2 
compounds 25b, 26a, 26b, 27a, 27b and 27c were all synthesised successfully. 25b interacted 
perpendicularly with the haem iron of CYP24A1 via ether oxygen with a distance of 2.20 Å. 
26a and 26b were designed without phenyl substituent by changing the position of the ether 
group from the 4 to the 3 position and formed hydrogen bonds between number of amino acids, 
with the nitrogen atom of pyridine interacting perpendicularly with the haem iron of CYP24A1 
with a distance 2.25 Å and 1.89 Å respectively. Compounds 27b and 27c interact with the haem 
iron via a hydroxyl group with a distance of 2.05 and 2.63 Å respectively for CYP24A1. 26a 
and 26b were the most promising CYP24A1 inhibitors (IC50 2.5 μM and 2.6 μM 
respectively) and so further evaluated against CYP27B1. However, 26a and 26b showed 
enzymatic inhibition (IC50 = 0.57 μM and 0.41 μM respectively) against CYP27B1. As a 
result, both compounds showed a 5- fold selectivity for CYP27B1 confirming the importance 
of Asp320 in particular and also Asn387 as important amino acids for CYP27B1 inhibitory 
activity (see Chapter 2).  
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3.13 Experimental 
3.13.1 Molecular modelling 
molecular modelling method information as previously described Chapter 2. 
 
3.13.2 CYP24A1 inhibitor enzymatic assay279 
All CYP24A1 inhibitor enzymatic assay method information as previously described in 
Chapter 3. 
 
3.13.3 CYP27b1 inhibitor enzymatic assay279 
Inhibition of CYP27B1 was assayed in a manner similar to that of CYP24A1 except that the 
buffer contained 20 mM Tris (pH 7.5), 125 mM NaCl, 0.1% CHAPS with (Adx + AdxR + 
CYP27B1 + 25-hydroxyvitamin D + inhibitors + NADPH)279 (Table 41). The HPLC mobile 
phase was isopropanol-hexane 7: 93 v/v. The assay for each compound was performed in 
duplicate (n = 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 41: The concentration and volume required in the CYP27B1 inhibition assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Material 
CYP24A1 
Concentration Volume 
Adx 2	𝛍𝐌 8	𝛍𝐋 
AdxR 0.2	𝛍𝐌 8	𝛍𝐋 
CYP27B1 0.1	𝛍𝐌 8	𝛍𝐋 
25-Hdroxyvitamin D 2.5	𝛍𝐌 5	𝛍𝐋 
Inhibitor 0 - 2	𝛍𝐌 2	𝛍𝐋 
NADPH 1	𝐦𝐌 2	𝛍𝐋 
Buffer solution 367	𝛍𝐋 
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3.13.4 Chemistry experimental 
3.13.4.1 2-Hydroxyethanaminium propionate (2- HEAP)289 (21) 
 
 
Method: 
A solution of propionic acid (3.7 g, 50 mmol) in ethanol (1.5 mL) was added dropwise to a 
stirring solution of 2-aminoethanol (3.1 g, 50 mmol) in ethanol (1.5 mL) at room temperature 
over 1 h. The resultant mixture was stirred at room temperature for another 24 h. Ethanol was 
removed in vacuo and the product was dried in a vacuum oven at 40 ℃ for 48 h289. 
Yield = 5.5 g (81 %), a yellow viscous liquid 
1H NMR (CDCl3):  
δ	: 7.28 (s, 3H, NH3), 5.01 (m, 1H, OH), 3.76 (m, 2H, CH2), 3.11 (m, 2H, CH2), 2.17 (m, 2H, 
CH2), 1.04 (m, 3H, CH3). 
3.13.4.2 4-(Pyridin-4-ylmethoxy)benzaldehyde (24b)291 
 
Method: 
A mixture of 4-hydroxylbenzaldehyde (1.2 g, 10 mmol), 4-(chloromethyl)pyridine 
hydrochloride (1.6 g, 10 mmol) and K2CO3 (4.2 g, 30 mmol) in dry DMF (12 mL) was stirred 
at 80	℃  for 7 h. The cooled mixture was extracted with EtOAc (100 mL). The organic layer 
was washed with brine (2 ×	100	mL), dried (MgSO4) and concentrated to dryness291. 
TLC: petroleum ether-EtOAc 1: 3 v/v, Rf = 0.24 
m. p. = 92 - 94	℃	(Lit. m. p. 57 - 58	℃)291. 
20 21
HO
+HN
Cl
Cl-
K2CO3 N
O
+
O
H
HO
Chemical Formula: C13H11NO2
Molecular Weight: 213.24
22a 24b
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Yield = 1.3 g (61 %), tan crystals, recrystallised with methanol. 
1H NMR (DMSO-d6):  
δ	: 9.89 (s, 1H, CHO), 8.60 (dd, J = 1.6, 4.5 Hz, 2H, Ar), 7.91 (m, 2H, Ar), 7.47 (d, J = 6.3 
Hz, 2H, Ar), 7.22 (dd, J = 1.8, 7Hz, 2H, Ar), 5.33 (s, 2H, CH2). 
3.13.4.3 3-(Pyridin-4-ylmethoxy)benzaldehyde (24c) 
 
Method: See 3.13.4.2 
 The crude product was purified by gradient flash column chromatography, the product was 
eluted with EtOAc-CH3OH 9:1v/v.  
Reagent: 3-Hydroxylbenzaldehyde (1.22 g, 10 mmol) 22b 
TLC: EtOAc-CH3OH 95: 5 v/v, Rf = 0.4 
m. p. = 94 - 96	℃	(Lit. m. p. 74 - 75 ℃)291 
Yield = 1.5 g (55 %), white solid  
1H NMR (CDCl3):  
δ	: 10.01 (s, 1H, CHO), 8.70 (d, J = 6 Hz, 2H, Ar), 7.54 (m, 3H, Ar), 7.30 (m, 1H, Ar), 7.22 
(dd, J = 1.8, 7.0 Hz, 2H, Ar), 5.31 (s, 2H, CH2). 
3.13.4.4 3-Phenyl-1H-pyrazole294 
 
               
 Benzaldehyde (0.3 g, 3 mmol) was added to a solution of p-toluenesulfonyl hydrazide (0.5 g, 
3 mmol) in dry acetonitrile (15 mL). After the mixture was stirred for 3 h at room temperature, 
a solution 5 N aqueous NaOH (10 mL) was added and the mixture was stirred for a further 20 
OH
+HN
Cl
Cl-
K2CO3 N
O
+
O
H
O
H
Chemical Formula: C13H11NO2
Molecular Weight: 213.24
22b 24c
HO
S NHNH2
O
O
NaOH
N
N
HN
N
+
Chemical Formula: C9H8N2
Molecular Weight: 144.18
24a 25a
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min. Vinyl imidazole (1.4 g, 15 mmol) was added, and the mixture was stirred at 50 °C for 
48 h. The mixture was evaporated under reduced pressure, and the residue was dissolved in a 
1:1 mixture of water- EtOAc (70 mL). The organic layer was separated and dried over MgSO4. 
After filtration and removal of the solvent under reduced pressure, the crude material was 
purified by gradient flash column chromatography, product was eluted with petroleum ether-
EtOAc 1:1 v/v 292. 
TLC: petroleum ether-EtOAc 1: 1 v/v, Rf = 0.42 
Yield = 0.08 g (20 %), yellow liquid. 
1H NMR (CDCl3):  
δ	: 9.62 (s, 1H, NH), 7.71 (d, J = 7.1 Hz, 2H, Ar), 7.54 (s, 1H, Ar), 7.31 (t, J = 7.6 Hz, 2H, 
Ar), 7.25 (d, J = 7.5 Hz, 1H, Ar), 6.54 (s, 1H, Ar). 
 
3.13.4.5 4-((4-(1H-Pyrazol-3-yl)phenoxy)methyl)pyridine 
 
 
Method: See 3.13.4.4 
The product was purified by gradient flash column chromatography, product was eluted with 
EtOAc-CH3OH 9.5: 0.5 v/v 
Reagent: 4-(Pyridin-4-ylmethoxy)benzaldehyde (0.5 g,  2.4 mmol) 24b 
TLC: EtOAc-CH3OH 9.5: 0.5 v/v, Rf = 0.40 
Yield = 0.17 g (28 %), yellow viscous liquid 
1H NMR (CDCl3):  
δ	: 10.01 (s, 1H, NH), 8.53 (dd, J = 1.4, 4.5 Hz, 2H, Ar), 7.66 (d, J = 2.2 Hz, 1H, Ar), 7.52 
(m, 2H, Ar), 7.45 (t, J = 1.7 Hz, 1H, Ar), 7.39 (d, J = 7.8 Hz, 1H, Ar), 7.05 (t, J = 7.8 Hz, 1H, 
Ar), 6.98 (dd, J = 1.3, 8.0 Hz, 1H), 6.66 (d, J = 2.2 Hz, 1H, Ar), 5.2 (s, 2H, CH2). 
 
 
N
O
HO
S NHNH2
O
O
NaOH
N
N
N
O
HN
N
+
Chemical Formula: C15H13N3O
Molecular Weight: 251.29
24b 25b
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13C NMR (DMSO-d6): 
δ : 157.9 (C), 148.5 (CH, Ar), 149.5, 146.5 (2	×	C), 129.2, 129.1 (2	×	CH, Ar) 125.4 (C) 
111.2, 110.9, 100.4 (7 × CH, Ar), 66.63 (CH2). 
LRMS (ES-TOF) 
m/z: 252 [ M + H]+ 
HRMS (ES-TOF) 
Calculated mass: 252.1145 [M + H]+, measured mass: 252.1175 [M + H]+ 
 
3.13.4.6 4,4'-((4-(Pyridin-4-ylmethoxy)phenyl)methylene)bis(3-methyl-1H-pyrazol-5-ol) 
(26a) 
 
Method: See 4.5.4.8 
Reagent: 4-(pyridin-4-ylmethoxy)benzaldehyde (0.30 g, 1.7 mmol) 24b 
TLC: CH2Cl2-CH3OH 9: 1 v/v, Rf = 0.34 
m. p. = 194 -198	℃ 
Yield = 0.20 g (36 %), tan solid, recrystallised with methanol 
1H NMR (CDCl3):  
δ: 8.69 (d, J = 6.0, 2H, Ar), 7.41 (d, J = 6 Hz, 2H, Ar), 7.16 (t, J = 8.0 Hz, 2H, Ar), 6.76 (m, 
2H, Ar), 5.08 (s, 2H, CH2), 4.47 (s, 1H, CH), 2.06 (s, 6H, 2CH3) 
13C NMR (CDCl3): 
δ: 158.2 (C), 150.1 (CH, Ar), 146.7, 145.8, 146.3 (8 × C), 129.3, 122.4, 121.0, 115.3, 123.4, 
111.4 (6 × CH, Ar), 102.4 (CH, Ar), 68.0 (CH2), 35.4 (CH), 10.8 (2 × CH3) 
LRMS (ES-TOF) 
m/z: 392 [ M + H]+ 
HRMS (ES-TOF) 
Calculated mass: 392.1717 [M + H]+, measured mass: 392.1720 [M + H]+ 
N
O
2-HEAP
N
NH
NHN
HO
OH
N
O
O H
Chemical Formula: C21H21N5O3
Molecular Weight: 391.43
NH2NH2.H2O
24b 26a
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3.13.4.7 4,4'-((3-(pyridin-4-ylmethoxy)phenyl)methylene)bis(3-methyl-1H-pyrazol-5-ol) 
(26b) 
 
Method: See 4.5.4.8 
Reagent: 4-(Pyridin-3-ylmethoxy)benzaldehyde (0.40 g, 1.9 mmol) 24c 
TLC: EtOAc-CH3OH 6: 1 v/v, Rf = 0.75 
m. p. = 264 - 268	℃ 
Yield = 0.18 g (25 %), tan solid, recrystallised with methanol. 
1H NMR (CDCl3):  
δ	: 8.55 (d, J = 5.7 Hz, 2H, Ar), 7.40 (d, J = 5.8 Hz, 2H, Ar), 7.15 (t, J = 8.3 Hz, 1H, Ar), 6.75 
(m, 3H, Ar), 5.08 (s, 2H, CH2), 4.72 (s, 1H, CH), 2.06 (s, 6H, 2CH3) 
13C NMR (DMSO-d6): 
δ: 158.2, 156.2 (2 × C), 150.7, 145.8 (2 × CH, Ar), 145.9, 141.3. 129.2, 128.3, 122.42 (6 
× CH, Ar), 121.0, 115.3, 111.4 (7 × C), 67.9 (CH2), 33.2 (CH), 11.2 (2 × CH3). 
LRMS (ES-TOF) 
m/z: 392 [ M + H]+ 
HRMS (ES-TOF) 
Calculated mass: 392.1717 [M + H]+, measured mass: 392.1707 [M + H]+ 
 
 
 
 
 
 
 
 
 
N
2-HEAP
N
NH
NHN
HO
OH
N
O
Chemical Formula: C22H23N5O2
Molecular Weight: 389.46
NH2NH2.H2O
24c 26b
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3.13.4.8 4,4'-(Phenylmethylene)bis(3-methyl-1-phenyl-1H-pyrazol-5-ol) (27a) 
 
 
Method: 
Phenylhydrazine (0.5 mL, 5 mmol) was mixed with ethyl acetoacetate (1.3 mL, 10 mmol). 
Then 2-hydroxy ethylammonium propionate (2-HEAP) (0.07 g, 0.5 mmol) was stirred under 
solvent free conditions for 40 min. Then, benzaldehyde (0.53 g, 5 mmol) was added and the 
reaction mixture heated at 90	℃	for 1 h. After completion, the reaction was cooled to room 
temperature, where upon it solidified. The pure product was obtained from this solid by 
recrystallisation with methanol293. 
TLC: petroleum ether- EtOAc 1: 3 v/v,  Rf = 0.41 
m. p. = 152 - 154	℃	(Lit. m. p. 169	℃)295  
Yield = 1.2 g (55 %), yellow solid, recrystallised with methanol 
1H NMR (DMSO-d6):  
δ	: 13.96 (s, 2H, 2 × OH), 7.73 (m, 4H, Ar), 7.29 (m, 6H, Ar), 7.18 (m, 5H, Ar), 4.98 (s, 1H, 
CH), 2.23 (s, 6H, 2 × CH3). 
HO
2-HEAP, ethyl acetoacetate
N
N
NN
HO
OH
H
N NH2
Chemical Formula: C27H24N4O2
Molecular Weight: 436.52
24a
27a
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3.13.4.9 4,4'-((4-(Pyridin-4-ylmethoxy)phenyl)methylene)bis(3-methyl-1-phenyl-1H-
pyrazol-5-ol) (27b) 
 
Method: See 4.5.4.8 
Reagent: 4-(pyridin-4-ylmethoxy)benzaldehyde (0.53 g, 5 mmol) 24b. 
 TLC: EtOAc-CH3OH 4:1v/v, Rf = 0.26 
m. p. = 210 - 214	℃   
Yield = 0.96 g (35 %), brown crystals, recrystallised with methanol. 
1H NMR (DMSO-d6):  
δ	:14.00 (s, 1H, OH), 13.12 (s, 1H, OH), 7.53 (dd, J = 1.5, 4.5, 2H, Ar), 7.71 (d, J = 7.7 Hz, 
4H, Ar), 7.45 (m, 6H, Ar), 7.32 (t, J = 7.4 Hz, 2H, Ar) 7.18 (d, J = 8.5 Hz, 2H, Ar), 6.93 (m, 
2H, Ar), 5.14 (s, 2H, CH2), 4.91 (s, 1H, CH), 2.30 (s, 6H, 2 × CH3) 
13C NMR (DMSO-d6): 
δ: 156.2 (C), 149.6 (CH, Ar), 146.5, 146.1, 134.8 (10 × C), 128.9, 128.3, 125.5, 121.8, 120.5, 
114.9 (17 × CH, Ar), 67.9 (CH2), 32.9 (CH), 12.1 (2 × CH3) 
LRMS (ES-TOF) 
m/z: 544 [M + H]+ 
HRMS (ES-TOF) 
Calculated mass: 544.2343 [M + H]+, measured mass: 544.2348 [M + H]+ 
N
O
2-HEAP
N
N
NN
HO
OH
H
N NH2
N
O
HO
Chemical Formula: C33H29N5O3
Molecular Weight: 543.63
24b 27b
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3.13.4.10 4,4'-((3-(Pyridin-4-ylmethoxy)phenyl)methylene)bis(3-methyl-1-phenyl-
1H-pyrazol-5-ol) (27c) 
 
  Method: See 4.5.4.8 
 The crude product was purified by preparative TLC EtOAc-CH3OH 9: 1 v/v 
Reagent: 3-(Pyridin-4-ylmethoxy)benzaldehyde (0.30 g, 1.7 mmol) 24c 
TLC: EtOAc-CH3OH 9: 1 v/v, Rf = 0.27  
m. p. = 180 -186	℃ 
Yield = 0.07 g (10 %), brown solid  
1H NMR (CDCl3):  
δ	: 8.51 (d, J = 5.6 Hz, 2H, Ar), 7.94 (d, J = 7.5 Hz, 2H, Ar), 7.42 (d, J = 6.0 Hz, 2H, Ar), 7.33 
(t, J = 7.5 Hz, 2H, Ar), 7.11 (t, J = 8.0 Hz, 2H, Ar), 7.05 (m, 4H, Ar), 6.99 (d, J = 8.0 Hz, 2H, 
Ar), 6.87 (d, J = 8.0 Hz, 2H, Ar), 5.05 (s, 2H, CH2), 4.93 (s, 1H, CH), 2.03 (s, 6H, 2 × CH3) 
13C NMR (CDCl3): 
δ: 158.2 (C), 157.7, 150.1, 149.2 (3 × CH, Ar), 146.7, 146.3, 141.2(10 × C), 128.8, 123.3, 
122.5, 120.9, 119.5, 114.9, 110.9, 102.4 (15 × CH, Ar), 67.9 (CH2), 35.5 (CH), 13.5 (2 × 
CH3) 
LRMS (ES-TOF) 
m/z: 544 [ M + H]+ 
HRMS (ES-TOF) 
Calculated mass: 544.2343 [M + H]+, measured mass: 544.2307 [M + H]+ 
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4 Development of Lead 3 
 
 
The docking study  for lead 3 compound191,296showed that the pair electron of the imidazole 
nitrogen was perpendicular to the haem iron of the CYP24A1 model at a distance of 2.28 Å. 
Furthermore, hydrogen bonds between the dimethoxy groups and Arg128 and Ile131 as well 
as several hydrophobic interactions with Leu129, Glue 130, Leu148, Ile149, Ala326, Glu329, 
Thr330 and Val391 (Figure 85) were observed. In addition, the validation of the accuracy of 
Leadit 2.1.2 was done by docking the known CYP24A1 inhibitor (R)-VID 400 (IC50 15nM)297, 
which showed interaction between the nitrogen of imidazole and the iron of the haem. Also, 
there were hydrophobic interactions with amino acid residues in the active site of the CYP24A1 
model191 (Leu148, Met246, Phe249, Thr330 and Ala326). 
 
Figure 85: 3D and 2D for lead 3 
 
IC50 0.40 μM 
Figure 86: lead 3 compound191 
 
Lead 3 (Figure 86) was modified and developed, specifically through (i) substitution of the 
phenyl ring on the imidazole side to explore structure activity-relationships, (ii) substitution of 
the phenyl ring of styrene to explore structure activity-relationships, and (iii) variation of the 
alkene position to allow the complete filling in the active site of t CYP24A1 (Figure 87). 
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Figure 87: Modification of lead 3 compounds 
 
This chapter is divided into six parts as follows: 
1. Synthesis of (E)-N-(2-(1H-imidazol-1-yl)-2-(substituted/unsubstituted phenyl)ethyl)-
4-(substituted/unsubstituted styryl)benzamides. 
2. Synthesis of (E)-N-(2-(1H-imidazol-1-yl)-2-(substituted/unsubstituted phenyl)ethyl)-
3-(substituted/unsubstituted styryl)benzamides 
3. Molecular modelling  
4. Biological assay 
5. Conclusions 
6. Experimental 
 
4.1 Synthetic pathway of (E)-N-(2-(1H-imidazol-1-yl)-2-(substituted/unsubstituted 
phenyl)ethyl)-4-(substituted/unsubstituted styryl)benzamides 
 
 
 
 
The synthetic pathway is illustrated in Scheme 39.  
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Scheme 39: Synthetic pathway of (E)-N-(2-(1H-imidazol-1-yl)-2-(substituted/unsubstituted phenyl)ethyl)-4-
(substituted/unsubstituted styryl)benzamides 
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4.1.1 Synthesis of substituted 2-nitro-1-phenyl-ethanol derivatives 
The Henry reaction of carbonyl compounds with alkyl nitro compounds bearing α-hydrogen 
atoms is one of the most fundamental and widely utilised methods for the construction of 
carbon-carbon bonds that lead to the formation of 𝛽-nitroalcohols298,299. 
The Henry reaction (nitroaldol) is an ideal, atom economical, and powerful method for stereo-
selective carbon-carbon bond formation, which is a nucleophilic addition of nitroalkanes to 
carbonyl compounds, the resulting chiral adducts, 𝛽-nitro alcohols, can be easily transformed 
into a variety of valuable synthetic intermediates such as 𝛽-amino alcohols300, 𝛼-hydroxy 
carboxylic acids, aziridines, and other complex target molecules that are highly useful as a 
framework for the synthesis of bioactive natural products and pharmaceutical agents299 (e.g. 
chloramphenicol, ephedrine, norephedrine, (S)-propanolol, (S)-pindolol and 
antibiotics)301,302,303,304.  
The 𝛽-nitroalcohols are generally obtained in good yield by the reaction of an aldehyde with 
nitroalkanes in the presence of a catalytic amount of base305. The choice of reaction conditions 
is important to stop the reaction at the stage of 𝛽-nitroalcohols306. So, the reaction is generally 
conducted at room temperature in the presence of around 10 % of base to give 𝛽-nitroalcohols 
in good yield. The most popular bases and solvents employed in the Henry reaction are NaOH, 
KOH, K2CO3, triethylamine and alkoxides in water or alcohols300. 
In addition, a more effective catalyst for the Henry reaction is a polymer base, such as 
amberlyst A-21, amberlite IRA-420 (OH) and DOWEX-1(OH) without a solvent300. 
Many methods have been attempted to synthesise substituted 2-nitro-1-phenyl-ethanol 
derivatives (30a - 30h).  
The first method followed the procedure of Langer et al.307  In this method, the	𝛽-nitroaldol 
reaction between benzaldehydes and nitromethane in ice-cooled methanol occurs in the 
presence of NaOH as a base catalyst to form the corresponding 𝛽-nitroalcohols 30a and 30d 
(Scheme 40). 
 
Scheme 40 
O
H OH
O2N
CH3-NO2+
R R
28 29
Where R
30a = Cl
30d = Br
NaOH
30
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Overall, aromatic aldehydes bearing strong electron-withdrawing substituents in the para 
position were easily converted in the presence of NaOH into the corresponding β-nitroalcohols; 
for example, 30a and 30d, gave excellent yields of 72 % and 92 % respectively. Compound 
30a was purified using flash chromatography; in contrast, compound 30d was used for further 
reaction without purification (Scheme 41). 
 
Scheme 41 
However, the aromatic aldehydes bearing electron-donating substituents produced very thick 
brown syrups that contained only trace amounts of the expected product (less than 5 %)  
As the method of Langer et al.307 was unsuccessful for aromatic aldehydes bearing electron-
donating substituents, which may be due to the use of the strong base NaOH as a catalyst, a 
second method followed the procedure of Bhabak and Arenz308, using triethylamine rather than 
NaOH; however, only one compound 30f, prepared and purified by column chromatography, 
gave a good yield of 85 % as a yellow liquid (Scheme 42). 
 
Scheme 42 
A third method followed the procedure of Won et al.309 Using this method, the β-nitroaldol 
was produced by the reaction of benzaldehydes and nitromethane in ice-cooled dry THF in the 
presence of a slurry of lithium aluminium hydride (10 mol %) in tetrahydrofuran as a base 
catalyst to form the corresponding 𝛽-nitroalcohols 30a, 30b, 30d, 30e, 30g and 30h with the 
isolated yields ranging from 71% to 92 % (Table 42 and  Scheme 43) 
O
H OH
O2N
CH3-NO2+
R1 R1
28 29
NaOH
30
R2 R2X
Where R:
a = R1 = OH, R2 = H
b = R1 =    H, R2 = CH3
c = R1 =    H, R2 = C2H5
O
H
N
OH
O2N
CH3-NO2+
28f 29 30f
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Scheme 43 
 
The fourth method followed the procedure of Lodh et al.310 This method begins with the 
condensation of benzaldehyde with nitromethane in the presence of 10 wt % of Ambersep 900 
(OH) under solvent-free conditions at room temperature (a further increase in the amount of 
catalyst did not improve the yield significantly). The corresponding 𝛽-nitroalcohols were 
obtained in yields ranging from 51 % to 86 % for compounds 30a, 30b, 30c, 30g and 30h 
(Scheme 44). These compounds were obtained as a yellow liquid or oil and were used for 
further reaction without purification.  
  
Scheme 44 
 
The method of Won et al.309 and Lodh et al.310 was found to be the optimal option for the 
synthesis of 𝛽-nitroalcohol derivatives.  
1H NMR confirmed the formation of the substituted 2-nitro-1-phenyl-ethanol derivatives by 
observation of the hydroxyl group with a peak at approximately δ ≅ 5.90, and an aliphatic 
(CH) group was observed with a peak at approximately at δ ≅ 5.40 for 30a - 30h.  A peak for 
the aldehyde group of the starting material was absent, confirming complete reaction. 
O
H OH
O2N
CH3-NO2+
R2 R3
R1
R3 R2
R4
Where R:
30a = R1 = H         R2 = H,       R3 = Cl,          R4 = H       
30b = R1 = H,        R2 = H ,      R3 = CF3,       R4 = H  
30d = R1 = H,        R2 = H ,      R3 = Br,          R4 = H      
30e = R1 = CH3,    R2 = H,       R3 = H,           R4 = H  
30g = R1 = H,        R2 = H,       R3 = OCH3,    R4 = H
30h = R1 = H,        R2 = OCH3,R3 = H,           R4 = OCH3
LiAlH4
28 29 30
R1
O
H OH
O2N
CH3-NO2+
R2 R2Ambersep 900(OH)
R1
R3 R1
R3
Where R:
30a = R1 = H         R2 = Cl,       R3 = H       
30b = R1 = H,        R2 = CF3,    R3 = H   
30c = R1 = CF3,    R2 = H,        R3 = H       
30g = R1 = H,        R2 = OCH3, R3 = H,       
30h = R1 = OCH3, R2 = H,        R3 = OCH3
28 29 30
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Table 42: Yield % and colour and appearance of 𝛃-nitroalcohols for each method 
 
4.1.2 Synthesis of 2-amino-1-(substituted phenyl)ethan-1-ol derivatives 
The amino alcohols were prepared by catalytic hydrogenation. 
 
 
Scheme 45 
The first method followed the procedure of Lee et al.311. In this method (1-(4-methoxyphenyl)-
2-nitroethan-1-ol) 30g was reduced using hydrogenation at 45 psi with palladium/carbon and 
methanol for 6 h to produce 2-amino-1-(4-methoxyphenyl)ethan-1-ol 31g in a 42 % yield 
(Scheme 45).  
 
Scheme 46 
 
OH OH
NH2
H2+NO2
30g 31g
O O
Pd/C
CH3OH
Where R:
31a = R1 = H,      R2 = H,        R3 = Cl,         R4 = H
31b = R1 = H,      R2 = H,        R3 = CF3,      R4 = H
31c = R1 = CF3,  R2 = H,        R3 = H,          R4 = H
31e = R1 = CH3   R2 = H,        R3 = H,         R4 = H 
31f  = R1 = H,      R2 = CH3,    R3 = CH3,     R4 = H
31g = R1 = H,      R2 = H,        R3 = OCH3,  R4 = H
31h = R1 = H,      R2 = OCH3, R3 = H,         R4 = OCH3
Raney Nickel
NH2
OH
R3
NO2
OH
R3 R1
R2
R4
R1
R2
R4
30 31
cpd 
% Yield 
Method 1 
% Yield 
Method 2 
% Yield 
Method 4 
% Yield 
Method 5 
Colour and appearance 
30a 72 - 90 76 Yellow liquid 
30b - - 92 85 Yellow liquid 
30c - - - 78 Yellow oil 
30d 92 - - - Brown oil 
30e - - 55 - Brown oil 
30f - 85 - - Brownish yellow liquid 
30g - - 86 20 Yellow oil 
30h - - 63 85 Yellow oil 
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The second method followed the procedure by Gowda et al.312 In this method, the 𝛽-
nitroalcohols were reduced to the corresponding amine derivatives using a slurry of Raney 
nickel and formic acid under H2 atmosphere at room temperature for 6 h. The yields obtained 
ranged from 17 % to 84 % for 31a, 31b, 31c, 31e, 31f, 31g and 31h (Scheme 46). All products 
were characterised by a comparison of their TLC, melting points, and 1H NMR with 
corresponding literature compounds (Table 43). 1H NMR confirmed the formation of the 
substituted 2-amino-1-phenylethan-1-ol by observation of an aliphatic hydroxyl and amine 
group as a broad singlet at approximately δ ≅ 3.00. 
 
 
 
 
 
 
 
 
 
 
 
Table 43: Identification data for 2-amino-1-(substituted phenyl)ethan-1-ol derivatives 
 
4.1.3 Substituted/unsubstituted (E)-4-styrylbenzoic acids 
More than four decades ago, Mizorokil315 and Heck316 discovered the palladium-catalysed 
arylation and vinylation of olefins. The Heck reaction is the vinylation of aryl/vinyl halides in 
the presence of a base and catalysed by Pd(0) complexes, resulting in the formation of a carbon-
carbon bond. 
The catalytic cycle for the Heck reaction involves three fundamental steps: the catalytic cycle 
with the oxidative addition of an aryl/alkenyl halide, the carbometalation reaction via the 
complex, and the 𝛽-hydride elimination317. The method of Aboraia et al.210 was used to 
synthesise compounds 34a and 34b (Scheme 47).  
 
Scheme 47 
O
OH
Pd(OAc)2
O
OH
Br
+ R1
R1
R2 R2
Where R:
34a = R1 = H,        R2 = H 
34b = R1 = OCH3, R2 = OCH3
32 33 34
cpd. Yield % 
m.p. Colour and 
appearance Practical Lit. 
31a 84 106 - 110℃ 94 - 95℃ 313 Pale yellow solid 
31b 53 60 - 64℃ Unrecorded White solid 
31c 67 80 - 86℃ Unrecorded White solid 
31e 57 - - Amber oil 
31f 63 64 - 68℃ Unrecorded Pale yellow solid 
31g 47 46 - 50 ℃ 70℃ 314 Yellow solid 
31h 17 - - Yellow oil 
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4-Bromobenzoic acid 33 reacted with alkenes 32 in the presence of 0.01 equivalents of 
palladium acetate; 0.05 equivalents of tri-o-tolylphosphine, and 2.5 equivalents of 
triethylamine were mixed in a sealed tube at 100 ℃	overnight to form unsubstituted/substituted 
(E)-4-styrylbenzoic acid 34a and 34b in yields of 51 % and 82 % respectively (Table 44). 
 
Table 44:  Analytical data for unsubstituted/substituted (E)-4-styrylbenzoic acids 
 
4.1.4 (E)-N-(-2-hydroxy-2-(substituted phenyl)ethyl)-4-(unsubstituted/substituted 
styryl)benzamides (35) 
 
Scheme 48 
 
The substituted/unsubstituted (E)-4-styrylbenzoic acids 34 were activated by CDI, and then 
intermediate compounds were reacted with substituted-2-amino-1-phenylethanol 31 at 0 ℃		 
to produce the desired compounds 35a - 35f. The obtained yields ranged from 35 % to 69 % 
(Table 45 and Scheme 48).  
 
 
 
 
 
 
Where R:  
35a = R1= H,     R2 = H,     R3 = Cl,        R' = H
35b = R1= H ,    R2 = H,     R3 =CF3,      R' = H
35c = R1= CF3, R2 = H,     R3 = H,         R' = H
35d = R1= H,     R2 = CH3, R3 = CH3,    R' = H
35e = R1= H,     R2 = H,     R3 = OCH3, R' = H
35f  = R1= H,     R2 = H,     R3 = Cl,       R' = OCH3
N
H
O R3
R'
R'
R1
R2
COOH
NH2
OH
R3
R1
R2R'
R'
CDI+
OH
34 31 35
Cpd 
Yield 
% 
m.p. Microanalysis Colour and 
appearance Practical Lit. 
24a 51 240 - 242℃ 257℃318 - Yellow crystals 
34b 59 
244 - 248℃ Novel Anal. Calcd for C17H16O4	∙	0.1H2O (286.1): 
C 71.37 %, H 5.71 %. Found C71.29 %, H 
5.47 %. 
Yellow crystals 
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Table 45: Anylitical data for (E)-N-(-2-hydroxy-2-(substituted phenyl)ethyl)-4-(unsubstituted/substituted 
styryl)benzamides (35) 
 
4.1.5 Synthesis of (E)-5-(substituted phenyl)-2-(4-(unsubstituted/substituted 
styryl)phenyl)-4,5-dihydrooxazole derivatives (36) 
The dihydrooxazoles were prepared following the procedure of Aboraia et al.210 The method 
involved the formation of the oxazole ring by reacting (E)-N-(-2-hydroxy-2-(substituted 
phenyl)ethyl)-4-(unsubstituted/substituted styryl)benzamides 35a - 35f with methansulfonyl 
chloride and triethylamine in dry THF (Scheme 49). 
 
Scheme 49 
Generally, the preparation of 4,5-diydrooxazole compounds 36a - 36f gave good yields ranging 
from 40 - 90 %, and these were used in the next step without further purification except for 
compound 36a, which was recrystallised with methanol. 
N
N
H
O
OH
CH3SO2Cl O
N
R1
R1
Where R:
36a = R1 = H,      R2 = H,     R3 = Cl,       R' = H
36b = R1 = H,      R2 = H,     R3 = CF3,     R' = H
36c = R1 = CF3,   R2 = H,     R3 = H,        R' = H
36d = R1 = H,      R2 = CH3, R3 = CH3,    R' = H 
36e = R1 = H,      R2 = H,     R3 = OCH3, R' = H
36f  = R1 = H,      R2 = H,     R3 = Cl,       R' = OCH3
R3
R3R'
R'
R'
R'
R2
R2
35
36
cpd 
Yield 
% 
m.p. 
 
Microanalysis/ HRMS 
 
Colour and 
appearance 
35a 67 
258 - 260℃ Anal. Calcd for C23H20ClNO2 ∙	0.3H2O (382.52): C 72.08 %, 
H 5.42 %, N 3.65 %. Found C72.20 %, H 5.26 %, N 3.86 %. 
White 
crystals 
35b 35 
220 - 224℃ Anal. Calcd for C24H20F3NO2 (411.42): C 70.07 %, H 4.90 
%, N 3.40 %. Found C 70.39 %, H 4.79 %, N 3.47 % 
White 
crystals 
35c 58 
160 - 166℃ Anal. Calcd for C24H20F3NO2 (411.42): C 70.07 %, H 4.90 
%, N 3.40 %. Found C 70.22 %, H 4.92 %, N 3.38 % 
White solid 
35d 60 
150 - 154℃ Anal. Calcd for C25H25NO2 (371.48): C 80.83 %, H 6.78 %, 
N 3.77 %. Found C 81.10 %, H 6.78 %, N 3.88 % 
White solid 
35e 35 
218 - 220℃ Anal. Calcd for C24H23NO3 (373.45): C 77.19 %, H 6.21 %, 
N 3.75 %. Found C 77.32 %, H 6.02 %, N 3.70 % 
White solid 
35f 69 
168 - 172℃ Calculated mass: 438.1472 [M + H]+, measured mass: 
438.1463 [M + H]+ 
White solid 
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4,5-diydrooxazole compounds was found to be unstable with the rearrangement leading to 
opening of the oxazole ring. TLC showed a mixture of two spots (3:1), one major and one 
minor. The 1H NMR spectra showed that one was the dihydrooxazole and the other was an 
unknown compound with an amide group as a triplet at approximately δ ≅ 8.9.  
 
4.1.6 Synthesis of (E)-N-(2-(1H-imidazol-1-yl)-2-(substituted phenyl)ethyl)-4-
(unsubstituted/substituted styryl)benzamide derivatives 
The procedure of Schuster et al.319 was used in the final step, and achieved refluxing oxazole 
compounds 36 in the presence of excess imidazole for 48 h at 125 ℃. The products were 
purified by recrystallisation with EtOAc or acetonitrile. The yields ranged between 12 % to 35 
% for 37a - 37f. The low yield resulted from the impure oxazole starting material 36. Column 
chromatography, rather than recrystallisation may have resulted in isolation of the product 37 
at high yields (Scheme 50). 
 
Scheme 50 
 
The use of imidazole as both a reactant and a solvent improved the yields compared with the 
use of isopropyl acetate as a solvent191,210,219(Table 46).  
 
 
 
 
 
 
 
N
H
O
N
O
N
R1
R1
Where R:
37a = R1 = H,      R2 = H,     R3 = Cl,        R' = H
37b = R1 = H,      R2 = H,     R3 = CF3,     R' = H
37c = R1 = CF3,   R2 = H,     R3 = H,        R' = H
37d = R1 = H,      R2 = CH3, R3 = CH3,    R' = H 
37e = R1 = H,      R2 = H,     R3 = OCH3,  R' = H
37f  = R1 = H,      R2 = H,     R3 = Cl,        R' = OCH3
R3
R3
R'
R'
R'
R'
R2
R2
3736
N
N
H
N
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Table 46: Analytical data for (E)-N-(2-(1H-imidazol-1-yl)-2-(substituted phenyl)ethyl)-4-
(unsubstituted/substituted styryl)benzamides 
 
 
 
 
 
 
 
 
 
cpd 
Yield 
% 
m.p. Microanalysis/ HRMS 
 
Colour and 
appearance 
37a 12 
238 - 240℃ Calculated mass: 428.1523 [M + H]+, measured mass: 
428.1524 [M + H]+ 
White 
crystals 
37b 33 
208 - 210℃ Anal. Calcd for C27H22F3N3O ∙ 0.15 H2O: (463.87), C 69.86 %, 
H 4.84 %, N 9.05 %. Found C 69.56 %, H 4.79 %, N 8.98 %. 
Creamy 
solid 
37c 35 
174 - 178℃ Anal. Calcd for C27H22F3N3O	∙ 0.1H2O (463.29): C 70.00 %, H 
4.83 %, N 9.07 %. Found C 69.64 %, H 4.84 %, N 9.07 %. 
Creamy 
solid 
37d 27 
134 - 136℃ Calculated mass: 422.225 [M + H]+, measured mass: 422.2232 
[M + H]+ 
Yellow 
solid 
37e 32 
218 - 222℃ Calculated mass: 424.2020 [M + H]+, measured mass: 
424.2016 [M + H]+ 
White solid 
37f 35 
204 - 208℃ Calculated mass: 488.1743 [M + H]+, measured mass: 488.174 
[M + H]+ 
White 
crystals 
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4.2 Synthesis of (E)-N-(2-(1H-imidazol-1-yl)-2-(substituted phenyl)ethyl)-3-
(unsubstituted/substituted styryl)benzamide derivatives 
 
Scheme 51: Synthesis of (E)-N-(2-(1H-imidazol-1-yl)-2-(substituted/unsubstituted) ethyl)-3-(substituted/ 
unsubstituted styryl)benzamides 
Ambersep 900 (OH)
Raney Ni
COOH
Pd(OAc)2
+
CDI
O
N
H OH
N
O
CH3SO2Cl
N
H
N
O
N
H N
N
R'
F F
K2CO3
+
LiAlH4
R
R  =  H, Cl, CF3
R' =  H, CF3
R'
R'
R'
NH2
OH
R
R'
R
Fusion
R
CH3-NO2
(28c)(38)(32)
Br
(39)
(40)
(41
(42)
(43)
(28)
(29)
(30)
(31)
HOOC
+
NO2
OH
R
O
R
H
O
H
FP+ Br
-
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4.2.1 1-(Trifluoromethyl)-2-vinylbenzene (32c) 
The Wittig reaction, discovered in 1954 by Georg Wittig320, is one of the most common 
techniques used for the stereoselective preparation of alkenes321; the reaction allows for the 
formation of an alkene product and a triphenylphosphine oxide side product from the reaction 
of an aldehyde and triphenylphosphonium ylide. The key step of the mechanism was the 
nucleophilic addition of the ylide to the electrophilic carbonyl group of an aldehyde or ketone, 
forming a four-membered ring that dissociates into the product molecule. 
The method of Zhang and Tang322 was used to synthesise compound 32c. In this procedure, 2-
(trifluoromethyl)benzaldehyde 28c was reacted with methyltriphenylphosphonium bromide 38 
and potassium carbonate in dry THF under reflux for 10 h to give 1-(trifluoromethyl)-2-
vinylbenzene 32 in a yield of 67 % as a colourless liquid (Scheme 52).  
 
 
                               28c                                  38                                                            32c 
Scheme 52 
1H NMR confirmed the presence of the CH of the alkene group with a peak at δ = 7.00 as a 
doublet of doublet of doublets (ddd) with J values (2.5, 11, and 17.3 Hz). The CH2 of the alkene 
group was observed as two peaks; one was observed at δ = 5.92 as a doublet with J value 17.3 
Hz and the other proton was observed at	δ = 5.50 as a doublet of doublets with J value 0.95 
and 11.05 Hz. The aldehyde group of the starting materials was absent, confirming the 
complete reaction. Other vinylbenzenes were purchased from Sigma Aldrich. 
 
4.2.2  (E)-3-styrylbenzoic acid (41) 
 
Scheme 53 
O
H
K2CO3
F F
F F
F
F+ P+Br
-
O
OH
Pd(OAc)2
O
OH
Where R:
40a = R = H
40b = R = CF3
R
R
+
32 39 40
Br
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3-Bromobenzoic acid 39 reacted with alkenes 32 in the presence of 0.01 equivalents of 
palladium acetate, 0.05 equivalents of tri-o-tolylphosphine and 2.5 equivalent of triethylamine 
in a sealed tube at 100 ℃	overnight to form (E)-3-styrylbenzoic acid 40 (Scheme 53). The 
products were obtained in yields of 73 % and 82 % for 40a and 40b respectively (Table 47). 
  
Table 47: Analytical data for substituted/substituted (E)-3-styrylbenzoic acids 
 
4.2.3 Synthesis of (E)-N-(2-(unsubstituted/substituted phenyl)-2-hydroxyethyl)-3-
(unsubstituted/substituted styryl)benzamides (41) 
 
 
Scheme 54 
	
The (E)-3-styrylbenzoic acids (40) were activated by CDI, and then intermediate compounds 
were reacted with substituted-2-amino-1-phenylethanol derivatives (31) at 0 ℃		 to produce 
the desired compounds 41a - 41f (Scheme 54). The desired compounds were obtained in yields 
ranging from 31 % to 75 % (Table 48). 
 
 
 
 
 
 
  
NH2
OH
CDI
N
H OH
R'
COOH
R' O
+
R R
Where: 
41a = R' =  H,     R = H
41b = R' =  H,     R = Cl
41c = R' =  H,     R = CF3
41d = R' =  CF3, R = H
40 31 41
cpd 
Yield 
% 
m.p. Microanalysis Colour and 
appearance Practical Lit. 
40a 73 188 - 192℃ 197 - 198℃323 - Brown crystals 
40b 82 
162 – 164℃ Novel Anal. Calcd for C16H11F3O2 (292.26): C 
65.76 %, H 3.79 %, N 0.00 %. Found C 
65.63 %, H 3.81 %, N <0.10 %. 
creamy crystals 
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Table 48: Analytical data for (E)-N-(2-(unsubstituted/substituted phenyl)-2-hydroxyethyl)-3-
(unsubstituted/substituted styryl)benzamides 
  
 
4.2.4 Synthesis of (E)-N-(2-(unsubstituted/substituted phenyl)-2-hydroxyethyl)-3-
(unsubstituted/substituted styryl)phenyl-4,5-dihydrooxazoles (42) 
 
Scheme 55 
	
Following the previously described method in (5.1.5). Compounds 42a - 42d were obtained in 
yields ranging from 40 % - 90 % (Scheme 55).  
 
CH3SO2Cl
R'
R
Where: 
42a = R' =  H,     R = H
42b = R' =  H,     R = Cl
42c = R' =  H,     R = CF3
42d = R' = CF3,  R = H
N
H OH
R' O R
O
N
41
42
N
cpd 
Yield 
% 
m.p. 
 
Microanalysis/ HRMS 
 
Colour and 
appearance 
41a 60 
128- 132 ℃ Anal. Calcd for C23H21NO2 ∙ 0.4 H2O (350.36): C 78.79 %, H 
6.27 %, N 3.99 %. Found C 78.35 %, H 6.56 %, N 3.83 %. 
White solid 
41b 50 
138 - 142℃ Anal. Calcd for C24H20ClNO2∙	0.2 H2O (381.47): C 72.42 %, 
H 5.39 %, N 3.67 %. Found C 72.11 %, H 5.36 %, N 3.77 %. 
creamy 
solid 
41c 31 
184 - 186℃ Anal. Calcd for C24H20F3NO2 ∙	0.1H2O (413.23): C 69.76 %, 
H 4.93 %, N 3.39 %. Found C 69.51%, H 4.94 %, N 3.42 %. 
White 
crystals 
41d 75 
88 - 90℃ Anal. Calcd for C24H20F3NO2 (411.42): C 70.07%, H 4.90 %, 
N 3.40 %. Found C 69.99 %, H 5.05 %, N 3.53 %. 
White solid 
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4.2.5 Synthesis (E)-N-(2-(1H-imidazol-1-yl)-2-(unsubstituted/substituted phenyl)ethyl) 
-3-(substituted/unsubstituted styryl)benzamides  
 
Scheme 56 
Following the previously described method in (5.1.6). Reaction of oxazole (42) with excess 
imidazole gave 43a - 43d in yields ranging from 32 % - 938 % (Scheme 56 and table 49).  
 
Table 49: Analytical data for (E)-N-(2-(1H-imidazol-1-yl)-2-(unsubstituted/substituted phenyl)ethyl)-3-
(unsubstituted/substituted styryl)benzamides 
 
 
 
 
 
 
 
 
Where: 
43a = R' =  H,     R = H
43b = R' =  H,     R = Cl
43c = R' =  H,     R = CF3
43d = R' =  CF3, R = H
R'
RO
N
N
H N
R' O R
43 N
N
H
N
42
cpd 
 
Yield 
% 
m.p. Microanalysis/ HRMS 
 
Colour and 
appearance 
43a 38 
158 - 160℃ Anal. Calcd for C26H23N3O	∙	0.25 H2O (397.99): C 
78.47 %, H 5.95 %, N 10.56 %. Found C 78.17 %, 
H 5.95 %, N 10.56. 
White solid 
43b 32 
148 - 152℃ Anal. Calcd for C26H22ClN3O (427.93): C 72.98 %, 
H 5.18 %, N 9.81 %. Found C 72.77 %, H 5.36 %, 
N 8.40 %. 
White solid 
43c 48 
126 - 130℃ Calculated mass 462.1793 [M + H]+, measured 
mass: 462.1799 [M + H]+ 
White solid 
43d 33 
110 - 114℃ Calculated mass 462.1793 [M + H]+, measured 
mass: 462.1795 [M + H]+ 
White solid 
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4.3 Molecular modelling 
Ferla et al.191 reported that the styrylphenyl ring was important to the activity and that the 
imidazole was essential for metal-ligand interaction with the haem group of the enzyme. 
Introduction of substituents on the styrylphenyl ring resulted in an improvement in the activity 
by up to four times, as the introduction of methoxy groups in positions 3 and 5 led to an increase 
in CYP24A1inhibitory activity. 
In this chapter, compounds were designed by taking lead 3 and using different substitutions to 
explore SAR. Compounds 37a - 37f have electron withdrawing and electron donating (4-
chloro, 4-trifluoromethyl, 2-trifluoromethyl, 3,4-dimethyl and 4-methoxy groups) actions on 
the phenyl ring. All compounds were designed without substitution on the styrene group except 
compound 37f, which has a 4-Cl on the phenyl ring and a 3,4-dimethoxy substitution on the 
styrene group. All the compounds reached the active site through the vitamin D access tunnel 
and were exposed to multiple hydrophobic residues (Arg128, Glu130, Ile131, Trp134, Leu148, 
Asn208, Phe212, Ile239, Ile242, Lys243, Met246, Ser247, Phe249, Ala326, Val328, Glu329, 
The330, Val391 and Thr500). Compounds 37b - 37d formed hydrogen bonds between the 
nitrogen of the amide group with Leu325. For compound 37e, an additional hydrogen bond 
between the methoxy group and Arg128 was observed.  The distance between the imidazole 
ring and the haem iron was between 2.18 Å and 2.58 Å (Table 50). 
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cpd. A B 
C 
37a 2.56 Å 
 
 
37b 2.18 Å 
 
 
37c 2.41 Å 
  
37d 2.42 Å 
  
N
H
O
NN
Cl
Fe3+Fe5201
Val391
Thr500
Thr330 Ser247
Phe249
Met246
Hem520
Ala326
N O
H
NN
F
F
F
R
O
HN
R
Leu325
Fe3+Fe5201
Val328
Thr330
Phe212
Met246
Lys243
Leu148
Ile242Ile239
Hem520
Glu329
Arg128
Ala326
N O
H
N
N
F
FF
R
O
HN
R
Leu325
Fe3+
Fe5201
Val391
Val328
Trp134Thr330
Phe212
Met246
Lys243
Leu325
Leu148
Ile242
Ile239
Hem520
Glu329
Ala326
N
H
O
NNFe3+Fe5201
Val391
Trp134
Thr330
Phe249
Ile131
Hem520 Glu130
Ala326
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Table 50: (A) Distance between N of heterocycle and iron of haem, (B) 3D and (C) 2D structure with 
binding interactions 
 
However, there are some poses of compounds 37c and 37e that form different interactions with 
the haem. The carbonyl of the amide group 37c interacts with the iron of the haem (distance 
2.28 Å), while 37e interacts with the iron of the haem via the methoxy group (distance 2.19 Å)  
(Figure 88). 
 
Figure 88: Example of some poses of compounds 37c and 37e interacting with the haem iron via carbonyl 
and methoxy groups 
37e 2.58 Å 
 
 
37f 2.44 Å 
 
 
N
H
O
NN
O
H
N
N
H
NH2
H
Arg128
Fe3+Fe5201
Val328Thr330
Met246
Lys243
Leu325
Leu148
Ile242
Ile239
Hem520
Glu329
Arg128
Ala326
O N
H N
N
Cl
O
O
R
O
HNR
Leu325 Fe3+
Fe5201
Val328
Thr330
Phe212
Lys243
Leu325
Leu148
Ile239
Hem520
Glu329
Asn208
Ala326
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4.3.1 Docking studies of (E)-N-(2-(1H-imidazol-1-yl)-2-(unsubstituted/substituted 
phenyl)ethyl) -3-(unsubstituted/substituted styryl)benzamides using a CYP24A1 
homology model191 
Compounds 43a - 43d were modified by changing the position of the alkene group from the 4 
to the 3 position. 
The compounds were docked using the LeadIT 2.1.2 programme, and the results were 
visualised on MOE. All compounds showed good interaction with the active site and 
interaction between the imidazole nitrogen and the iron of the haem with distances ranging 
between 2.04 Å and 2.29 Å. Hydrogen bonds were observed between the amide group, through 
the C=O and/or NH, and amino acids Glu329, Thr330 and Leu325 (Table 51). 
 
cpd. A B 
C 
43a 2.04 Å 
 
 
43b 2.29 Å 
 
 
N
H
O
NN
R
O
N
R
H
Glu329
R
O
N R
H
Thr330
Fe3+Fe5201
Val391
Val328
Thr330
Phe212
Met246Lys243
Leu325
Ile242Ile239
Hem520
Glu329
Ala326
N O
H
NN
Cl
R
O
HN
R
Leu325
R
O
N
RH
Thr330
Fe3+Fe5201
Val391
Val328
Thr500
Thr330
Phe212
Met246
Lys243
Leu325
Ile242
Ile239
Hem520
Glu329
Gln324
Asn208
Ala327
Ala326
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Table 51: (A) Distance between N of heterocycle and iron of haem, (B) 3D and (C) 2D models showing key 
binding interactions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43c 2.22 Å 
  
43d 2.28 Å 
 
 
N
H
O
N
N
F
F
F
R
O
N R
H
Glu329
R
O
N
R
H
Thr330
Fe3+Fe5201
Val328
Trp134
Thr330
Phe249
Phe212
Met246
Lys243
Leu325
Leu148
Ile242
Ile239
Ile131
Hem520
Glu329
Asn208
Ala326
N O
H
N
N
F
FF
R
O
HNR
Leu325
Fe3+
Fe5201
Trp134
Thr330
Met246
Lys243
Leu325
Leu148
Hem520
Glu329
Ala326
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4.4 CYP24A1 inhibitor  enzymatic assay279 
All the final compounds 37a - 37f and 43a - 43d were evaluated by enzymatic assay to 
determine CYP24A1 inhibitory activity (see 3.6.1).  
In general, the compounds displayed potent inhibition of CYP24A1 activity when compared 
with the ketoconazole standard and comparable with or more active than lead 3 (IC50 0.40 
μM)191.  
The IC50 values ranged between 11 and 35 μM, and the best IC50 value was obtained for 
compound 37e (0.11µM) (Figure 89 and 90).  
All of the imidazole styrylbenzamide derivatives exhibited significant activity, but the 
compound with methoxy substitution in the phenyl ring was noted as having optimal activity 
(0.11 μM). Altering the position of the alkene double bond from position 4 to 3 was not 
beneficial in terms of the activity. However, a slight difference in the inhibitory effect was 
recorded, with compounds having different substituents in the phenyl ring where 43b, 43c and 
43d were proved to be better than 37a, 37b and 37c. Moreover, 4, 5-dimethoxy substitution on 
the styrene ring (compound 37f) and methoxy substitution on the phenyl ring (compound 37e) 
was better than electron withdrawing substituents. For example, compound 37f was more 
active than the compound with trifluoromethyl substitution in the styrene ring (43d). 
Interestingly, the unsubstituted phenyl ring (compound 43a) was more active than the 
unsubstituted phenyl ring for lead 3. 
 
Figure 89: Chemical structure compounds 37a - 37f and 43a - 43d 
N
H
O
N
R1
Where R:
37a = R1 = H,      R2 = H,     R3 = Cl,        R' = H
37b = R1 = H,      R2 = H,     R3 = CF3,     R' = H
37c = R1 = CF3,   R2 = H,     R3 = H,        R' = H
37d = R1 = H,      R2 = CH3, R3 = CH3,    R' = H 
37e = R1 = H,      R2 = H,     R3 = OCH3,  R' = H
37f  = R1 = H,      R2 = H,     R3 = Cl,        R' = OCH3
R3
R'
R'
R2
37
N
Where R: 
43a = R' =  H,     R = H
43b = R' =  H,     R = Cl
43c = R' =  H,     R = CF3
43d = R' =  CF3, R = H
N
H N
R' O R
43 N
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Figure 90: CYP24A1 inhibitor enzymatic assay 
 
In general, binding energies (Figure 91) and IC50 showed a good correlation with the exception 
of compounds 11b and 17c. Substitution of these compounds with the more bulky 
trifluoromethyl group in the para position of the phenyl ring results in a slightly less favourable 
conformer energy compared with the other inhibitors, which affects the overall binding energy. 
 
Figure 91: Correlation between CYP24A1 IC50 and binding energy for imidazole derivatives 37 and 43 
 
Computational molecular docking of two exemplar compounds 37e and 37f in the CYP27B1 
homology model would predict some inhibitory activity of this enzyme. Both compounds were 
found to interact with the haem iron via the amide carbonyl, however the imidazole nitrogen 
forms H-bonding interaction with Asn387, one of the amino acids identified as important for 
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CYP27B1 inhibitory activity. Whether just one H-bonding interaction with Asn387, rather than 
interaction with all three of the identified amino acids (Arg107, Asp320, Asn387), would 
produce significant or low inhibition would need to be determined experimentally (Figure 92 
and 93). 
 
 
Figure 92: 3D and 2D models showing key binding interactions of 37e with CYP27B1 model 
 
 
 
Figure 93: 3D and 2D models showing key binding interactions of 37f with CYP27B1 model 
 
 
 
 
 
 
 
 
N
H
O
N
N
O
H
N
O
H
Asn387
Fe3+Fe5201
Val494
Trp113
Thr493
Thr321
Pro385
Phe110
Leu495
Leu127
Fe5201
Efa*
Ala317
O N
H
N
N
Cl
O
O
H
N
O
H
Asn387
Fe3+Fe5201
Val494
Trp328
Trp113
Thr493
Thr321
Pro385
Leu495
Leu127
Fe5201
Efa*
Ala317
Chapter five                                                                                                             Lead 3 
	
	
	
183	
4.5 Conclusion 
The aim of current chapter was to develop potential CYP24A1 inhibitors that could be used in 
combination with calcitriol for the treatment of various diseases. The compounds were 
prepared by the modification of lead 3, specifically through substitution of the phenyl ring on 
the imidazole side, substitution of the phenyl ring of styrene, and variation of the alkene double 
bond. Imidazole styrylbenzamide derivatives 37a - 37f and 43a - 43d were prepared from 
various aldehydes comprising six steps: aldehydes   β-nitroalcohols  amino alcohols 
 styrylbenzamides  dihydrooxazoles  imidazole styrylbenzamides. Synthesis of β-nitroalcohols involves five different methods. Ambersep 900 (OH) was used as a catalyst, 
which is considered as environmentally friendly. Amino alcohols were prepared by catalytic 
hydrogenation employing a slurry of Raney nickel as a catalyst. (E)-substituted and 
unsubstituted styrylbenzoic acids were prepared by Heck reaction and then coupled with amino 
alcohols to give styrylbenzamides. Dihydrooxazoles were prepared from 
methansulfonylchloride, which were used as the crude product without further purification. 
Excess imidazole was used as reactant and solvent for the reaction of imidazole and 
styrylbenzamides and gave impressive yields. Docking studies revealed that all compounds 
access the active site of CYP24A1, occupying the same hydrophobic tunnel and with 
interacting amino acid residues as the known inhibitor. The hydrogen bond formed between 
the methoxy group of compounds 37e and Arg128 stabilises the docked compound in a 
favourable conformation.  All the synthesised compounds were tested for their ability to inhibit 
CYP24A1 demonstrating significant activity in vitro. Compounds 37e and 37f emerged as 
potential inhibitors displaying pronounced activity IC50 0.11	μM and 0.12	μM respectively 
comparable with the CYP inhibitor ketoconazole (IC50 0.50 μM).  
However, although collaboration at delivery the University of Wisconsin sent CYP27B1 
enzyme on two different occasions, the enzyme was denatured (owing to customs holdup) on 
both deliveries. Owing to the time in enzyme preparation, extraction and the costs involved 
there was no further attempts to send compounds. 
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4.6 Experimental 
4.6.1 Molecular modelling 
molecular modelling method information as previously described Chapter 2. 
 
4.6.2 CYP24A1 inhibitor enzymatic assay279 
All CYP24A1 inhibitor enzymatic assay method information as previously described in 
Chapter 3. 
 
4.6.3 Chemistry 
4.6.3.1 1-(4-Chlorophenyl)-2-nitroethan-1-ol (30a)307 
 
 
 
O
H
OH
NO2
CH3-NO2+
Chemical Formula: C8H8ClNO3
Molecular Weight: 201.61
ClCl
28a 29 30a
Method 1 Method 4 
To a solution of 4-chlorobenzaldehyde 28a (5 g, 35.4 
mmol) in methanol (20 mL), cooled to 0 °C, 
nitromethane 29 (3.8 mL, 71 mmol) and aqueous NaOH 
(10 M, 14 mL) were added and the resulting solution 
was stirred at 0 °C for 24 h. After addition of aqueous 
acetic acid (2 %, v/v, 10 mL) the reaction mixture was 
stirred at room temperature for 1 h, the methanol was 
removed under vacuum and the resulting solution 
extracted with dichloromethane (100 mL). The organic 
layer was washed with brine (2 ×	100	mL), dried 
(MgSO4) concentrated and purified by gradient flash 
column chromatography, product eluted with petroleum 
ether- EtOAc 1:1 v/v307. 
To a solution of 4-chlorobenzaldehyde 28a (3 g, 21.4 
mmol) in nitromethane 29 (10 mL, 183.3 mmol) was 
added Ambersep 900 (OH) (0.1 eq./1 mmol). The 
solution was stirred overnight and progress of the 
reaction was monitored by TLC. The Ambersep 900 
was removed by filtration. The crude product was 
extracted with EtOAc (100 mL) and washed with 
brine (2×	100	mL), dried (Mg2SO4) and 
concentrated under vaccum to dryness310. 
 
Yield = 5.1 g (72 %), yellow liquid Yield = 3.3 g (76 %), yellow liquid 
Method 3 
To a slurry of LiAlH4 (2 mmol, 5 mL), was added to nitromethane 29 (10 mL, 183.3 mmol) and the reaction 
stirred for 30 min at 0 °C. Then, 4-chlorobenzaldehyde 28a (3 g, 21.4 mmol) was added and the mixture stirred 
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4.6.3.2 2-Nitro-1-(4-(trifluoromethyl)phenyl)ethan-1-ol (30b) 
 
 
 
 
4.6.3.3 2-Nitro-1-(2-(trifluoromethyl)phenyl)ethan-1-ol (30c) 
 
O
H
OH
NO2
CH3-NO2+
F
F
F FF
F
28b 29 30b
Chemical Formula: C9H8F3NO3
Molecular Weight: 235.16
O
H
OH
NO2
CH3-NO2
Ambersep 900 (OH)
Chemical Formula: C9H8F3NO3
Molecular Weight: 235.16
F
FF F
F
F
28c 29 30c
+
overnight and then quenched with 1N aqueous HCl (20 mL). Then extracted with EtOAc (100 mL), washed 
with brine (2 ×	100	mL), dried (Mg2SO4) and concentrated under vaccum309. 
Yield = 3.8 g (90 %), yellow liquid 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.38 
1H NMR (CD3OD): 
δ: 7.45 (d, J = 8.4 Hz, 2H, Ar), 7.38 (m, 2H, Ar), 5.41 (dd, J = 3.5, 9.7 Hz, 1H,  CH-OH ), 4.72 (dd, J = 3.5, 
12.6 Hz, 1H, CH2), 4.61 (dd, J = 9.7, 12.6 Hz, 1H, CH2).   
Method 3 Method 4 
Method 3: See 4.6.3.1 
Reagent: 4-(trifluoromethyl)benzaldehyde (0.75 g, 4.3 
mmol) 28b  
Method 2: See 4.6.3.1 
Reagent: 4-(trifluoromethyl)benzaldehyde (1.1g, 
7.3 mmol) 28b 
Yield = 1.1 g (92 %), yellow liquid Yield = 1.5 g (85 %), yellow liquid 
TLC: CH2Cl2: CH3OH 9:1 v/v, Rf  = 0.5 
 1H NMR (DMSO-d6): 
δ: 7.76 (d, J = 8.3 Hz, 2H, Ar), 7.69 (d, J = 8.3 Hz, 2H, Ar), 6.31 (d, J = 4.7 Hz, 1H, OH), 5.41 (m, 1H, CH-
OH), 4.94 (dd, J = 3.0, 12.3 Hz, 1H, CH2), 4.64 (dd, J = 10.1, 12.7 Hz, 1H, CH2). 
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Method 4: See 4.6.3.1 
Reagent: 2-(trifluoromethyl)benzaldehyde (2 g, 11.5 mmol) 28c 
TLC:  petroleum ether-EtOAc 4:1 v/v, Rf = 0.50 
Yield = 2.1 g (78 %), yellow oil 
1H NMR (DMSO–d6): 
δ: 7.9 (d, J = 8.0 Hz, 1H, Ar), 7.77 (t, J = 7.5 Hz, 2H, Ar), 7.58 (t, J = 7.5 Hz, 1H, Ar), 6.43 
(dd, 1.0, 4.7 Hz, 1H, OH), 5.64 (t, J = 5.0 Hz 1H, CH-OH), 4.75 (dd, J =1.0, 2.7 Hz, 1H, CH2), 
4.64 (dd, J = 10.1, 12.7 Hz, 1H, CH2). 
 
4.6.3.4 1-(4-Bromophenyl)-2-nitroethan-1-ol (30d) 
 
 
 
Method 1: See 4.6.3.1 
Reagent: 4-Bromobenzaldehyde (3 g, 16.2 mmol) 28d 
TLC: CH2Cl2-CH3OH 9: 1 v/v, Rf = 0.36 
Yield = 3.6 g (92 %), brown oil 
1H-NMR (DMSO–d6): 
δ: 7.58 (dd, J = 1.8, 6.6 Hz, 2H, Ar), 7.43 (dd, J = 2.2, 10.5 Hz, 2H, Ar), 6.19 (d, J = 4.3 Hz, 
1H, OH), 5.29 (dd, J = 3.8, 5.6 Hz, 1H, CH-OH), 4.87 (dd, J = 3.5, 12.6 Hz, 1H, CH2), 4.60 
(dd, J = 9.7, 12.6 Hz, 1H, CH2).  
 
4.6.3.5 2-Nitro-1-(o-tolyl)ethan-1-ol (30e) 
 
 
 
O
H
OH
NO2
CH3-NO2+
Br
Br
28d 29 30d
Chemical Formula: C8H8BrNO3
Molecular Weight: 246.06
NaOH
O
H
OH
NO2
CH3-NO2+
28e 29 30e
Chemical Formula: C9H11NO3
Molecular Weight: 181.19
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Method 3: See 4.6.3.1 
Reagent: 2- methylbenzaldehyde 28e (1 g, 0.83 mmol) 28d 
TLC: hexane-EtOAc 5:1 v/v, Rf = 0.12 
Yield = Yield = 1.6 g (55 %), brown oil 
 
4.6.3.6 1-(3,5-Dimethylphenyl)-2-nitroethan-1-ol (30f) 
 
Method: 
To a stirred solution of 3,5-dimethylbenzaldehyde 38f (0.5 g, 3.7 mmol,) in nitromethane 29 
(2.1g, 37 mmol) was added triethylamine (5 mL) and the resulting solution was stirred at room 
temperature until consumption of the aldehyde was indicated by TLC. The solution was diluted 
with EtOAc (100 mL), washed with sodium bicarbonate (2 ×	50	mL), brine (2 ×	50	mL) and 
water (2 ×	50	mL). The organic layer was dried (MgSO4) and concentrated in vacuo. The crude 
product was purified by gradient flash column chromatography; the product was eluted with 
petroleum ether-EtOAc 3:1 v/v308. 
TLC: petroleum ether-EtOAc 3:1 v/v, Rf = 0.57 
m. p. = 54 - 56 °C  
Yield = 0.67 g (85 %), brownish yellow solid. 
1H NMR (DMSO-d6): 
δ: 7.32 (s, 1H, Ar), 7.10 (m, 2H, Ar), 5.94 (dd, J = 1.1, 4.8 Hz, 1H, OH), 5.44 (m, 1H, CH-
OH), 4.79 (dd, J = 1.1, 3.0 Hz, 1H, CH2), 4.47 (dd, J = 10.0, 12.6 Hz, 1H, CH2), 2.30 (s, 3H, 
CH3), 2.28 (s, 3H, CH3). 
 
4.6.3.7 1-(4-Methoxyphenyl)-2-nitroethan-1-ol (30g) 
 
O
H OH
NO2
CH3-NO2
28f 29 30f
Chemical Formula: C10H13NO3
Molecular Weight: 195.22
N
+
O
H OH
NO2
CH3-NO2
Chemical Formula: C9H11NO4
Molecular Weight: 197.19
OO
28g 29 30g
+
Chapter five                                                                                                             Lead 3 
	
	
	
188	
 
 
4.6.3.8 1-(3,5-Dimethoxyphenyl)-2-nitroethan-1-ol 
 
 
 
O
H OH
NO2
CH3-NO2
Chemical Formula: C10H13NO5
Molecular Weight: 227.22
28h 29 30h
+
O
O
O
O
Method 3 Method 2 
Method 3: See 4.6.3.1 
 Reagent: 4-methoxybenzaldehyde (2 g, 14.7 mmol) 28g 
Purified by gradient flash column chromatography, 
product was eluted with petroleum ether- EtOAc 4:1 v/v. 
Method 2: See 4.6.3.1 
Reagent: 4-methoxybenzaldehyde (1.4 g, 10 
mmol) 28g 
Purified by gradient flash column 
chromatography, product was eluted with 
petroleum ether- EtOAc 4:1 v/v. 
Yield = 2.5 g (86 %), yellow oil Yield = 0.4 g (20 %), yellow oil 
TLC: petroleum ether-EtOAc 4:1 v/v, Rf = 0.4 
1H NMR (DMSO-d6): 
δ: 7.36 (d, J = 8.6 Hz, 2H, Ar), 6.94 (d, J = 11.6 Hz, 2H, Ar), 5.98 (dd, J = 0.8, 5.0 Hz, 1H, OH), 5.23 (m, 1H, 
CH-OH), 4.80 (dd, J = 2.8, 12.5 Hz, 1H, CH2), 4.57 (dd, J =10.1, 12.7 Hz, 1H, CH2), 3.75 (s, 3H, OCH3). 
Method 4 Method 2 
Method 4: See 4.6.3.5 
Reagent: 3,5-dimethoxybenzaldehyde (3 g, 18 mmol) 
28h 
Purified by gradient flash column chromatography, 
product was eluted with petroleum ether-EtOAc 3:1 
v/v. 
Method 2: See 4.6.3.1 
Reagent: 3,5-dimethoxybenzaldehyde (3 g, 18 
mmol) 28h 
Yield = 2.5 g (63 %), yellow oil Yield = 3.3 g (85 %), yellow oil 
TLC: petroleum ether-EtOAc 4:1 v/v, Rf = 0.6 
1H NMR (DMSO–d6): 
δ: 6.62 (d, J = 2.3 Hz, 2H, Ar), 6.43 (t, J = 2.3 Hz, 1H, Ar), 6.07 (d, J = 5 Hz, 1H, OH), 5.23 (m, 1H, CH-OH), 
4.86 (dd, J = 3.2, 12.5 Hz, 1H, CH2), 4.56 (dd, J = 10.1, 12.5 Hz, 1H, CH2), 3.74 (s, 6H, OCH3). 
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4.6.3.9 2-Amino-1-(4-chlorophenyl)ethan-1-ol (31a) 
 
Method: 
Raney nickel (50 % slurry in H2O, 3 mL) was added to a solution of 1-(4-chlorophenyl)-2-
nitroethan-1-ol 30a (1.5 g, 7.5 mmol) in methanol (40 mL) and aqueous formic acid (50 % v/v, 
8 mL). The reaction flask was then degassed and a hydrogen balloon was used until all starting 
material had been consumed. The reaction mixture was filtered, and the methanol was removed 
under vacuum. The aqueous residue was made alkaline with NH4OH and extracted with EtOAc 
(100 mL) and washed with brine (2 ×	100 mL), dried (MgSO4), filtered and reduced under 
vacuum to give yellow solid312. 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.20 
m. p. = 106 - 110 °C (Lit. m. p. 94 - 95 °C)313 
Yield = 1.28 g (84 %), pale a yellow solid 
1H NMR (CD3OD): 
δ: 7.38 (m, 4H, Ar), 4.53 (m, 1H, CH-OH), 3.41 (br. s, 3H, OH, NH2), 2.73 (dd, J = 3.8, 12.9 
Hz, 1H, CH2), 2.61 (dd, J = 7.9, 12.9 Hz, 1H, CH2).  
 
4.6.3.10 2-Amino-1-(4-(trifluoromethyl)phenyl)ethan-1-ol (31b) 
 
 
 
Method: 
Raney nickel (50 % slurry in H2O, 3 mL) was added to a solution of 2-nitro-1-(4-
(trifluoromethyl)phenyl)ethan-1-ol 30b (1 g, 4.25 mmol) in methanol (40 mL) and aqueous 
OH OH
NH2
H2+
Raney nickel
NO2
Chemical Formula: C8H10ClNO
Molecular Weight: 171.62
Cl Cl
30a 31a
OH OH
NH2
H2+
Raney nickel
NO2
Chemical Formula: C9H10F3NO
Molecular Weight: 205.18
30b 31b
F F
F
F
F
F
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formic acid (50 % v/v, 8 mL). The suspension was subject to hydrogenation at 45 psi for 6 h. 
The reaction mixture was filtered, and the methanol was removed under vacuum. The aqueous 
residue was made alkaline with NH4OH and extracted with EtOAc (100 mL), washed with 
brine (2 ×	100 mL), dried (MgSO4), filtered and reduced under vacuum to give a white solid312. 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.30 
m. p. = 60 - 64 °C  
Yield = 0.46 g (53 %), white solid 
1H NMR (DMSO-d6):  
δ: 7.68 (d, J = 8.1 Hz, 2H, Ar), 7.56 (d, J = 8.1 Hz, 2H, Ar), 4.56 (𝜑t, J = 4.2, 6.6 Hz, 1H, 
CH-OH), 3.14 (br. s, 3H, OH, NH2), 2.73 (d, J = 3.3 Hz, 1H, CH2), 2.62 (m, 1H, CH2). 
 
4.6.3.11 2-Amino-1-(2-(trifluoromethyl)phenyl)ethan-1-ol (31c) 
 
Method: See 4.6.3.10 
Reagent: 2-nitro-1-(2-(trifluoromethyl)phenyl)ethan-1-ol (1 g, 4.5 mmol) 31c. 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.60 
m. p. = 80 - 86 °C  
Yield = 0.60 g (67 %), white solid 
1H NMR (DMSO-d6):  
δ: 7.77 (d, J = 7.8 Hz, 1H, Ar), 7.69 (m, 2H, Ar), 7.47 (t, J = 7.6 Hz,1H, Ar), 4.80 (m, 1H, 
CH-OH), 3.01 (br. s, 3H, OH, NH2), 2.67 (d, J = 3.3 Hz, 1H, CH2), 2.55 (m, 1H, CH2). 
 
4.6.4 2-Amino-1-(o-tolyl)ethan-1-ol (31e) 
 
OH OH
NH2
H2+
Raney nickel
NO2
Chemical Formula: C9H10F3NO
Molecular Weight: 205.18
30c 31c
F
F
F F
F
F
OH OH
NH2
H2+
Raney nickel
NO2
Chemical Formula: C9H13NO
Molecular Weight: 151.21
30e 31e
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Method: See 4.6.3.10 
Reagent: 2-nitro-1-(o-tolyl)ethan-1-ol (1 g, 5.5 mmol) 31e 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.6 
Yield = 0.46 g (57 %), amber oil. Purified by gradient flash column chromatography, product 
was eluted with CH2Cl2-CH3OH 9:1 v/v. 
1H NMR (CDCl3):  
δ: 7.50 (d, J = 8.6 Hz, 1H, Ar), 7.25 (m, 3H, Ar), 5.08 (dd, J = 3.0, 8.4 Hz, 1H, CH-OH), 3.77 
(m, 1H, CH2), 3.24 (m, 1H, CH2), 3.15 (br. s, 3H, OH, NH2), 2.36 (s, 3H, CH3). 
 
4.6.4.1 2-Amino-1-(3,4-dimethylphenyl)ethan-1-ol (31f) 
 
 
Method: See 4.6.3.10 
Reagent: 1-(3,4-dimethylphenyl)-2-nitroethan-1-ol (0.67 g, 3.5 mmol) 31f 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.1 
m. p. = 64 - 68 °C  
Yield = 0.35 g (63 %), pale yellow solid 
1H NMR (DMSO-d6):  
δ: 7.21 (s, 1H, Ar), 6.99 (d, J = 7.6 Hz, 2H, Ar), 4.62 (m, 1H, CH-OH), 3.38 (br. s, 3H, OH, 
NH2), 2.63 (dd, J = 3.8, 12.9 Hz, 1H, CH2), 2.57 (dd, J = 7.9, 12.9 Hz, 1H, CH2), 2.25 (s, 3H, 
CH3), 2.22 (s, 3H, CH3). 
 
4.6.4.2 2-Amino-1-(4-methoxyphenyl)ethan-1-ol (31g) 
 
OH OH
NH2
H2+
Raney nickel
NO2
Chemical Formula: C10H15NO
Molecular Weight: 165.24
30f 31f
OH OH
NH2
H2+NO2
Chemical Formula: C9H13NO2
Molecular Weight: 167.21
30g 31g
O O
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4.6.4.3 2-Amino-1-(3,5-dimethoxyphenyl)ethan-1-ol (31h) 
 
Method: See 4.6.3.10 
The product was purified by gradient flash column chromatography, product was eluted with 
CH2Cl2-CH3OH 9:1 v/v. 
Reagent: 1-(3,5-dimethoxyphenyl)-2-nitroethan-1-ol (3.5 g, 15.4 mmol) 30h 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.76 
Yield = 0.5 g (17 %), yellow oil 
 
OH OH
NH2
H2+
Raney nickel
NO2
Chemical Formula: C10H15NO3
Molecular Weight: 197.23
30h 31h
O
O O
O
Method 1 Method 2 
Method 1: See 4.6.3.10 
Reagent: 1-(4-methoxyphenyl)-2-nitroethan-1-ol 
(1 g, 5 mmol) 30g 
 
Method 2: 
Pd/C (100 mg) was added to a solution of 1-(4-
methoxyphenyl)-2-nitroethan-1-ol 30g (1 g, 5 mmol) in 
methanol (20 mL) and subject to hydrogenation 45 psi for 
6 h. The reaction mixture was filtered, and the methanol 
was removed under vacuum. The residue was made 
alkaline with NH4OH and extracted with EtOAc (100 mL) 
and washed with brine (2 ×	100 mL), dried over 
anhydrous (MgSO4), filtered and reduced under vacuum. 
The product was purified by gradient flash column 
chromatography, product eluted with  CH2Cl2-CH3OH 9:1 
v/v to give a yellow solid311. 
Yield = 0.40 g (47 %), yellow solid Yield = 0.36 g (42 %), yellow solid 
m. p. = 46 - 50 °C (Lit. 70°C314)   
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.6 
1H NMR (DMSO-d6):  
δ: 7.28 (d, J = 8.6 Hz, 2H, Ar), 6.90 (d, J = 8.6 Hz, 2H, Ar), 4.61 (m, 1H, CH-OH), 3.81 (s, 3H, OCH3), 3.93 
(d, J = 3.3 Hz, 1H, CH2), 3.60 (m, 1H, CH2), 2.29 (br. s, 3H, OH, NH2). 
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1H NMR (DMSO-d6):  
δ: 6.52 (d, J = 2.3 Hz, 2H, Ar), 6.38 (t, J = 2.3 Hz, 1H, Ar), 4.56 (m, 1H, CH-OH), 3.73 (s, 
6H, 2 × OCH3), 3.07 (br.s, 3H, OH & NH2),  2.46 (m, 1H, CH2), 2.18 (m, 1H, CH2). 
 
4.6.4.4  (E)-4-styrylbenzoic acid (34a) 
               
Method: 
Styrene 32a (3.2 g, 31.1 mmol), 4-bromobenzoic acid 33 (5 g, 24.9 mmol) and triethylamine 
(69 mL, 77.7 mmol) were heated in the presence of tri(o-tolyphosphine) (0.3 g, 0.99 mmol) 
and Pd(OAc)2 (50 mg, 0.27 mmol) in a sealed glass tube at 100 °C overnight. After the 
reaction was complete, a white-gray precipitate formed. Then cold aqueous 1M HCl (15 mL) 
was added and the mixture was extracted with EtOAc (100 mL) and washed with brine (2 ×	100 mL), dried (MgSO4), filtered and reduced under vacuum.  
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.63 
m. p. = 240 - 242 °C ( Lit. 257 ℃318 ) 
Yield = 3.5 g (51 %), yellow crystals, recrystallised with ethanol 
1H NMR (DMSO-d6): 
δ: 12.91 (s, 1H, COOH), 7.95 (d, J = 8.4 Hz, 2H, Ar), 7.73 (d, J = 8.4 Hz, 2H, Ar), 7.65 (d, J 
= 7.4 Hz, 2H, Ar), 7.35 (m, 5H, Ar). 
 
4.6.4.5 (E)-4-(3,4-dimethoxystyryl)benzoic acid (34b) 
 
O
OH Pd(OAc)2
O
OH
Chemical Formula: C15H12O2
Molecular Weight: 224.26
Br
+
33 34a32a
O
OH Pd(OAc)2
O
OH
Chemical Formula: C17H16O4
Molecular Weight: 284.31
Br
+
33 34b
O
O
O
O
32b
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Method: See 4.6.4.4 
Reagent: 1,2-dimethoxy-4-vinylbenzene (1 g, 6 mmol) 32b 
TLC: petroleum ether-EtOAc 1:3 v/v, Rf = 0.22 
m. p. = 244 - 248 °C  
Yield = 1 g (59 %), yellow crystals, recrystallised with ethanol. 
1H NMR (DMSO-d6): 
δ: 12.88 (s, 1H, COOH), 7.94 (d, J = 8.4 Hz, 2H, Ar), 7.69 (d, J = 8.4 Hz, 2H, Ar), 7.36 (d, J 
= 16.4 Hz, 1H, alkene), 7.24 (d, J = 16.4 Hz, 1H, alkene), 7.16 (dd, J = 1.9, 8.4 Hz, 2H), 6.98 
(d, J = 8.4 Hz, 1H, Ar), 3.83 (s, 3H, OCH3), 3.78 (s, 3H, OCH3). 
13C NMR (DMSO-d6): 
δ: 167.6 (CO), 149.6, 149.4, 142.3 (3	× C), 131.5, 130.3 (2 × CH, Ar), 130.0, 129.4 (2	× C), 
126.5, 125.6, 121.1, 112.2, 109.8 (7 × CH, Ar), 55.9 (2 × OCH3, Ar). 
Microanalysis 
Anal. Calcd for C17H16O4∙	0.1H2O (286.1): C 71.37 %, H 5.71 %. Found C71.29 %, H 5.47 %. 
 
4.6.4.6 (E)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-4-styrylbenzamide (35a) 
 
Method:  
 A suspension of (E)-4-styrylbenzoic acid 34a (0.9 g, 4.1 mmol) in dry DMF (16 mL) was 
combined with CDI (0.7 g, 4.5 mmol). The reaction was stirred for 1 h at room temperature 
under nitrogen. The mixture was cooled to 0 °C then added to a solution of 2-Amino-1-(4-
chlorophenyl)ethan-1-ol 31a (0.7 g, 4.1 mmol) in dry DMF (5 mL). The resulting mixture was 
stirred at room temperature overnight. On completion, ice was added into the flask and the 
resulting white solid collected by filtration, washed with ice-cold water and dried210.  
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.86 
m. p. = 258 - 260 °C 
Yield = 1 g (67 %), white crystals, recrystallised with methanol 
 
O
OH
+
Cl
NH2
OH
CDI N
H
O
OH
Cl
Chemical Formula: C23H20ClNO2
Molecular Weight: 377.87
34a 31a 35a
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1H NMR (DMSO-d6): 
δ: 8.52 (t, J = 5.3 Hz, 1H, NH), 7.85 (d, J = 8.2 Hz, 2H, Ar), 7.73 (d, J = 8.4 Hz, 2H, Ar), 7.74 
(d, J = 8.2 Hz, 2H, Ar), 7.42 (m, 5H, Ar) 7.24 (m, 4H, Ar), 5.64 (s, 1H, OH), 4.80 (m, 1H, 
CHOH), 3.49 (m,1H, CH2), 3.40 (m, 1H, CH2).   
13C NMR (DMSO-d6): 
δ: 167.6 (CO), 140.9, 137.5, 135.2, 133.6, 133.2 (5	× C), 129.4, 128.5, 128.1, 127.3, 127.2, 
127.1, 126.9 (15 × CH, Ar), 72.2 (CH), 47.1 (CH2) 
Microanalysis 
Anal. Calcd for C23H20ClNO2∙	0.3H2O (382.52): C 72.08 %, H 5.42 %, N 3.65 %. Found 
C72.20 %, H 5.26 %, N 3.86 %. 
 
4.6.4.7  (E)-N-(2-hydroxy-2-(4-(trifluoromethyl)phenyl)ethyl)-4-styrylbenzamide (35b) 
 
Method: See 4.6.4.6 
Reagent: (E)-4-styrylbenzoic acid (0.4g, 2 mmol) 34a 
TLC: petroleum ether-EtOAc 3:1 v/v, Rf = 0.75 
m. p. = 220 - 224 °C 
Yield = 0.35 g (35 %), white crystals, recrystallised with methanol. 
1H NMR (DMSO-d6): 
δ: 8.58 (t, J = 5.7 Hz, 1H, NH), 7.84 (d, J = 8.4 Hz, 2H, Ar), 7.72 (φt, J = 8.4, 10.5 Hz, 4H, 
Ar), 7.65 (m, 4H, Ar), 7.42 (m, 3H, Ar) 7.33 (m, 2H, Ar), 5.77 (d, J = 4.5 Hz, 1H, OH), 4.89 
(t, J = 5.5 Hz, 1H, CHOH), 3.53 (m,1H, CH2), 3.43 (m, 1H, CH2).  
13C NMR (DMSO-d6): 
δ: 166.6 (CO), 149.0, 140.3, 137.2, 133.6 (4	× C), 129.2, 128.5 (2	× CH, Ar), 128.3, 128.0 
(2	× C), 127.9, 127.3, 127.2, 127.1, 126.7, 125.4 (13 × CH, Ar), 71.2 (CH), 47.9 (CH2) 
Microanalysis 
Anal. Calcd for C24H20F3NO2 (411.42): C 70.07 %, H 4.90 %, N 3.40 %. Found C 70.39 %, H 
4.79 %, N 3.47 %. 
O
OH
+
NH2
OH
CDI NH
O
OH
Chemical Formula: C24H20F3NO2
Molecular Weight: 411.42
F
F F
F
FF
34a 31b
35b
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4.6.4.8 (E)-N-(2-hydroxy-2-(2-(trifluoromethyl)phenyl)ethyl)-4-styrylbenzamide (35c) 
 
Method: See 4.6.4.6 
Reagent: (E)-4-styrylbenzoic acid (0.7 g, 3 mmol) 34a 
TLC: petroleum ether-EtOAc 3:1 v/v, Rf = 0.40 
m. p. = 160 - 166 °C 
Yield = 0.7 g (58 %), white solid, recrystallised with methanol. 
1H NMR (DMSO-d6): 
δ: 8.58 (t, J = 6 Hz, 1H, NH), 7.87 (d, J = 8.5 Hz, 3H, Ar), 7.74 (m, 4H, Ar), 7.68 (d, J = 15.5 
Hz, 2H, Ar), 7.51 (t, J = 7.7 Hz, 1H, Ar), 7.42 (m, 2H, Ar) 7.33 (m, 3H, Ar), 5.81 (d, J = 4.0 
Hz, 1H, OH), 5.14 (dd, J = 5.1, 11.9 Hz, 1H, CHOH), 3.51 (m, 2H, CH2).   
13C NMR (DMSO-d6): 
δ: 169.6 (CO), 141 (C), 140.3, 131.0 (CH),128.8 (C), 128.2, 128.1, 127.8, 127.3, 127.0, 126.3, 
126.6, 125.1, 126.7, 125.4 (14 × CH, Ar), 124.3, 123.2 (5 × C), 77.2 (CH), 48.3 (CH2) 
Microanalysis 
Anal. Calcd for C24H20F3NO2 (411.42): C 70.07 %, H 4.90 %, N 3.40 %. Found C 70.22 %, H 
4.92 %, N 3.38 %. 
 
4.6.4.9 (E)-N-(2-(3,4-dimethylphenyl)-2-hydroxyethyl)-4-styrylbenzamide (35d) 
 
 Method: See 4.6.4.6 
Reagent: 2-amino-1-(3,4-dimethylphenyl)ethan-1-ol (0.50 g, 3 mmol) 31d 
TLC: CH2Cl2- CH3OH 9.5:0.5 v/v, Rf = 0.80 
O
OH +
NH2
OH
CDI
N
H
O
OH
Chemical Formula: C24H20F3NO2
Molecular Weight: 411.42
34a 31c 35c
FF
F
F FF
O
OH +
NH2
OH
CDI
N
H
O
OH
Chemical Formula: C25H25NO2
Molecular Weight: 371.48
34a 31d 35d
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m. p. = 150 - 154°C  
Yield: 0.70 g (60 %), white solid, recrystallised with ethanol 
1H NMR (CDCl3): 
δ: 8.08 (s, 1H, Ar), 8.63 (d, J = 8.0 Hz, 1H, Ar), 7.57 (d, J = 7.5 Hz, 2H, Ar), 7.42 (t, J = 7.5 
Hz, 2H, Ar), 7.33 (t, J = 7.5 Hz, 2H, Ar), 7.28 (s, 1H, Ar), 7.26 (s, 1H, Ar) 7.19 (d, J = 4.5 Hz, 
2H, Ar), 7.15 (m, 3H, Ar), 5.88 (t, J = 10.0 Hz, 1H, OH), 4.56 (dd, J = 10.0, 15.0 Hz, 1H, 
CHOH), 4.17 (m, 1H, CH2), 3.93 (dd, J = 8.5, 14.5 Hz, 1H, CH2), 3.5 (s, 6H, 2CH3).   
13C NMR (CDCl3): 
δ: 166.5 (CO), 142.1, 140.1, 137.3, 134.9, 133.7, 131.6 (6	× C), 130.6, 130.3, 129.2, 128.4, 
128.2, 128.0, 127.8, 127.2, 126.7 (14× C, Ar), 68.6 (CH), 47.4 (CH2), 21.35, 18.71 (2	× CH3). 
Microanalysis 
Anal. Calcd for C25H25NO2 (371.48): C 80.83 %, H 6.78 %, N 3.77 %. Found C 81.10 %, H 
6.78 %, N 3.88 % 
 
4.6.4.10 (E)-N-(2-hydroxy-2-(4-methoxyphenyl)ethyl)-4-styrylbenzamide (35e) 
 
Method: See 4.6.4.6 
Reagent: (E)-4-styrylbenzoic acid (0.6 g, 2 mmol) 34a 
TLC: petroleum ether-EtOAc 1:3 v/v, Rf = 0.70 
m. p. = 218 - 220 °C 
Yield = 0.35 g (35 %), white solid, recrystallised with methanol. 
1H NMR (DMSO-d6): 
δ: 8.50 (t, J = 5.5 Hz, 1H, NH), 7.87 (d, J = 8.3 Hz, 2H, Ar), 7.70 (d, J = 8.3 Hz, 4H, Ar), 7.65 
(q, J = 7.6 Hz, 3H, Ar), 7.33 (m, 2H, Ar), 7.33 (m, 2H, Ar), 6.92 (d, J = 8.3 Hz, 2H), 5.43 (d, J 
= 4.5 Hz, 1H, OH), 4.76 (m, 1H, CHOH), 3.74 (s, 3H, OCH3), 3.50 (m,1H, CH2), 3.34 (m, 1H, 
CH2).   
13C NMR (DMSO-d6): 
δ: 166.5 (CO), 158.8, 140.2, 137.3, 136.3, 133.8 (5	× C), 130.6, 129.2, 128.5, 128.1, 127.6, 
127.2, 1114.3 (15 × CH, Ar), 71.2 (CH), 55.4 (OCH3) 48.2 (CH2) 
O
OH +
NH2
OH
CDI
N
H
O
OH
Chemical Formula: C24H23NO3
Molecular Weight: 373.45
34a 31e 35e
O
O
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Microanalysis 
Anal. Calcd for C24H23NO3 (373.45): C 77.19 %, H 6.21 %, N 3.75 %. Found C 77.32 %, H 
6.02 %, N 3.70 %. 
 
4.6.4.11  (E)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-4-(3,4-dimethoxystyryl)benzamide 
(35f) 
 
Method: See 4.6.4.6 
Reagent: (E)-4-(3,4-dimethoxystyryl)benzoic acid (1 g, 3.5 mmol) 34b 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.2 
m. p. = 168 - 172 °C 
Yield = 0.9 g (69 %), white solid, recrystallised with acetonitrile 
1H NMR (DMSO-d6): 
δ: 8.53 (t, J = 6.0 Hz, 1H, NH), 7.84 (d, J = 8.0 Hz, 2H, Ar), 7.65 (d, J = 8.5 Hz, 2H, Ar), 7.40 
(s, 2H, Ar), 7.36 (m, 2H, Ar), 7.21 (m, 2H, Ar) 7.00 (m, 3H, Ar), 5.66 (d, J = 4.5 Hz, 1H, OH), 
4.81 (m, 1H, CHOH), 3.87 (s, 6H, 2 × OCH3), 3.49 (m, 2H, CH2).  
13C NMR (DMSO-d6): 
δ: 166.5 (CO), 149.5, 149.4, 143.3, 133.2, 131.9, 128.2 (6 × C), 130.7 (CH, Ar), 130.2 
(C),128.4, 128.3, 128.2, 126.3, 125.8, 120.7, 112.3, 109.7 (12 × CH, Ar), 71.0 (CH), 56.3 (2 × OCH3), 47.3 (CH2). 
LRMS (ES-TOF) 
M/Z: 440 [M37Cl + H]+, 438 [M35Cl  + H]+ 
HRMS (ES-TOF) 
Calculated mass: 438.1472 [M + H]+, measured mass: 438.1463 [M + H]+ 
 
O
OH
NH2
OH
CDI
N
H
O
OH
Chemical Formula: C25H24ClNO4
Molecular Weight: 437.92
34b 31f 35f
Cl
Cl
O
O
+ O
O
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4.6.4.12  (E)-5-(4-chlorophenyl)-2-(4-styrylphenyl)-4,5-dihydrooxazole (36a) 
  
 
Method: 
A solution of (E)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-4-styrylbenzamide 35a (1.3 g, 3.4 
mmol) in dry THF (30 mL) was cooled to 0 °C. Then methansulfonylchloride (2.2 mL, 27 
mmol) was added and the resulting mixture stirred at 0 °C for 3 h. Triethylamine (6.2 mL, 
40.8 mmol) was added dropwise and the solution was stirred overnight at room temperature. 
The mixture was quenched by the addition of NH4OH (28 %, 3 mL) and the reaction stirred at 
room temperature for 30 min. Then THF was removed under reduce pressure and the residue 
was extracted by EtOAc (100mL) and water (2 × 100 mL). The organic layer was collected, 
dried (MgSO4) and concentrated under vaccum191.  
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.47 
m. p. = 128 - 130 °C 
Yield: 0.6 g (40 %), tan crystals, recystallised with methanol 
1H NMR (DMSO-d6): 
δ: 7.94 (d, J = 8.3 Hz, 2H, Ar), 7.74 (d, J = 8.3 Hz, 2H, Ar), 7.66 (d, J = 7.4 Hz, 2H, Ar), 7.48 
(d, J = 8.4 Hz, 2H, Ar), 7.42 (m, 5H, Ar), 7.32 (dd, J = 2.6, 7.3 Hz, 2H, Ar), 5.82 (dd, J = 3.0, 
10.0 Hz, 1H, CH), 4,48 (dd, J = 10, 14.9 Hz, 1H, CH2), 3.85 (dd, J = 7.4, 15.0 Hz,1H, CH2).   
 
4.6.4.13  (E)-2-(4-styrylphenyl)-5-(4-(trifluoromethyl)phenyl)-4,5-dihydrooxazole (36b) 
                                  
 
Method: See 4.6.4.12 
N
H
O
CH3SO2Cl O
N
Cl
Chemical Formula: C23H18ClNO
Molecular Weight: 359.85
Cl
OH
35a 36a
N
H
O
CH3SO2Cl O
N
Chemical Formula: C24H18F3NO
Molecular Weight: 393.41
OH
35b 36b
F
F
F
F
F
F
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Reagent: (E)-N-(2-hydroxy-2-(4-(trifluoromethyl)phenyl)ethyl)-4-styrylbenzamide (0.30 g, 
0.73 mmol) 35b 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.70 
Yield: 0.29 g (90 %), yellow solid 
1H NMR indicated a mixture of oxazole product and an apparent amide in approximately 2: 1 
ratio. The oxazole signals are as described below: 
1H NMR (DMSO-d6): 
δ: 7.97 (d, J = 8.3 Hz, 2H, Ar), 7.80 (m, 4H, Ar), 7.65 (d, J = 7.4 Hz, 4H, Ar), 7.61 (d, J = 8.3 
Hz, 2H, Ar), 7.34 (m, 3H, Ar), 5.93 (dd, J = 7.4, 10 Hz, 1H, CH), 4,53 (dd, J = 10, 15 Hz, 1H, 
CH2), 3.87 (dd, J = 7.2, 10 Hz, 1H, CH2).  
 
4.6.4.14 (E)-2-(4-styrylphenyl)-5-(2-(trifluoromethyl)phenyl)-4,5-dihydrooxazole (36c) 
 
 
Method: See 4.6.4.12 
Reagent: (E)-N-(2-hydroxy-2-(2-(trifluoromethyl)phenyl)ethyl)-4-styrylbenzamide (0.6 g, 1.5 
mmol) 35c 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.65 
m. p. = 112 - 118 °C 
Yield: 0.4 g (70 %), yellow solid 
1H NMR (DMSO-d6): 
δ: 8.1 (m, 4H, Ar), 7.89(m, 3H, Ar), 7.85 (m, 4H, Ar), 7.82 (d, J = 16.2 Hz, H, alkene), 7.59 
(m, 3H, Ar), 5.71 (dd, J = 8.0, 10.1 Hz, 1H, CH), 4.51 (dd, J = 10.3, 15.0 Hz, 1H, CH2), 4.01 
(dd, J = 8.0, 15.0 Hz, 1H, CH2).  
 
N
H
O
CH3SO2Cl O
N
Chemical Formula: C24H18F3NO
Molecular Weight: 393.41
OH
35c 36c
F
F
F F
F F
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4.6.4.15 (E)-5-(3,4-dimethylphenyl)-2-(4-styrylphenyl)-4,5-dihydrooxazole (36d) 
 
 
Method: See 4.6.4.12 
Reagent: (E)-N-(2-(3,4-dimethylphenyl)-2-hydroxyethyl)-4-styrylbenzamide (0.70 g, 2.1 
mmol) 35d 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.40 
Yield: 0.5 g (75 % crude yield), tan solid. 
1H NMR indicated a mixture of oxazole product and an apparent amide in approximately 2:1 
ratio. The oxazole signals are as described below: 
1H NMR (DMSO-d6): 
δ: 7.97 (d, J = 8.3 Hz, 2H, Ar), 7.76 (d, J = 8.3 Hz, 2H, Ar), 7.66 (d, J = 7.4 Hz, 2H, Ar), 7.42 
(t, J = 7.4 Hz, 3H, Ar), 7.36 (s, 1H, Ar), 7.33 (t, J = 7.4 Hz, 2H, Ar), 7.13 (d, J = 7.4 Hz, 2H, 
Ar), 5.92 (dd, J = 8.2, 10.1 Hz, 1H, CH), 4.52 (dd, J = 10.3, 14.9 Hz, 1H, CH2), 3.73 (dd, J = 
8.0, 14.9 Hz, 1H, CH2), 2.26 (s, 1H, CH3), 2.24 (s, 1H, CH3). 
 
4.6.4.16 (E)-5-(4-methoxyphenyl)-2-(4-styrylphenyl)-4,5-dihydrooxazole (36e) 
                        
 
 Method: See 4.6.4.12 
Reagent: (E)-N-(2-hydroxy-2-(4-methoxyphenyl)ethyl)-4-styrylbenzamide (0.3 g, 0.8 mmol) 
35e 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.55 
m. p. = 144 - 146 °C 
N
H
O
CH3SO2Cl O
N
Chemical Formula: C25H23NO
Molecular Weight: 353.47
OH
35d 36d
N
H
O
CH3SO2Cl O
N
Chemical Formula: C24H21NO2
Molecular Weight: 355.44
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Yield: 0.27 g (90 %), tan solid 
1H NMR indicated a mixture of oxazole product and an apparent amide in approximately 2:1 
ratio. The oxazole signals are as described below: 
1H NMR (DMSO-d6): 
δ: 7.92 (d, J = 8.3 Hz, 2H, Ar), 7.73 (d, J = 8.3 Hz, 2H, Ar), 7.65 (d, J = 7.5 Hz, 2H, Ar), 7.42 
(m, 2H, Ar), 7.34 (m, 5H, Ar), 6.98 (d, J = 8.3 Hz, 2H, Ar), 5.74 (φt, J = 7.8, 9.8 Hz, 1H, CH), 
4.26 (m, 1H, CH2), 4.03 (m, 1H, CH2), 3.76 (s, 3H, OCH3).  
4.6.4.17 (E)-5-(3-chlorophenyl)-2-(3-(3,4-dimethoxystyryl)phenyl)-4,5-dihydrooxazole 
(36f) 
 
 
Method: See 4.6.4.12 
Reagent: (E)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-4-(3,4-dimethoxystyryl)benzamide 
 (1g, 2.5 mmol) 35f 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.71 
Yield: 0.6 g (63 %), tan solid 
1H NMR indicated a mixture of oxazole product and an apparent amide in approximately 2:1 
ratio. The oxazole signals are as described below: 
1H NMR (DMSO-d6): 
δ: 7.59 (d, J = 8.4 Hz, 3H, Ar), 7.43 (d, J = 7.5 Hz, 2H, Ar), 7.17 (m, 2H, Ar), 7.15 (m, 3H, 
Ar), 6.73 (m, 3H, Ar), 5.68 (m, 1H, CH), 4.52 (m, 1H, CH2), 4.1 (m, 1H, CH2), 3.86 (s, 3H, 
OCH3), 3.72 (s, 3H, OCH3).  
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4.6.4.18  (E)-N-(2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-4-styrylbenzamide (37a) 
 
Method: 
A mixture of (E)-5-(4-chlorophenyl)-2-(4-styrylphenyl)-4,5-dihydrooxazole (36a) (1.2 g, 2.7 
mmol) and imidazole (7.3 g, 108 mmol) was refluxed at 125 °C for 48 h. On completion, the 
mixture was extracted between EtOAc (100 mL) and brine (2	× 100 mL). The organic layer 
was dried (MgSO4) and concentrated under vaccum319.  
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.85 
m. p. = 238 - 240°C  
Yield: 0.15 g (12 %), white solid, recrystallised with EtOAc  
1H NMR (DMSO-d6): 
δ: 8.73 (t, J = 5.2 Hz, 1H, NH), 7.86 (s, 1H, imid), 7.77 (d, J = 8.2 Hz, 4H, Ar), 7.68 (d, J = 
8.2 Hz, 3H, Ar), 7.64 (d, J = 7.5 Hz, 1H, imid), 7.46 (m, 8H, Ar), 6.92 (s, 1H, imid), 5.70 (dd, 
J = 6.5, 8.2 Hz, 1H, CH), 4.06 (m,1H, CH2), 3.44 (m, 1H, CH).  
13C NMR (DMSO-d6): 
δ: 166.8 (CO), 140.5, 138.7,133.2, 133.1 (5	× C), 137.2, 130.7, 129.3, 129.2, 129.1, 128.5, 
127.9,127.1, 126.7, 118.7 (18 × CH, Ar), 59.1 (CH), 43.7 (CH2). 
LRMS (ES-TOF) 
m/z: 430 [M37Cl + H]+, 428 [M35Cl  + H]+, 362 [M - imid]+ 
HRMS (ES-TOF) 
Calculated mass: 428.1523 [M + H]+, measured mass: 428.1524 [M + H]+ 
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Chemical Formula: C26H22ClN3O
Molecular Weight: 427.93
36a
37a
Chapter five                                                                                                             Lead 3 
	
	
	
204	
4.6.4.19 (E)-N-(2-(1H-imidazol-1-yl)-2-(4-(trifluoromethyl)phenyl)ethyl)-4-
styrylbenzamide (37b) 
 
Method: See 4.6.4.18 
Reagent: (E)-2-(4-styrylphenyl)-5-(4-(trifluoromethyl)phenyl)-4,5-dihydrooxazole (1.6 g, 4.1 
mmol) 37b 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.32 
m. p. = 208 - 210 °C  
Yield: 0.6 g (33 %), creamy solid, recrystallised with EtOAc 
1H NMR (DMSO-d6): 
δ: 8.80 (t, J = 5.0 Hz, 1H, NH), 7.91 (s, 1H, imid), 7.78 (dd, J = 3.0, 8.5 Hz, 4H, Ar), 7.69 (d, 
J = 8.5 Hz, 2H, Ar), 7.64 (d, J = 7.5 Hz, 2H, Ar), 7.60 (s, 1H, imid), 7.42 (m, 4H, Ar), 7.32 (m, 
3H, Ar), 6.95 (s, 1H, imid), 5.83 (t, J = 7.5 Hz, 1H, CH), 4.13 (m, 12 Hz, 2H, CH2).  
13C NMR (DMSO-d6): 
δ: 166.8 (CO), 144.4, 140.5,137.4, 137.1, 135.4, 133.1 (6	× C), 130.8, 129.2, 128.5, 128.2, 
128.1, 127.9, 127.1,126.7, 126.1, 118.9 (18 × CH, Ar), 59.3 (CH), 43.7 (CH2). 
Microanalysis 
Anal. Calcd for C27H22F3N3O	∙	0.15H2O (463.87): C 69.86 %, H 4.84 %, N 9.05 %. Found C 
69.56 %, H 4.79 %, N 8.98 % 
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4.6.4.20 (E)-N-(2-(1H-imidazol-1-yl)-2-(2-(trifluoromethyl)phenyl)ethyl)-4 
styrylbenzamide (37c) 
 
Method: See 4.6.4.18 
Reagent:(E)-2-(4-styrylphenyl)-5-(2-(trifluoromethyl)phenyl)-4,5-dihydrooxazole (1.5 g, 3.8 
mmol) 37c 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.21 
m. p. = 174 -178 °C  
Yield: 0.64 g (35 %), creamy solid, recrystallised with EtOAc 
1H NMR (DMSO-d6): 
δ  8.79 (t, J = 5.0 Hz, 1H, NH), 7.5 (d, J = 8.0 Hz, 1H, imid), 7.80 (m, 5H, Ar), 7.68 (d, J = 
8.5 Hz, 2H, Ar), 7.64 (d, J = 7.5 Hz, 2H, Ar), 7.61 (t, J = 7.5 Hz, 1H, imid), 7.41 (m, 3H, Ar), 
7.32 (m, 3H, Ar), 6.90 (t, J = 1.0 Hz, 1H, imid), 6.01 (dd, J = 6.0, 9.0 Hz, 1H, CH), 4.33 (m, 
2H, CH2)  
13C NMR (DMSO-d6): 
δ: 166.8 (CO), 140.5, 137.2, 136.8 (3	× C), 133.1, 131.9 (2	× CH, Ar), 135.2, 134.7 (2	× C), 
129.7, 129.5, 129.3, 128.9, 128.8, 128.5, 127.9, 127.7,126.4, 126.7, 125.7, 118.9 (16 × CH, 
Ar), 59.9 (CH), 44.1 (CH2). 
Microanalysis 
Anal. Calcd for C27H22F3N3O	∙ 0.1H2O (463.29): C 70.00 %, H 4.83 %, N 9.07 %. Found C 
69.64 %, H 4.84 %, N 9.07 %. 
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4.6.4.21 (E)-N-(2-(3,4-dimethylphenyl)-2-(1H-imidazol-1-yl)ethyl)-4-styrylbenzamide 
(37d)   
 
Method: See 4.6.4.18 
Reagent: (E)-5-(3,4-dimethylphenyl)-2-(4-styrylphenyl)-4,5-dihydrooxazole (1.1 g, 3.1 
mmol) 37d 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.65 
m. p. = 134 -136 °C  
Yield: 0.35 g (27 %), yellow solid, recrystallised with EtOAc 
1H NMR (DMSO-d6): 
δ: 8.73 (t, J = 5.5 Hz, 1H, NH), 7.82 (s, 1H, imid), 7.78 (d, J = 8.5 Hz, 2H, Ar), 7.69 (m, 2H, 
Ar), 7.41 (m, 2H, Ar), 7.33 (m, 5H, Ar), 7.18 (s,1H, imid), 7.14 (m, 2H, Ar), 7.02 (s, 1H, imid), 
6.89 (s, 1H, Ar), 5.59 (dd, J = 5.5, 9.0 Hz, 1H, CH), 4.09 (m,1H, CH2), 3.94 (m, 1H, CH2), 2.18 
(s, 6H, 2CH3).  
13C NMR (DMSO-d6): 
δ: 167.8 (CO), 157.5, 140.9, 138.7, 137.5, 136.7, 133.4 (6	× C), 133.2, 130.7, 129.3, 129.2, 
129.1, 128.5, 127.9, 127.1, 126.7, 118.7 (17 × CH, Ar), 59.9 (CH), 43.7 (CH2), 25.7 (2	×	CH3). 
LRMS (ES-TOF) 
m/z: 422 [M + H]+, 214 [M - C6H5CH=CH-C6H5C=O]+ 
HRMS(ES-TOF) 
Calculated mass: 422.2251 [M + H]+, measured mass: 422.2232 [M + H]+ 
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Chemical Formula: C28H27N3O
Molecular Weight: 421.54
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4.6.4.22  (E)-N-(2-(1H-imidazol-1-yl)-2-(4-methoxyphenyl)ethyl)-4-styrylbenzamide 
(37g) 
 
Method: See 4.6.4.18 
Reagent: (E)-5-(4-methoxyphenyl)-2-(4-styrylphenyl)-4,5-dihydrooxazole (0.27 g, 0.8 mmol) 
36g 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.41 
m. p. = 218 - 222°C  
Yield: 0.3 g (32 %), white solid, recrystallised with EtOAc 
1H NMR (CDCl3): 
δ: 8.06 (s, 1H, imid), 7.78 (d, J = 7.7 Hz, 2H, Ar), 7.52 (d, J = 7.5 Hz, 2H, Ar), 7.36 (t, J = 7.0 
Hz, 2H, Ar), 7.31 (m, 5H, Ar), 7.24 (d, J = 8 Hz, 2H, Ar), 717 (m, 2H, Ar), 6.94 (d, J = 8.0 Hz, 
2H, Ar), 5.70 (dd, J = 4.0, 9.5 Hz, 1H, CH), 4.34 (m, 1H, CH2), 4.04 (m, 1H, CH), 3.81 (s, 3H, 
OCH3). 
13C NMR (DMSO-d6): 
δ: 167.8 (CO), 157.5, 140.9, 138.7, 137.5, 136.7, 133.4 (6	× C), 133.2, 130.7, 129.3, 129.2, 
129.1, 128.5, 127.9, 127.1, 126.7, 118.7 (18 × CH, Ar), 59.9 (CH), 55.1 (s, 3H, OCH3), 43.7 
(CH2). 
LRMS (ES-TOF) 
m/z: 424 [M + H]+, 356 [M - imid]+  
HRMS (ES-TOF) 
Calculated mass: 424.2020 [M + H]+, measured mass: 424.2016 [M + H]+ 
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4.6.4.23  (E)-N-(2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-4-(3,4-dimethoxystyryl) 
benzamide (37f) 
                              
 
Method: See 4.6.4.18 
Reagent: (E)-5-(4-chlorophenyl)-2-(4-(3,4-dimethoxystyryl)phenyl)-4,5-dihydrooxazole (1.4 
g, 3.6 mmol) 36e 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.66 
m. p. = 204 - 208°C  
Yield: 0.6 g (35 %), white crystals, recrystallised with acetonitrile 
1H NMR (DMSO-d6): 
δ: 8.74 (t, J = 5.4 Hz, 1H, NH), 7.86 (s, 1H, imid), 7.75 (d, J = 8.4 Hz, 2H, Ar), 7.64 (d, J = 
8.4 Hz, 2H, Ar), 7.46 (m, 2H, Ar), 7.37 (s, 1H, imid), 7.32 (s, 2H, Ar), 7.29 (d, J = 5.1 Hz, 2H, 
Ar), 7.17 (s, 1H, imid), 7.14 (dd, J = 1.8, 8.4 Hz, 1H, Ar), 6.98 (d, J = 8.4 Hz, 2H, Ar), 6.92 (s, 
1H, Ar), 5.71 (dd, J = 6.3, 8.7 Hz, 1H, CH), 4.08 (m, 2H, CH2), 3.83 (s, 3H, OCH3), 3.78 (s, 
3H, OCH3).  
13C NMR (DMSO-d6) 
δ: 166.8 (CO), 149.5, 149.4, 140.9, 138.8 (4	× C), 137.3 (CH, Ar), 133.2, 132.6 (2×C), 130.8 
(CH, Ar), 130.1 (C), 129.3, 129.2, 129.1, 128.1, 126.3,120.8, 118.7, 112.1, 109.6 (14 × CH, 
Ar), 59.2 (CH), 55.8 (2 × OCH3), 43.7 (CH2). 
LRMS (ES-TOF) 
m/z: 490 [ M37Cl + H]+, 488 [M35Cl  + H]+  
HRMS (ES-TOF) 
Calculated mass 488.1743 [M + H]+, measured mass: 488.1741[M + H]+ 
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4.6.4.24 1-(Trifluoromethyl)-2-vinylbenzene (32c) 
 
 method: 
2-(Trifluoromethyl)benzaldehyde 28c (3g, 17.2 mmol) was added to a solution  of  
methyltriphenylphosphonium bromide 38 (7.4 g, 20.6 mmol) and K2CO3 ( 4g, 29 mmol) in dry 
THF (30 mL). The mixture was refluxed at 75 °C for 10 h. THF was removed and the residue 
diluted, filtered through celite and concentrated under vaccum.  The crude product was purified 
using gradient flash column chromatography, the product was eluted with petroleum ether-
EtOAc 3:1 v/v322. 
TLC: petroleum ether-EtOAc 3:1 v/v, Rf = 0.81  
Yield = 2 g (67 %), colourless liquid. 
1H NMR (DMSO-d6): 
δ: 7.94 (d, J = 7.8 Hz, 1H, Ar), 7.69 (m, 2H, Ar), 7.50 (t, J = 7.7 Hz, 1H, Ar), 7.00 (m, 1H, 
CH), 5.92 (d, J = 17.3 Hz, 1H, CH2), 5.50 (dd, J = 0.95, 11.05 Hz, 1H, CH2). 
 
4.6.4.25  (E)-3-styrylbenzoic acid (40a) 
                      
 
Method: See 4.6.4.4 
Reagent: styrene (2.5 g, 24.0 mmol) 32a 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.7  
m. p. = 188 -192 °C (Lit. 197 - 198 °C323) 
Yield = 4.0 g (73 %), brown crystals, recrystallised with acetonitrile 
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1H NMR (DMSO-d6): 
δ: 13.11 (s, 1H, COOH), 8.17 (s, 1H, Ar), 7.88 (dd, J = 7.5, 12.0 Hz, 2H, Ar), 7.66 (d, J = 7.5 
Hz, 2H, Ar), 7.52 (t, J = 8.0 Hz, 1H, Ar), 7.41 (m, 4H, Ar), 7.31 (t, J = 7.5 Hz, 1H, Ar). 
 
4.6.4.26 (E)-3-(2-(trifluoromethyl)styryl)benzoic acid (40b) 
 
Method: See 4.6.4.4 
Reagent: 1-(trifluoromethyl)-2-vinylbenzene	(1 g, 6 mmol) 32c 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf= 0.74  
m. p. = 162 -164 °C  
Yield = 0.9 g (82 %), creamy crystals, recrystallised with acetonitrile 
1H NMR (CDCl3): 
δ: 8.27 (s, 1H, Ar), 8.09 (d, J = 7.7 Hz, 1H, Ar), 7.84 (t, J = 7.3 Hz, 2H, Ar), 7.72 (d, J = 7.8 
Hz, 3H, Ar), 7.61 (m, 1H, Ar),7.43 (t, J = 7.6 Hz, 2H, Ar). 
13C NMR (DMSO-d6): 
δ:167.6 (CO), 137.2, 135.7 (2	× C), 133.3, 132.8 (2	× CH, Ar), 132.2 (C), 131.5, 131.2, 124.0, 
12.6 (8	× CH, Ar). 
Microanalysis 
Anal. Calcd for C16H11F3O2 (292.26): C 65.76%, H 3.79 %, N 0.00 %. Found C 65.63 %, H 
3.81 %, N <0.10 %. 
 
4.6.4.27 (E)-N-(2-hydroxy-2-phenylethyl)-3-styrylbenzamide (41a) 
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Method: See 4.6.4.6 
Reagent: (E)-3-styrylbenzoic acid (1 g, 4.5mmol) 40a 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.68 
m. p. = 128 - 132 °C 
Yield = 0.9 g (60 %), white sold, recrystallised with methanol 
1H NMR (DMSO-d6): 
δ: 8.64 (t, J = 6.0 Hz, 1H, NH), 8.11 (s, 1H, Ar), 7.73 (d, J = 8.0 Hz, 2H, Ar), 7.65 (d, J = 7.5 
Hz, 3H, Ar), 7.49 (t, J = 8.0 Hz, 3H, Ar) 7.42 (t, J = 7.5 Hz, 3H, Ar), 7.37 (m, 4H, Ar), 5.64 (s, 
1H, OH), 4.80 (m, 1H, CHOH), 3.49 (m, 1H, CH2), 3.40 (m, 1H, CH2).  
13C NMR (DMSO–d6): 
δ: 166.8 (CO), 144.3, 137.5, 137.3, 135.5 (4	× C), 129.8, 129.7, 129.3, 129.1, 127.9, 128.5, 
128.4, 128.3, 127.5, 127.0, 126.9, 126.5, (16 × CH, Ar), 71.6 (CH), 48.2 (CH2). 
Microanalysis 
Anal. Calcd for C23H21NO2	∙	0.4 H2O (350.36): C 78.79 %, H 6.27 %, N 3.99 %. Found C 78.35 
%, H 6.56 %, N 3.83 %. 
 
4.6.4.28 (E)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-3-styrylbenzamide (41b) 
 
Method: See 4.6.4.6 
Reagent: (E)-3-styrylbenzoic acid (0.6 g, 2.7 mmol) 40a 
TLC: petroleum ether-EtOAc 2:1 v/v, Rf = 0.44 
m. p. = 138 - 142 °C 
Yield = 0.6 g (50 %), creamy solid, recrystallised with methanol. 
1H NMR (DMSO-d6): 
δ: 8.63 (t, J = 5.0 Hz, 1H, NH), 8.09 (s, 1H, Ar), 7.63 (d, J = 7.5 Hz, 4H, Ar), 7.48 (t, J = 8.0 
Hz, 4H, Ar), 7.42 (t, J = 7.5 Hz, 3H, Ar) 7.36 (m, 3H, Ar), 5.69 (d, J = 4.0 Hz, 1H, OH), 4.83 
(m, 1H, CHOH), 3.51 (m, 1H, CH2), 3.39 (m, 1H, CH2).  
 
+
Cl
NH2
OH
CDI HN
OH
Cl
COOH
O
Chemical Formula: C23H20ClNO2
Molecular Weight: 377.87
40a 31a 41b
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13C NMR (DMSO-d6): 
δ: 166.9 (CO), 138.6 137.5, 135.8, 134.2, 133.2 (5	× C), 131.9, 128.7,128.6, 127.9, 127.3, 
127.4,127.1, 126.9, 126.7,123.4 (15 × CH, Ar), 72.2 (CH), 48.9 (CH2) 
Microanalysis 
Anal. Calcd for C24H20ClNO2∙	0.2 H2O (381.47): C 72.42 %, H 5.39 %, N 3.67 %. Found C 
72.11 %, H 5.36 %, N 3.77 %. 
 
4.6.4.29 (E)-N-(2-hydroxy-2-(4-(trifluoromethyl)phenyl)ethyl)-3-styrylbenzamide (41c) 
 
Method: see 4.6.4.6 
Reagent: (E)-3-styrylbenzoic acid (0.8 g, 3.6 mmol) 40a 
TLC: petroleum ether-EtOAc 2:1 v/v, Rf = 0.52 
m. p. = 184 - 186 °C 
Yield = 0.46 g (31 %), white crystals, recrystallised with acetonitrile. 
1H NMR (DMSO-d6): 
δ: 8.66 (t, J = 5.6 Hz, 1H, NH), 8.08 (s, 1H, Ar), 7.74 (φt, J = 6.6, 7.7 Hz, 4H, Ar), 7.64 (φt, 
J = 8.3, 10.0 Hz, 4H, Ar), 7.49 (t, J = 7.7 Hz, 1H, Ar), 7.42 (t, J = 7.6 Hz, 2H, Ar) 7.33 (m, 3H, 
Ar), 5.80 (d, J = 4.5 Hz, 1H, OH), 4.93 (dd, J = 5.1, 11.9 Hz, 1H, CHOH), 3.54 (m,1H, CH2), 
3.44 (m, 1H, CH2).   
13C NMR (DMSO-d6): 
δ: 166.9 (CO), 149.0, 137.5, 137.2, 135.4 (4	× C), 129.8, 129.7, 129,2, 129.1 (4	× CH, Ar), 
128.3, 128.0 (2	× C), 127.7, 127.3, 127.2,127.1, 126.8, 125.9 (11 × CH, Ar), 71.2 (CH), 47.9 
(CH2). 
Microanalysis 
Anal. Calcd for C24H20F3NO2 ∙	0.1H2O (413.23): C 69.76 %, H 4.93 %, N 3.39 %. Found C 
69.51%, H 4.94 %, N 3.42 %. 
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4.6.4.30  (E)-N-(2-hydroxy-2-phenylethyl)-3-(2-(trifluoromethyl)styryl)benzamide (41d) 
 
Method: See 4.6.4.6 
Reagent: (E)-3-(2-(trifluoromethyl)styryl)benzoic acid (1 g, 3.4mmol) 40b 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.7 
m. p. = 88 - 90 °C 
Yield = 1.2 g (75 %), white solid, purified by gradient flash column chromatography, product 
was eluted with petroleum ether-EtOAc 1:1 v/v. 
1H NMR (CDCl3): 
δ: 7.89 (s, 1H, Ar), 7.75 (d, J = 7.7 Hz, 1H, Ar), 7.68 (m, 3H, Ar), 7.56 (t, J = 7.7 Hz, 2H, 
Ar), 7.50 (m, 5H, Ar), 7.41 (t, J = 8 Hz, 1H, Ar), 7.36 (t, J = 7.7 Hz, 1H, Ar) 7.29 (m, 1H, Ar), 
4.97 (dd, J = 3.2, 8.1 Hz, 1H, CHOH), 3.93 (m, 1H, CH2), 3.55 (m, 1H, CH2).   
13C NMR (CDCl3): 
δ: 167.5 (CO), 141.5, 137.3, 136.3 (3	×C), 133.6, 129.1, 128.7, 128.4, 127.9, 127.6, 125.7 
(14	× CH, Ar), 122.6, 122.2 (2× C), 114.3 (CH, Ar), 71.2 (CH), 48.2 (CH2). 
Microanalysis 
Anal. Calcd for C24H20F3NO2 (411.42): C 70.07%, H 4.90 %, N 3.40 %. Found C 69.99 %, H 
5.05 %, N 3.53 %. 
 
4.6.4.31  (E)-5-phenyl-2-(3-styrylphenyl)-4,5-dihydrooxazole (42a) 
               
 
 Method: See 4.6.4.12 
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Reagent: (E)-N-(2-hydroxy-2-phenylethyl)-3-styrylbenzamide (1.5 g, 4.4 mmol) 41a 
TLC: petroleum ether-EtOAc 3:1 v/v, Rf = 0.55 
Yield: 1.2 g (85 %), creamy solid 
1H NMR indicated a mixture of oxazole product and an apparent amide in approximately 2:1 
ratio. The oxazole signals are as described below: 
1H NMR (DMSO-d6): 
δ: 8.01 (d, J = 7.3 Hz, 2H, Ar), 7.87 (m, 5H, Ar), 7.52 (d, J = 7.3 Hz, 2H, Ar), 7.44 (m, 5H, 
Ar), 7.38 (d, 7.3 Hz, 2H, Ar), 5.66 (dd, J = 3.0, 9.7 Hz, 1H, CH), 4.56 (dd, J = 9.7, 15.0 Hz, 
1H, CH2), 4.51 (dd, J = 7.3, 15.0 Hz,1H, CH2).   
 
4.6.4.32 (E)-5-(4-chlorophenyl)-2-(3-styrylphenyl)-4,5-dihydrooxazole (42b) 
                               
 
 
Method: see 4.6.4.12 
Reagent: (E)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-3-styrylbenzamide (0.8 g, 2.1 mmol) 
41b 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.40 
Yield: 0.6 g (80 %), creamy solid 
1H NMR indicated a mixture of oxazole product and an apparent amide in approximately 2:1 
ratio. The oxazole signals are as described below: 
1H NMR (DMSO-d6): 
δ: 8.19 (d, J = 8.5 Hz, 2H, Ar), 7.99 (d, 8.5 Hz, 2H, Ar), 7.50 (m, 2H, Ar), 7.41 (m, 4H, Ar), 
7.32 (m, 3H, Ar) 7.18 (m, 3H, Ar), 5.79 (dd, J = 8.2, 10.2 Hz, 1H, CH), 4.50 (dd, J = 10.2, 15.3 
Hz, 1H, CH2), 4.31 (dd, J = 8.2, 15.3 Hz,1H, CH2).   
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4.6.4.33 (E)-2-(3-styrylphenyl)-5-(4-(trifluoromethyl)phenyl)-4,5-dihydrooxazole (42c) 
 
Method: See 4.6.4.12 
Reagent: (E)-N-(2-hydroxy-2-(4-(trifluoromethyl)phenyl)ethyl)-3-styrylbenzamide (0.4 g, 0.9 
mmol) 41c 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.57 
Yield: 0.35 g (92 %), tan solid 
1H NMR indicated a mixture of oxazole product and an apparent amide in approximately 2:1 
ratio. The oxazole signals are as described below: 
1H NMR (DMSO-d6): 
δ: 8.02 (d, J = 8.5 Hz, 2H, Ar), 7.56 (d, 8.5 Hz, 2H, Ar), 7.36 (m, 5H, Ar), 7.17 (m, 3H, Ar), 
7.08 (m, 2H, Ar) 7.97 (m, 1H, Ar), 5.51 (dd, J = 10.1, 15.0 Hz, 1H, CH), 4.09 (dd, J = 8.5, 15.0 
Hz, 1H, CH2), 3.99 (dd, J = 8.2, 15.3 Hz,1H, CH2).   
 
4.6.4.34 (E)-5-phenyl-2-(3-(2-(trifluoromethyl)styryl)phenyl)-4,5-dihydrooxazole (42d)  
 
Method: See 4.6.4.12 
Reagent: ((E)-N-(2-hydroxy-2-phenylethyl)-3-(2-(trifluoromethyl)styryl)benzamide (1.3 g, 
3.2 mmol) 41d 
TLC: petroleum ether-EtOAc 1:1 v/v, Rf = 0.60 
Yield: 0.7 g (56 %), creamy solid 
1H NMR indicated a mixture of oxazole product and an apparent amide in approximately 2:1 
ratio. The oxazole signals are as described below: 
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1H NMR (DMSO-d6): 
δ: 7.95 (d, J = 8.3 Hz, 2H, Ar), 7.66 (d, J = 8.3 Hz, 2H, Ar), 7.58 (d, J = 8.3 Hz, 2H, Ar), 7.52 
(d, J = 8.3 Hz, 2H, Ar), 7.32 (m, 7H, Ar), 5.80 (dd, J = 7.7, 10.1 Hz, 1H, CH), 4.45 (dd, J = 
10.1, 14.9 Hz, 1H, CH2), 3.89 (dd, J = 7.5, 14.9 Hz,1H, CH2).   
 
4.6.4.35 (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-3-styrylbenzamide (43a) 
 
Method: See 4.6.4.18 
Reagent: (E)-5-phenyl-2-(3-styrylphenyl)-4,5-dihydrooxazole (1.4 g, 4.2 mmol) 42a 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.27 
m. p. = 158 -160 °C  
Yield: 0.62 g (38 %), white solid, recrystallised with EtOAc 
1H NMR (DMSO-d6): 
δ: 8.82 (t, J = 5.7 Hz, 1H, NH), 7.97 (s, 1H, Ar), 7.75 (d, J = 8.0 Hz, 1H, Ar), 7.64 (d, J = 8.0 
Hz, 4H, Ar), 7.47 (s, 1H, Ar), 7.42 (m, 7H, Ar), 7.35 (m, 4H, Ar), 6.92 (s,1H, imid), 5.71 (dd, 
J = 6.0, 9.5 Hz, 1H, CH), 4.13 (m,1H, CH2), 4.02 (m, 1H, CH2).  
13C NMR (DMSO-d6): 
δ: 167.2 (CO), 139.7, 137.6 (2	× C), 137.3 (CH, Ar), 137.2, 135.2 (2	× C), 129.9, 129.8, 
129.6, 129.2, 128.5, 128.3, 128.1, 127.7, 127.4,126.7, 126.3, 125.5, 118.9 (18 × CH, Ar), 59.9 
(CH), 43.9 (CH2). 
Microanalysis 
Anal. Calcd for C26H23N3O	∙ 0.25 H2O (397.99): C 78.47 %, H 5.95 %, N 10.56 %. Found C 
78.17 %, H 5.95 %, N 10.56. 
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4.6.4.36    (E)-N-(2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-3-styrylbenzamide (43b) 
  
Method: See 4.6.4.18 
Reagent: (E)-5-(4-chlorophenyl)-2-(3-styrylphenyl)-4,5-dihydrooxazole (0.9 g, 2.4 mmol) 
42b 
m. p. = 148 - 152 °C  
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.8 
Yield: 0.3 g (32 %), white solid, recrystallised with EtOAc 
1H NMR (DMSO-d6): 
δ: 8.82 (t, J = 5.5 Hz, 1H, NH), 7.95 (s, 1H, imid), 7.88 (s, 1H, Ar), 7.75 (d, J = 7.5 Hz, 2H, 
Ar), 7.47 (m, 5H, Ar), 7.31 (m, 8H, Ar), 6.93 (s, 1H, imid), 5.71 (dd, J = 6.0, 8.5 Hz, 1H, CH), 
4.11 (m, 1H, CH), 3.91 (m,1H, CH2). 
13C NMR (DMSO-d6): 
δ: 167.2 (CO), 138.7, 137.6 (2	× C), 137.2 (CH, Ar), 137.1, 135.1, 133.2 (3	× C), 129.9, 
129.8, 129.4, 192.2, 129.1, 129.0, 128.4, 128.4,128.1, 127.1, 126.7, 125.5, 118.8 (17 × CH, 
Ar), 59.1 (CH), 43.7 (CH2). 
Microanalysis 
Anal. Calcd for C26H22ClN3O (427.93): C 72.98 %, H 5.18 %, N 9.81 %. Found C 72.77 %, H 
5.36 %, N 9.40  
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4.6.4.37  (E)-N-(2-(1H-imidazol-1-yl)-2-(2-(trifluoromethyl)phenyl)ethyl)-3-
styrylbenzamide (43c) 
 
Method: See 4.6.4.18 
Reagent: (E)-2-(3-styrylphenyl)-5-(2-(trifluoromethyl)phenyl)-4,5-dihydrooxazole (0.35 g, 
0.9 mmol) 42c 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.60 
m. p. = 126 -130 °C  
Yield: 0.12 g (48 %), white solid, recrystallised with EtOAc 
1H NMR (DMSO-d6): 
δ: 8.84 (t, J = 5.5 Hz, 1H, NH), 7.96 (m, 2H, Ar), 7.78 (m, 4H, Ar), 7.64 (m, 5H, Ar), 7.49 
(m, 4H, Ar), 7.33 (m, 2H, Ar), 6.96 (s,1H, imid) 5.84 (m, 1H, CH), 4.15 (m, 2H, CH2).  
13C NMR (DMSO-d6): 
δ: 166.9 (CO), 149.0, 144.4, 137.6, 137.5, 135.4, 135.1, 134.9 (7	× C), 129.9, 129.8, 129.7, 
129.2, 129.1, 128.4, 128.3, 128.2, 128.1, 127.3, 127.0, 126.1, 125.5, 125.4, 118.9 (18 × CH, 
Ar), 59.3 (CH), 43.7 (CH2). 
LRMS (ES-TOF) 
m/z: 462 [M + H]+  
HRMS (ES-TOF) 
Calculated mass: 462.1793 [M + H]+, measured mass: 462.1799 [M + H]+ 
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4.6.4.38  (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-3-(2-(trifluoromethyl)styryl) 
benzamide (43d) 
 
Method: See 4.6.4.18 
Reagent: (E)-2-(3-styrylphenyl)-5-(2-(trifluoromethyl)phenyl)-4,5-dihydrooxazole(0.7 g, 1.8 
mmol) 42d 
TLC: CH2Cl2-CH3OH 9:1 v/v, Rf = 0.5 
m. p. = 110 -114 °C  
Yield: 0.27 g (33 %), white solid, recrystallised with EtOAc 
1H NMR (DMSO-d6): 
δ: 8.87 (t, J = 5.5 Hz, 1H, NH), 8.02 (d, J = 7.5 Hz, 2H, Ar), 7.86 (s, 1H, imid), 7.78 (m, 4H, 
Ar), 7.54 (m, 5H, Ar), 7.40 (m, 5H, Ar), 6.91 (s,1H, Ar), 5.71 (dd, J = 6.0, 9.0 Hz, 1H, CH), 
4.12 (m, 2H, CH2).  
13C NMR (DMSO-d6): 
δ: 167.9 (CO), 149.0, 144.4, 138.6, 138.5, 136.4, 134.9 (6	× C), 129.9, 129.8, 129.7, 129.2, 
129.1, 128.4, 128.3, 128.2, 128.1, 127.3, 127.0, 126.1, 125.5, 125.4, 12.4 (18 × CH, Ar), 59.3 
(CH), 43.7 (CH2). 
LRMS (ES-TOF) 
m/z: 462 [ M + H]+, 394 [M - imid]+  
HRMS (ES-TOF) 
Calculated mass: 462.1793 [M + H]+, measured mass: 462.1795 [M + H]+ 
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5 Conclusions 
Vitamin D is synthesised from skin by exposure to ultra violet β radiation and undergoes 
hydroxylation to produce the biologically active metabolite calcitriol. Calcitriol has been 
shown to exhibit anticancer activity. However, therapy using calcitriol is limited owing to the 
short duration of action resulting from metabolism by 24-hydroxyvitamin D-24-hydroxylase 
(CYP24A1). 
Figure 94: Site of of CYP24A1 inhibitor 
Currently, the aim of this work is to develop a CYP27B1 homology model as a tool in the 
design of a selective inhibitor of vitamin D metabolism, specifically to aid in the design of 
chemical compounds with a selective inhibition of CYP24A1 and not the inhibition of 
CYP27B1, which inactivates the active form of vitamin D, calcitriol (Figure 94). A model of 
CYP24A1 using the rat CYP24A1 crystal structure as a template has previously been described 
by our group. To assist in the design of a selective CYP24A1 inhibitor, a CYP27B1 homology 
model was required. This required the generation of a homology modeling for CYP27B1 in 
order to analyse any differences in active site architecture and binding interactions. was built 
using Molecular Operating Environment (MOE) in order to try and understand the 
requirements of the enzyme active site binding where CYP24A1 has been previously 
developed and published. 
CYP27B1 homology model was subject to validation, with further optimisation of the active 
site architecture achieved by molecular dynamics simulations. Understanding protein-ligand 
interactions is essential for designing more selective and potent CYP24A1 inhibitors. 
Monitoring RMSD during simulations indicated that it is a structurally stable homology model. 
Docking results for CYP27B1 showed amino acids Arg107, Asn387 and Asp320 have an 
HO
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CYP27B1
Kidney
HO
OH
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OH
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OH
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important role in binding interaction to form hydrogen bonds with inhibitors. Asp320 was part 
of the αI helix for the CYP27B1 model, which covers the haem binding site and contains 
SRS-4, and plays a key role in orientating the ligand at the active site by electrostatic 
interactions.  
 The main strategy that can be used to build selective inhibitor CYP24A1 over CYP27B1, is to 
design compound unable to form hydrogen bonding interactions with CYP27B1 especially 
with Arg107, Asn387 and Asp320.  
Using the data from modelling a lead compound, identified through screening of the SPECS 
database. The docking studies and synthesis of the modified lead compounds were described 
in (Figure 95, 96 and 97). Two of these compounds were selected as lead compounds (lead 1 
and lead 2) for further development. In addition, lead 3 was synthesised in our laboratory and 
showed potent CYP24A1 inhibitory activity. 
Figure 95: Modifications of lead 1 compound 
Development of lead 1 by replacement with pyridine and imidazole was synthesised 
successfully. Replacement with triazole was also synthesised by the same methods. All the 
compounds accessed the vitamin D channel and interacted with the active site of CYP24A1. 
The compounds exhibited weak potency and IC50 ranging between 10.2 to 28.4 µM against 
CYP24A1 (Figure 95). 
Figure 96: Modifications of lead 2 compound 
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The modified lead 2 compounds 25b, 26a, 26b, 27a, 27b and 27c were all synthesised 
successfully. 25b interacted perpendicularly with the haem iron of CYP24A1 via ether oxygen 
with a distance of 2.20 Å. 26a and 26b were designed without phenyl substituent by changing 
the position of the ether group from the 4 to the 3 position and formed hydrogen bonds between 
number of amino acids, with the nitrogen atom of pyridine interacting perpendicularly with the 
haem iron of CYP24A1 with a distance 2.63 Å and 2.05 Å respectively. However, 26a and 26b 
showed enzymatic inhibition (IC50 = 0.57 μM and 0.41 μM respectively) against CYP27B1. 
As a result, both compounds have inhibitor selectivity for CYP27B1 that is five times greater 
than CYP24A1 owing to Asp320 and Asn387 have been identified as important amino acids 
for CYP27B1 inhibitory activity (Figure 96).  
  
Figure 97: Modifications of lead 2 compound 
 
A series of 3- and 4-styrylbenzamide imidazole derivatives have been prepared using an 
efficient synthetic route (Figure 97). All the derivatives showed very good inhibitory activity 
against CYP24A1 and, although there were some small differences in IC50 values depending 
on substituents, overall both 3- and 4-styrylbenzamide imidazoles and a range of substituents 
were very well tolerated without any significant loss of inhibitory activity. This inhibitory data 
would agree with the molecular docking where all the compounds fit well within the active site 
and showed a good fill of the hydrophobic channel of the CYP24A1 active site as well as 
transition metal interaction between the iron of the haem and the imidazole ring of the 
derivatives. However, although collaboration at delivery the University of Wisconsin sent 
CYP27B1 enzyme on two different occasions, the enzyme was denatured (owing to customs 
holdup) on both deliveries. Owing to the time in enzyme preparation, extraction and the costs 
involved we were unable to perform CYP27B1 enzyme inhibition assay. 
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